Datasets:

mrojas
/

shared-task

Modalities:

Text

Size:

< 1K

Libraries:

Datasets

Dataset card Data Studio Files Files and versions

xet

Community

shared-task / data /test.conll

Matías Rojas

Datos

1f5cc7e almost 3 years ago

raw

history blame

137 kB

	Paciente B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	sexo I-PRESENT_ILLNESS
	femenino I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	10 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	edad, I-PRESENT_ILLNESS
	oriunda B-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	la I-PAST_MEDICAL_HISTORY
	provincia I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	Misiones, I-PAST_MEDICAL_HISTORY
	que B-PRESENT_ILLNESS
	consultó I-PRESENT_ILLNESS
	al I-PRESENT_ILLNESS
	servicio I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	Dermatología I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	presentar I-PRESENT_ILLNESS
	múltiples I-PRESENT_ILLNESS
	placas I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	aspecto I-PRESENT_ILLNESS
	verrugoso I-PRESENT_ILLNESS
	con I-PRESENT_ILLNESS
	numerosas I-PRESENT_ILLNESS
	pápulas I-PRESENT_ILLNESS
	negruzcas I-PRESENT_ILLNESS
	sobre I-PRESENT_ILLNESS
	su I-PRESENT_ILLNESS
	superficie, I-PRESENT_ILLNESS
	localizadas I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	los I-PRESENT_ILLNESS
	sitios I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	apoyo I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	ambos I-PRESENT_ILLNESS
	pies I-PRESENT_ILLNESS
	(punta I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	dedos, I-PRESENT_ILLNESS
	metatarso I-PRESENT_ILLNESS
	y I-PRESENT_ILLNESS
	talones), I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	reciente I-PRESENT_ILLNESS
	aparición. I-PRESENT_ILLNESS
	<EOS> I-PRESENT_ILLNESS
	Las I-PRESENT_ILLNESS
	lesiones I-PRESENT_ILLNESS
	le I-PRESENT_ILLNESS
	ocasionaban I-PRESENT_ILLNESS
	dolor I-PRESENT_ILLNESS
	y I-PRESENT_ILLNESS
	dificultaban I-PRESENT_ILLNESS
	su I-PRESENT_ILLNESS
	deambulación. I-PRESENT_ILLNESS
	Realizada B-TREATMENT
	la I-TREATMENT
	extracción I-TREATMENT
	quirúrgica, I-TREATMENT
	se B-EXPLORATION
	obtuvieron I-EXPLORATION
	alrededor I-EXPLORATION
	de I-EXPLORATION
	20 I-EXPLORATION
	tungas I-EXPLORATION
	y I-EXPLORATION
	las I-EXPLORATION
	muestras I-EXPLORATION
	extraídas I-EXPLORATION
	se I-EXPLORATION
	enviaron I-EXPLORATION
	al I-EXPLORATION
	servicio I-EXPLORATION
	de I-EXPLORATION
	anatomopatología, I-EXPLORATION
	que I-EXPLORATION
	confirmó I-EXPLORATION
	el I-EXPLORATION
	diagnóstico I-EXPLORATION
	de I-EXPLORATION
	tungiasis. I-EXPLORATION
	La B-TREATMENT
	paciente I-TREATMENT
	fue I-TREATMENT
	tratada I-TREATMENT
	con I-TREATMENT
	ivermecti-na I-TREATMENT
	vía I-TREATMENT
	oral I-TREATMENT
	200 I-TREATMENT
	µg/kg I-TREATMENT
	como I-TREATMENT
	terapia I-TREATMENT
	coadyuvante, I-TREATMENT
	debido I-TREATMENT
	al I-TREATMENT
	gran I-TREATMENT
	compromiso I-TREATMENT
	cutáneo I-TREATMENT
	y I-TREATMENT
	la I-TREATMENT
	multiplicidad I-TREATMENT
	de I-TREATMENT
	lesiones. I-TREATMENT
	Las B-EVOLUTION
	lesiones I-EVOLUTION
	evolucionaron I-EVOLUTION
	favorablemente I-EVOLUTION
	con I-EVOLUTION
	resolución I-EVOLUTION
	completa. I-EVOLUTION
	<EOS> I-EVOLUTION

	Paciente B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	sexo I-PRESENT_ILLNESS
	femenino I-PRESENT_ILLNESS
	internada I-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	los I-PRESENT_ILLNESS
	cuatro I-PRESENT_ILLNESS
	meses I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	vida I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	fiebre I-PRESENT_ILLNESS
	y I-PRESENT_ILLNESS
	depresión I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	sensorio. I-PRESENT_ILLNESS
	Antecedentes: B-PAST_MEDICAL_HISTORY
	recién I-PAST_MEDICAL_HISTORY
	nacida I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	término, I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	peso I-PAST_MEDICAL_HISTORY
	adecuado I-PAST_MEDICAL_HISTORY
	para I-PAST_MEDICAL_HISTORY
	su I-PAST_MEDICAL_HISTORY
	edad I-PAST_MEDICAL_HISTORY
	gestacional, I-PAST_MEDICAL_HISTORY
	con I-PAST_MEDICAL_HISTORY
	diagnóstico I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	ictericia I-PAST_MEDICAL_HISTORY
	por I-PAST_MEDICAL_HISTORY
	incompatibilidad I-PAST_MEDICAL_HISTORY
	ABO, I-PAST_MEDICAL_HISTORY
	tratada I-PAST_MEDICAL_HISTORY
	con I-PAST_MEDICAL_HISTORY
	luminoterapia I-PAST_MEDICAL_HISTORY
	dentro I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	las I-PAST_MEDICAL_HISTORY
	primeras I-PAST_MEDICAL_HISTORY
	24 I-PAST_MEDICAL_HISTORY
	h I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	vida. I-PAST_MEDICAL_HISTORY
	Al I-PAST_MEDICAL_HISTORY
	momento I-PAST_MEDICAL_HISTORY
	del I-PAST_MEDICAL_HISTORY
	egreso I-PAST_MEDICAL_HISTORY
	los I-PAST_MEDICAL_HISTORY
	valores I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	bilirrubina I-PAST_MEDICAL_HISTORY
	total I-PAST_MEDICAL_HISTORY
	eran I-PAST_MEDICAL_HISTORY
	9, I-PAST_MEDICAL_HISTORY
	9 I-PAST_MEDICAL_HISTORY
	mg/dl I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	directa I-PAST_MEDICAL_HISTORY
	0, I-PAST_MEDICAL_HISTORY
	5 I-PAST_MEDICAL_HISTORY
	mg/dl. I-PAST_MEDICAL_HISTORY
	Reingresó I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	Neonatología I-PAST_MEDICAL_HISTORY
	al I-PAST_MEDICAL_HISTORY
	mes I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	vida I-PAST_MEDICAL_HISTORY
	por I-PAST_MEDICAL_HISTORY
	ictericia I-PAST_MEDICAL_HISTORY
	prolongada. I-PAST_MEDICAL_HISTORY
	Durante I-PAST_MEDICAL_HISTORY
	la I-PAST_MEDICAL_HISTORY
	internación I-PAST_MEDICAL_HISTORY
	se I-PAST_MEDICAL_HISTORY
	realizó I-PAST_MEDICAL_HISTORY
	ecografía I-PAST_MEDICAL_HISTORY
	abdominal I-PAST_MEDICAL_HISTORY
	cuyo I-PAST_MEDICAL_HISTORY
	informe I-PAST_MEDICAL_HISTORY
	mencionaba I-PAST_MEDICAL_HISTORY
	presencia I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	vías I-PAST_MEDICAL_HISTORY
	biliares I-PAST_MEDICAL_HISTORY
	intrahepática I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	extrahepáticas, I-PAST_MEDICAL_HISTORY
	sin I-PAST_MEDICAL_HISTORY
	dilatación. I-PAST_MEDICAL_HISTORY
	Laboratorio: I-PAST_MEDICAL_HISTORY
	bilirrubinemia I-PAST_MEDICAL_HISTORY
	total I-PAST_MEDICAL_HISTORY
	11, I-PAST_MEDICAL_HISTORY
	3 I-PAST_MEDICAL_HISTORY
	mg/dl I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	directa I-PAST_MEDICAL_HISTORY
	1, I-PAST_MEDICAL_HISTORY
	7 I-PAST_MEDICAL_HISTORY
	mg/dl, I-PAST_MEDICAL_HISTORY
	FAL I-PAST_MEDICAL_HISTORY
	257 I-PAST_MEDICAL_HISTORY
	UI/L, I-PAST_MEDICAL_HISTORY
	TGP I-PAST_MEDICAL_HISTORY
	55 I-PAST_MEDICAL_HISTORY
	UI/L, I-PAST_MEDICAL_HISTORY
	TGO I-PAST_MEDICAL_HISTORY
	69 I-PAST_MEDICAL_HISTORY
	UI/L. I-PAST_MEDICAL_HISTORY
	Fue I-PAST_MEDICAL_HISTORY
	dada I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	alta I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	continuó I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	seguimiento I-PAST_MEDICAL_HISTORY
	ambulatorio I-PAST_MEDICAL_HISTORY
	por I-PAST_MEDICAL_HISTORY
	gastroenterólogo I-PAST_MEDICAL_HISTORY
	pediatra, I-PAST_MEDICAL_HISTORY
	hasta I-PAST_MEDICAL_HISTORY
	la I-PAST_MEDICAL_HISTORY
	internación I-PAST_MEDICAL_HISTORY
	por I-PAST_MEDICAL_HISTORY
	la I-PAST_MEDICAL_HISTORY
	hemorragia I-PAST_MEDICAL_HISTORY
	intracraneal. I-PAST_MEDICAL_HISTORY
	Evolución: B-EXPLORATION
	al I-EXPLORATION
	ingreso I-EXPLORATION
	se I-EXPLORATION
	encontró I-EXPLORATION
	ictericia I-EXPLORATION
	generalizada, I-EXPLORATION
	hepatomegalia I-EXPLORATION
	y I-EXPLORATION
	sopor. I-EXPLORATION
	Dentro B-EVOLUTION
	de I-EVOLUTION
	las I-EVOLUTION
	primeras I-EVOLUTION
	24 I-EVOLUTION
	h I-EVOLUTION
	de I-EVOLUTION
	internación I-EVOLUTION
	presentó I-EVOLUTION
	episodio I-EVOLUTION
	convulsivo I-EVOLUTION
	focal I-EVOLUTION
	en I-EVOLUTION
	hemicuerpo I-EVOLUTION
	derecho; I-EVOLUTION
	en B-TREATMENT
	la I-TREATMENT
	tomografía I-TREATMENT
	computada I-TREATMENT
	cerebral I-TREATMENT
	(TC) I-TREATMENT
	se I-TREATMENT
	constató I-TREATMENT
	hematoma I-TREATMENT
	subdural I-TREATMENT
	que I-TREATMENT
	requirió I-TREATMENT
	drenaje I-TREATMENT
	quirúrgico I-TREATMENT
	y I-TREATMENT
	asistencia I-TREATMENT
	respiratoria I-TREATMENT
	mecánica I-TREATMENT
	hasta I-TREATMENT
	48 I-TREATMENT
	h I-TREATMENT
	del I-TREATMENT
	postoperatorio. I-TREATMENT
	Laboratorio B-EXPLORATION
	de I-EXPLORATION
	ingreso: I-EXPLORATION
	GOT I-EXPLORATION
	120 I-EXPLORATION
	UI/L, I-EXPLORATION
	GPT I-EXPLORATION
	180 I-EXPLORATION
	UI/L, I-EXPLORATION
	FAL I-EXPLORATION
	1053 I-EXPLORATION
	UI/L, I-EXPLORATION
	gammaglutamiltranspeptidasa I-EXPLORATION
	1119 I-EXPLORATION
	UI/L, I-EXPLORATION
	LDH I-EXPLORATION
	1262 I-EXPLORATION
	UI/L, I-EXPLORATION
	bilirrubinemia I-EXPLORATION
	total I-EXPLORATION
	6 I-EXPLORATION
	mg/dl I-EXPLORATION
	y I-EXPLORATION
	directa I-EXPLORATION
	3, I-EXPLORATION
	9 I-EXPLORATION
	mg/ I-EXPLORATION
	dl, I-EXPLORATION
	amonio I-EXPLORATION
	51, I-EXPLORATION
	8 I-EXPLORATION
	mcg/dl, I-EXPLORATION
	lactacidemia I-EXPLORATION
	7 I-EXPLORATION
	mmol/L, I-EXPLORATION
	tiempo I-EXPLORATION
	de I-EXPLORATION
	protrombina I-EXPLORATION
	59%, I-EXPLORATION
	KPTT I-EXPLORATION
	100 I-EXPLORATION
	segundos I-EXPLORATION
	(no I-EXPLORATION
	se I-EXPLORATION
	le I-EXPLORATION
	administró I-EXPLORATION
	vitamina I-EXPLORATION
	K I-EXPLORATION
	ni I-EXPLORATION
	plasma I-EXPLORATION
	frasco I-EXPLORATION
	congelado I-EXPLORATION
	previo I-EXPLORATION
	a I-EXPLORATION
	la I-EXPLORATION
	toma I-EXPLORATION
	de I-EXPLORATION
	muestra). I-EXPLORATION
	Serologías I-EXPLORATION
	para I-EXPLORATION
	VIH, I-EXPLORATION
	sífilis, I-EXPLORATION
	toxoplasmosis, I-EXPLORATION
	hepatitis I-EXPLORATION
	B, I-EXPLORATION
	hepatitis I-EXPLORATION
	A I-EXPLORATION
	y I-EXPLORATION
	citomegalovirus I-EXPLORATION
	negativas. I-EXPLORATION
	Se I-EXPLORATION
	realizó I-EXPLORATION
	centellograma I-EXPLORATION
	con I-EXPLORATION
	HIDA I-EXPLORATION
	que I-EXPLORATION
	mostró I-EXPLORATION
	falta I-EXPLORATION
	de I-EXPLORATION
	captación I-EXPLORATION
	de I-EXPLORATION
	contraste I-EXPLORATION
	intrahepático I-EXPLORATION
	y I-EXPLORATION
	extrahepático, I-EXPLORATION
	sin I-EXPLORATION
	pasaje I-EXPLORATION
	de I-EXPLORATION
	contraste I-EXPLORATION
	al I-EXPLORATION
	intestino. I-EXPLORATION
	Se B-TREATMENT
	decidió I-TREATMENT
	realizar I-TREATMENT
	portoenteroanastomosis I-TREATMENT
	por I-TREATMENT
	laparoscopia, I-TREATMENT
	después I-TREATMENT
	de I-TREATMENT
	confirmar I-TREATMENT
	el I-TREATMENT
	diagnóstico I-TREATMENT
	de I-TREATMENT
	atresia I-TREATMENT
	de I-TREATMENT
	vías I-TREATMENT
	biliares I-TREATMENT
	durante I-TREATMENT
	la I-TREATMENT
	cirugía. I-TREATMENT
	A B-EVOLUTION
	los I-EVOLUTION
	6 I-EVOLUTION
	meses I-EVOLUTION
	de I-EVOLUTION
	vida I-EVOLUTION
	presentaba I-EVOLUTION
	maduración I-EVOLUTION
	neurológica I-EVOLUTION
	adecuada I-EVOLUTION
	a I-EVOLUTION
	la I-EVOLUTION
	edad. I-EVOLUTION
	Requirió B-TREATMENT
	trasplante I-TREATMENT
	hepático I-TREATMENT
	cerca I-TREATMENT
	del I-TREATMENT
	año I-TREATMENT
	de I-TREATMENT
	edad. I-TREATMENT
	<EOS> I-TREATMENT

	Niño B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	30 I-PRESENT_ILLNESS
	meses, I-PRESENT_ILLNESS
	nacido B-PAST_MEDICAL_HISTORY
	a I-PAST_MEDICAL_HISTORY
	término, I-PAST_MEDICAL_HISTORY
	cesárea I-PAST_MEDICAL_HISTORY
	programada, I-PAST_MEDICAL_HISTORY
	embarazo I-PAST_MEDICAL_HISTORY
	controlado, I-PAST_MEDICAL_HISTORY
	peso I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	talla I-PAST_MEDICAL_HISTORY
	acordes I-PAST_MEDICAL_HISTORY
	con I-PAST_MEDICAL_HISTORY
	la I-PAST_MEDICAL_HISTORY
	edad I-PAST_MEDICAL_HISTORY
	gestacional. I-PAST_MEDICAL_HISTORY
	Antecedentes I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	dos I-PAST_MEDICAL_HISTORY
	episodios I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	otitis I-PAST_MEDICAL_HISTORY
	media, I-PAST_MEDICAL_HISTORY
	sin I-PAST_MEDICAL_HISTORY
	cirugías, I-PAST_MEDICAL_HISTORY
	internaciones I-PAST_MEDICAL_HISTORY
	previas I-PAST_MEDICAL_HISTORY
	ni I-PAST_MEDICAL_HISTORY
	alergias. I-PAST_MEDICAL_HISTORY
	Inmunizaciones I-PAST_MEDICAL_HISTORY
	completas I-PAST_MEDICAL_HISTORY
	según I-PAST_MEDICAL_HISTORY
	el I-PAST_MEDICAL_HISTORY
	calendario I-PAST_MEDICAL_HISTORY
	oficial. I-PAST_MEDICAL_HISTORY
	Crecimiento I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	desarrollo I-PAST_MEDICAL_HISTORY
	normales. I-PAST_MEDICAL_HISTORY
	Historia B-FAMILY_HISTORY
	familiar I-FAMILY_HISTORY
	con I-FAMILY_HISTORY
	ambos I-FAMILY_HISTORY
	padres I-FAMILY_HISTORY
	obesos I-FAMILY_HISTORY
	con I-FAMILY_HISTORY
	cirugía I-FAMILY_HISTORY
	bariátrica I-FAMILY_HISTORY
	realizada, I-FAMILY_HISTORY
	y I-FAMILY_HISTORY
	dos I-FAMILY_HISTORY
	hermanas I-FAMILY_HISTORY
	mayores I-FAMILY_HISTORY
	con I-FAMILY_HISTORY
	antecedentes I-FAMILY_HISTORY
	de I-FAMILY_HISTORY
	asma I-FAMILY_HISTORY
	e I-FAMILY_HISTORY
	hipotiroidismo, I-FAMILY_HISTORY
	respectivamente. I-FAMILY_HISTORY
	<EOS> I-FAMILY_HISTORY
	Es B-DERIVED_FROM/TO
	derivado I-DERIVED_FROM/TO
	a I-DERIVED_FROM/TO
	nuestro I-DERIVED_FROM/TO
	hospital I-DERIVED_FROM/TO
	con I-DERIVED_FROM/TO
	diagnóstico I-DERIVED_FROM/TO
	de I-DERIVED_FROM/TO
	síndrome I-DERIVED_FROM/TO
	ascítico I-DERIVED_FROM/TO
	edematoso. I-DERIVED_FROM/TO
	Comenzó B-PRESENT_ILLNESS
	una I-PRESENT_ILLNESS
	semana I-PRESENT_ILLNESS
	antes I-PRESENT_ILLNESS
	con I-PRESENT_ILLNESS
	un I-PRESENT_ILLNESS
	edema I-PRESENT_ILLNESS
	palpebral I-PRESENT_ILLNESS
	bilateral I-PRESENT_ILLNESS
	leve. I-PRESENT_ILLNESS
	Dos I-PRESENT_ILLNESS
	días I-PRESENT_ILLNESS
	después, I-PRESENT_ILLNESS
	presentó I-PRESENT_ILLNESS
	un I-PRESENT_ILLNESS
	exantema I-PRESENT_ILLNESS
	urticariante I-PRESENT_ILLNESS
	generalizado I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	todo I-PRESENT_ILLNESS
	el I-PRESENT_ILLNESS
	cuerpo, I-PRESENT_ILLNESS
	no I-PRESENT_ILLNESS
	pruriginoso, I-PRESENT_ILLNESS
	que I-PRESENT_ILLNESS
	revirtió I-PRESENT_ILLNESS
	espontáneamente I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	menos I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	24 I-PRESENT_ILLNESS
	horas. I-PRESENT_ILLNESS
	A I-PRESENT_ILLNESS
	las I-PRESENT_ILLNESS
	48 I-PRESENT_ILLNESS
	horas, I-PRESENT_ILLNESS
	apareció I-PRESENT_ILLNESS
	un I-PRESENT_ILLNESS
	edema I-PRESENT_ILLNESS
	bipalpebral I-PRESENT_ILLNESS
	más I-PRESENT_ILLNESS
	pronunciado, I-PRESENT_ILLNESS
	distensión I-PRESENT_ILLNESS
	abdominal I-PRESENT_ILLNESS
	e I-PRESENT_ILLNESS
	irritabilidad. I-PRESENT_ILLNESS
	Se I-PRESENT_ILLNESS
	consultó I-PRESENT_ILLNESS
	al I-PRESENT_ILLNESS
	pediatra, I-PRESENT_ILLNESS
	que I-PRESENT_ILLNESS
	constató I-PRESENT_ILLNESS
	un I-PRESENT_ILLNESS
	aumento I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	2 I-PRESENT_ILLNESS
	kg I-PRESENT_ILLNESS
	con I-PRESENT_ILLNESS
	respecto I-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	peso I-PRESENT_ILLNESS
	previo I-PRESENT_ILLNESS
	(2 I-PRESENT_ILLNESS
	meses I-PRESENT_ILLNESS
	antes). I-PRESENT_ILLNESS
	No B-PAST_MEDICAL_HISTORY
	tenía I-PAST_MEDICAL_HISTORY
	antecedentes I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	infecciones. I-PAST_MEDICAL_HISTORY
	Fue B-DERIVED_FROM/TO
	derivado I-DERIVED_FROM/TO
	a I-DERIVED_FROM/TO
	un I-DERIVED_FROM/TO
	médico I-DERIVED_FROM/TO
	nefrólogo, I-DERIVED_FROM/TO
	quien I-DERIVED_FROM/TO
	solicitó I-DERIVED_FROM/TO
	estudios I-DERIVED_FROM/TO
	de I-DERIVED_FROM/TO
	laboratorio I-DERIVED_FROM/TO
	cuyos I-DERIVED_FROM/TO
	resultados I-DERIVED_FROM/TO
	mostraron I-DERIVED_FROM/TO
	marcada I-DERIVED_FROM/TO
	hipoproteinemia I-DERIVED_FROM/TO
	e I-DERIVED_FROM/TO
	hipoalbuminemia, I-DERIVED_FROM/TO
	hipertrigliceridemia, I-DERIVED_FROM/TO
	hipocalcemia I-DERIVED_FROM/TO
	leve I-DERIVED_FROM/TO
	y I-DERIVED_FROM/TO
	orina I-DERIVED_FROM/TO
	normal. I-DERIVED_FROM/TO
	Se I-DERIVED_FROM/TO
	trasladó I-DERIVED_FROM/TO
	al I-DERIVED_FROM/TO
	niño I-DERIVED_FROM/TO
	a I-DERIVED_FROM/TO
	nuestro I-DERIVED_FROM/TO
	hospital I-DERIVED_FROM/TO
	para I-DERIVED_FROM/TO
	su I-DERIVED_FROM/TO
	diagnóstico I-DERIVED_FROM/TO
	y I-DERIVED_FROM/TO
	tratamiento. I-DERIVED_FROM/TO
	<EOS> I-DERIVED_FROM/TO
	Examen B-EXPLORATION
	físico: I-EXPLORATION
	niño I-EXPLORATION
	lúcido, I-EXPLORATION
	vigil, I-EXPLORATION
	orientado, I-EXPLORATION
	irritable. I-EXPLORATION
	TA I-EXPLORATION
	109/78 I-EXPLORATION
	mm I-EXPLORATION
	Hg, I-EXPLORATION
	TAM I-EXPLORATION
	92 I-EXPLORATION
	mm I-EXPLORATION
	Hg, I-EXPLORATION
	FC I-EXPLORATION
	130 I-EXPLORATION
	lpm, I-EXPLORATION
	FR I-EXPLORATION
	32 I-EXPLORATION
	rpm, I-EXPLORATION
	temperatura I-EXPLORATION
	36, I-EXPLORATION
	7°C, I-EXPLORATION
	saturación I-EXPLORATION
	de I-EXPLORATION
	O2 I-EXPLORATION
	96% I-EXPLORATION
	respirando I-EXPLORATION
	aire I-EXPLORATION
	ambiente. I-EXPLORATION
	Peso I-EXPLORATION
	14, I-EXPLORATION
	600 I-EXPLORATION
	kg, I-EXPLORATION
	palidez I-EXPLORATION
	generalizada, I-EXPLORATION
	facies I-EXPLORATION
	abotagada. I-EXPLORATION
	Edema I-EXPLORATION
	palpebral I-EXPLORATION
	bilateral. I-EXPLORATION
	Algunos I-EXPLORATION
	crepitantes I-EXPLORATION
	basales I-EXPLORATION
	en I-EXPLORATION
	ambos I-EXPLORATION
	campos I-EXPLORATION
	pulmonares. I-EXPLORATION
	Edema I-EXPLORATION
	pretibial I-EXPLORATION
	bilateral. I-EXPLORATION
	Abdomen I-EXPLORATION
	globuloso, I-EXPLORATION
	distendido, I-EXPLORATION
	onda I-EXPLORATION
	ascítica I-EXPLORATION
	positiva, I-EXPLORATION
	sin I-EXPLORATION
	hepatoesplenomegalia. I-EXPLORATION
	Edema I-EXPLORATION
	escrotal I-EXPLORATION
	y I-EXPLORATION
	suprapúbico. I-EXPLORATION
	El I-EXPLORATION
	resto I-EXPLORATION
	del I-EXPLORATION
	examen I-EXPLORATION
	no I-EXPLORATION
	presentó I-EXPLORATION
	particularidades. I-EXPLORATION
	<EOS> I-EXPLORATION
	Laboratorio I-EXPLORATION
	inicial: I-EXPLORATION
	leucocitos: I-EXPLORATION
	17 I-EXPLORATION
	700/mm3, I-EXPLORATION
	fórmula: I-EXPLORATION
	27% I-EXPLORATION
	neutrófilos, I-EXPLORATION
	14% I-EXPLORATION
	eosinófilos, I-EXPLORATION
	49% I-EXPLORATION
	linfocitos, I-EXPLORATION
	6% I-EXPLORATION
	monocitos I-EXPLORATION
	y I-EXPLORATION
	4% I-EXPLORATION
	linfocitos I-EXPLORATION
	atípicos. I-EXPLORATION
	Calcio I-EXPLORATION
	total I-EXPLORATION
	7, I-EXPLORATION
	4 I-EXPLORATION
	mmol/L I-EXPLORATION
	(VN I-EXPLORATION
	8, I-EXPLORATION
	5-10), I-EXPLORATION
	proteínas I-EXPLORATION
	totales I-EXPLORATION
	3 I-EXPLORATION
	g/dl I-EXPLORATION
	(VN I-EXPLORATION
	6, I-EXPLORATION
	6-8, I-EXPLORATION
	7), I-EXPLORATION
	albúmina I-EXPLORATION
	1, I-EXPLORATION
	6 I-EXPLORATION
	g/dl I-EXPLORATION
	(VN I-EXPLORATION
	3, I-EXPLORATION
	5-3), I-EXPLORATION
	IgG I-EXPLORATION
	136 I-EXPLORATION
	mg/dl I-EXPLORATION
	(VN I-EXPLORATION
	490-1450), I-EXPLORATION
	IgE I-EXPLORATION
	140 I-EXPLORATION
	UI/ I-EXPLORATION
	ml I-EXPLORATION
	(VN I-EXPLORATION
	hasta I-EXPLORATION
	75), I-EXPLORATION
	triglicéridos I-EXPLORATION
	196 I-EXPLORATION
	mg/dl I-EXPLORATION
	(N I-EXPLORATION
	< I-EXPLORATION
	150), I-EXPLORATION
	TGO I-EXPLORATION
	62 I-EXPLORATION
	U/L I-EXPLORATION
	(VN I-EXPLORATION
	< I-EXPLORATION
	37), I-EXPLORATION
	TGP I-EXPLORATION
	43 I-EXPLORATION
	U/L I-EXPLORATION
	(VN I-EXPLORATION
	< I-EXPLORATION
	41), I-EXPLORATION
	<EOS> I-EXPLORATION
	colesterol I-EXPLORATION
	total I-EXPLORATION
	129 I-EXPLORATION
	mg/dl I-EXPLORATION
	(VN I-EXPLORATION
	< I-EXPLORATION
	200), I-EXPLORATION
	HDL I-EXPLORATION
	25 I-EXPLORATION
	mg/ I-EXPLORATION
	dl I-EXPLORATION
	(VN I-EXPLORATION
	> I-EXPLORATION
	35). I-EXPLORATION
	PCR I-EXPLORATION
	1, I-EXPLORATION
	3mg/dl I-EXPLORATION
	(VN I-EXPLORATION
	< I-EXPLORATION
	0, I-EXPLORATION
	06). I-EXPLORATION
	Orina I-EXPLORATION
	normal I-EXPLORATION
	sin I-EXPLORATION
	proteinuria. I-EXPLORATION
	Relación I-EXPLORATION
	Prot/Cr I-EXPLORATION
	0, I-EXPLORATION
	26. I-EXPLORATION
	Hormonas I-EXPLORATION
	tiroideas I-EXPLORATION
	normales I-EXPLORATION
	y I-EXPLORATION
	anticuerpos I-EXPLORATION
	para I-EXPLORATION
	enfermedad I-EXPLORATION
	celíaca I-EXPLORATION
	negativos. I-EXPLORATION
	Prueba I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	tuberculina I-EXPLORATION
	negativa. I-EXPLORATION
	<EOS> I-EXPLORATION
	Al B-EVOLUTION
	segundo I-EVOLUTION
	día I-EVOLUTION
	de I-EVOLUTION
	internación, I-EVOLUTION
	el I-EVOLUTION
	niño I-EVOLUTION
	presentó I-EVOLUTION
	dos I-EVOLUTION
	picos I-EVOLUTION
	febriles, I-EVOLUTION
	fauces I-EVOLUTION
	congestivas, I-EVOLUTION
	subcrepitantes I-EVOLUTION
	pulmonares I-EVOLUTION
	bibasales I-EVOLUTION
	leves. I-EVOLUTION
	Radiografía B-EXPLORATION
	de I-EXPLORATION
	tórax I-EXPLORATION
	y I-EXPLORATION
	ecografía I-EXPLORATION
	renal I-EXPLORATION
	sin I-EXPLORATION
	particularidades. I-EXPLORATION
	Ecografía I-EXPLORATION
	abdominal I-EXPLORATION
	sin I-EXPLORATION
	visceromegalia, I-EXPLORATION
	con I-EXPLORATION
	líquido I-EXPLORATION
	ascítico I-EXPLORATION
	moderado, I-EXPLORATION
	mucosa I-EXPLORATION
	gástrica I-EXPLORATION
	sin I-EXPLORATION
	agrandamiento I-EXPLORATION
	ni I-EXPLORATION
	hipertrofia I-EXPLORATION
	de I-EXPLORATION
	pliegues. I-EXPLORATION
	<EOS> I-EXPLORATION
	Se I-EXPLORATION
	descartó I-EXPLORATION
	la I-EXPLORATION
	etiología I-EXPLORATION
	cardiovascular, I-EXPLORATION
	renal I-EXPLORATION
	o I-EXPLORATION
	hepática I-EXPLORATION
	por I-EXPLORATION
	la I-EXPLORATION
	clínica I-EXPLORATION
	y I-EXPLORATION
	los I-EXPLORATION
	estudios I-EXPLORATION
	realizados. I-EXPLORATION
	<EOS> I-EXPLORATION
	Ante I-EXPLORATION
	la I-EXPLORATION
	sospecha I-EXPLORATION
	de I-EXPLORATION
	gastroenteropatía I-EXPLORATION
	perdedora I-EXPLORATION
	de I-EXPLORATION
	proteínas, I-EXPLORATION
	se I-EXPLORATION
	realizó I-EXPLORATION
	una I-EXPLORATION
	endoscopia I-EXPLORATION
	esofagogastroduodenal I-EXPLORATION
	con I-EXPLORATION
	biopsia, I-EXPLORATION
	cuyo I-EXPLORATION
	informe I-EXPLORATION
	reveló: I-EXPLORATION
	esófago I-EXPLORATION
	con I-EXPLORATION
	cambio I-EXPLORATION
	mucoso I-EXPLORATION
	a I-EXPLORATION
	23 I-EXPLORATION
	cm, I-EXPLORATION
	mucosa I-EXPLORATION
	pálida I-EXPLORATION
	y I-EXPLORATION
	muy I-EXPLORATION
	edematosa; I-EXPLORATION
	estómago I-EXPLORATION
	con I-EXPLORATION
	presencia I-EXPLORATION
	de I-EXPLORATION
	pliegues I-EXPLORATION
	engrosados, I-EXPLORATION
	seudopólipos I-EXPLORATION
	y I-EXPLORATION
	erosiones I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	mucosa. I-EXPLORATION
	Duodeno I-EXPLORATION
	con I-EXPLORATION
	pliegues I-EXPLORATION
	engrosados I-EXPLORATION
	y I-EXPLORATION
	mucosa I-EXPLORATION
	edematosa. I-EXPLORATION
	El I-EXPLORATION
	informe I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	biopsia I-EXPLORATION
	correspondió I-EXPLORATION
	a I-EXPLORATION
	esofagitis, I-EXPLORATION
	gastritis I-EXPLORATION
	y I-EXPLORATION
	duodenitis I-EXPLORATION
	crónica I-EXPLORATION
	leve I-EXPLORATION
	a I-EXPLORATION
	moderada I-EXPLORATION
	con I-EXPLORATION
	frecuentes I-EXPLORATION
	eosinófilos. I-EXPLORATION
	No I-EXPLORATION
	se I-EXPLORATION
	realizó I-EXPLORATION
	depuración I-EXPLORATION
	de I-EXPLORATION
	α1-antitripsina I-EXPLORATION
	por I-EXPLORATION
	la I-EXPLORATION
	falta I-EXPLORATION
	de I-EXPLORATION
	accesibilidad I-EXPLORATION
	al I-EXPLORATION
	método. I-EXPLORATION
	<EOS> I-EXPLORATION
	Se I-EXPLORATION
	solicitó I-EXPLORATION
	en I-EXPLORATION
	sangre, I-EXPLORATION
	IgM-IgG I-EXPLORATION
	para I-EXPLORATION
	CMV: I-EXPLORATION
	positivo; I-EXPLORATION
	antígeno I-EXPLORATION
	temprano: I-EXPLORATION
	reactivo; I-EXPLORATION
	PCR: I-EXPLORATION
	2075 I-EXPLORATION
	copias I-EXPLORATION
	(no I-EXPLORATION
	reactivo I-EXPLORATION
	< I-EXPLORATION
	750 I-EXPLORATION
	copias). I-EXPLORATION
	No I-EXPLORATION
	se I-EXPLORATION
	analizó I-EXPLORATION
	material I-EXPLORATION
	de I-EXPLORATION
	biopsia I-EXPLORATION
	para I-EXPLORATION
	la I-EXPLORATION
	detección I-EXPLORATION
	del I-EXPLORATION
	virus. I-EXPLORATION
	<EOS> I-EXPLORATION
	El B-TREATMENT
	paciente I-TREATMENT
	fue I-TREATMENT
	sometido I-TREATMENT
	a I-TREATMENT
	una I-TREATMENT
	dieta I-TREATMENT
	hiperproteica I-TREATMENT
	y I-TREATMENT
	gastroprotectora. I-TREATMENT
	Recibió I-TREATMENT
	una I-TREATMENT
	infusión I-TREATMENT
	intravenosa I-TREATMENT
	de I-TREATMENT
	albúmina I-TREATMENT
	(25% I-TREATMENT
	1 I-TREATMENT
	g/ I-TREATMENT
	kg, I-TREATMENT
	una I-TREATMENT
	dosis), I-TREATMENT
	omeprazol I-TREATMENT
	20 I-TREATMENT
	mg/día I-TREATMENT
	por I-TREATMENT
	vía I-TREATMENT
	intravenosa I-TREATMENT
	y I-TREATMENT
	espironolactona I-TREATMENT
	3 I-TREATMENT
	mg/kg/día I-TREATMENT
	por I-TREATMENT
	vía I-TREATMENT
	oral. I-TREATMENT
	Al I-TREATMENT
	no I-TREATMENT
	mejorar I-TREATMENT
	clínicamente, I-TREATMENT
	a I-TREATMENT
	los I-TREATMENT
	6 I-TREATMENT
	días I-TREATMENT
	se I-TREATMENT
	comenzó I-TREATMENT
	la I-TREATMENT
	administración I-TREATMENT
	de I-TREATMENT
	ganciclovir I-TREATMENT
	por I-TREATMENT
	vía I-TREATMENT
	intravenosa I-TREATMENT
	(5 I-TREATMENT
	mg/kg I-TREATMENT
	cada I-TREATMENT
	12 I-TREATMENT
	horas). I-TREATMENT
	A I-TREATMENT
	las I-TREATMENT
	48 I-TREATMENT
	horas I-TREATMENT
	se I-TREATMENT
	rotó I-TREATMENT
	a I-TREATMENT
	valganciclovir I-TREATMENT
	oral I-TREATMENT
	(400 I-TREATMENT
	mg/día) I-TREATMENT
	por I-TREATMENT
	la I-TREATMENT
	imposibilidad I-TREATMENT
	de I-TREATMENT
	mantener I-TREATMENT
	la I-TREATMENT
	venoclisis. I-TREATMENT
	<EOS> I-TREATMENT
	A B-EVOLUTION
	los I-EVOLUTION
	10 I-EVOLUTION
	días I-EVOLUTION
	de I-EVOLUTION
	internación, I-EVOLUTION
	dada I-EVOLUTION
	la I-EVOLUTION
	buena I-EVOLUTION
	evolución, I-EVOLUTION
	se I-EVOLUTION
	le I-EVOLUTION
	otorgó I-EVOLUTION
	el I-EVOLUTION
	alta I-EVOLUTION
	hospitalaria. I-EVOLUTION
	Laboratorio B-EXPLORATION
	al I-EXPLORATION
	alta: I-EXPLORATION
	proteínas I-EXPLORATION
	totales I-EXPLORATION
	4, I-EXPLORATION
	6 I-EXPLORATION
	g/ I-EXPLORATION
	dl I-EXPLORATION
	(VN I-EXPLORATION
	6, I-EXPLORATION
	6-8, I-EXPLORATION
	7), I-EXPLORATION
	albúmina I-EXPLORATION
	2, I-EXPLORATION
	6 I-EXPLORATION
	g/dl I-EXPLORATION
	(VN I-EXPLORATION
	3, I-EXPLORATION
	5-5), I-EXPLORATION
	triglicéridos I-EXPLORATION
	254 I-EXPLORATION
	mg/dl I-EXPLORATION
	(VN I-EXPLORATION
	< I-EXPLORATION
	150). I-EXPLORATION
	Carga I-EXPLORATION
	viral I-EXPLORATION
	para I-EXPLORATION
	CMV I-EXPLORATION
	< I-EXPLORATION
	750 I-EXPLORATION
	copias. I-EXPLORATION
	Se B-TREATMENT
	indicó I-TREATMENT
	continuar I-TREATMENT
	con I-TREATMENT
	dieta I-TREATMENT
	hiperproteica, I-TREATMENT
	protectores I-TREATMENT
	gástricos I-TREATMENT
	y I-TREATMENT
	valganciclovir I-TREATMENT
	por I-TREATMENT
	vía I-TREATMENT
	oral I-TREATMENT
	hasta I-TREATMENT
	completar I-TREATMENT
	6 I-TREATMENT
	semanas I-TREATMENT
	de I-TREATMENT
	tratamiento. I-TREATMENT
	Cuatro B-EXPLORATION
	meses I-EXPLORATION
	después, I-EXPLORATION
	se I-EXPLORATION
	repitió I-EXPLORATION
	la I-EXPLORATION
	endoscopia I-EXPLORATION
	esofagogastroduodenal, I-EXPLORATION
	cuyo I-EXPLORATION
	resultado I-EXPLORATION
	fue I-EXPLORATION
	normal. I-EXPLORATION
	<EOS> I-EXPLORATION

	Niña B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	3 I-PRESENT_ILLNESS
	meses I-PRESENT_ILLNESS
	con I-PRESENT_ILLNESS
	lesión I-PRESENT_ILLNESS
	eritematosa I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	antifaz, I-PRESENT_ILLNESS
	pequeñas I-PRESENT_ILLNESS
	placas I-PRESENT_ILLNESS
	redondeadas, I-PRESENT_ILLNESS
	ligeramente I-PRESENT_ILLNESS
	atróficas I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	región I-PRESENT_ILLNESS
	temporooccipital I-PRESENT_ILLNESS
	bilateral I-PRESENT_ILLNESS
	y I-PRESENT_ILLNESS
	cuello I-PRESENT_ILLNESS
	y I-PRESENT_ILLNESS
	finas I-PRESENT_ILLNESS
	telangiectasias I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	su I-PRESENT_ILLNESS
	superficie. I-PRESENT_ILLNESS
	En I-PRESENT_ILLNESS
	región I-PRESENT_ILLNESS
	genital, I-PRESENT_ILLNESS
	lesión I-PRESENT_ILLNESS
	eritematosa, I-PRESENT_ILLNESS
	atrófica, I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	bordes I-PRESENT_ILLNESS
	definidos I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	2 I-PRESENT_ILLNESS
	meses I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	evolución. I-PRESENT_ILLNESS
	<EOS> I-PRESENT_ILLNESS
	Madre B-FAMILY_HISTORY
	con I-FAMILY_HISTORY
	alopecia I-FAMILY_HISTORY
	cicatrizal, I-FAMILY_HISTORY
	ojo I-FAMILY_HISTORY
	seco, I-FAMILY_HISTORY
	boca I-FAMILY_HISTORY
	seca I-FAMILY_HISTORY
	y I-FAMILY_HISTORY
	anemia, I-FAMILY_HISTORY
	sin I-FAMILY_HISTORY
	diagnóstico I-FAMILY_HISTORY
	de I-FAMILY_HISTORY
	su I-FAMILY_HISTORY
	enfermedad I-FAMILY_HISTORY
	al I-FAMILY_HISTORY
	momento I-FAMILY_HISTORY
	de I-FAMILY_HISTORY
	la I-FAMILY_HISTORY
	consulta. I-FAMILY_HISTORY
	<EOS> I-FAMILY_HISTORY
	Exámenes B-EXPLORATION
	complementarios: I-EXPLORATION
	Hb I-EXPLORATION
	11, I-EXPLORATION
	2g/dl, I-EXPLORATION
	Hto I-EXPLORATION
	33%, I-EXPLORATION
	TGO I-EXPLORATION
	265 I-EXPLORATION
	UI/L, I-EXPLORATION
	TGP I-EXPLORATION
	212 I-EXPLORATION
	UI/L, I-EXPLORATION
	FAL I-EXPLORATION
	927 I-EXPLORATION
	UI/L, I-EXPLORATION
	C3 I-EXPLORATION
	54 I-EXPLORATION
	mg/dl, I-EXPLORATION
	C4 I-EXPLORATION
	2 I-EXPLORATION
	mg/dl, I-EXPLORATION
	FAN I-EXPLORATION
	+ I-EXPLORATION
	1/1000 I-EXPLORATION
	patrón I-EXPLORATION
	moteado I-EXPLORATION
	grueso I-EXPLORATION
	y I-EXPLORATION
	anti I-EXPLORATION
	La I-EXPLORATION
	positivo I-EXPLORATION
	(paciente), I-EXPLORATION
	FAN I-EXPLORATION
	+ I-EXPLORATION
	1/2000 I-EXPLORATION
	patrón I-EXPLORATION
	homogéneo I-EXPLORATION
	y I-EXPLORATION
	anti I-EXPLORATION
	La I-EXPLORATION
	y I-EXPLORATION
	anti I-EXPLORATION
	Ro I-EXPLORATION
	positivos I-EXPLORATION
	(madre) I-EXPLORATION
	<EOS> I-EXPLORATION
	Estudio I-EXPLORATION
	histopatológico: I-EXPLORATION
	capa I-EXPLORATION
	córnea I-EXPLORATION
	engrosada, I-EXPLORATION
	epidermis I-EXPLORATION
	adelgazada, I-EXPLORATION
	intensa I-EXPLORATION
	vacuolización I-EXPLORATION
	de I-EXPLORATION
	queratinocitos I-EXPLORATION
	basales, I-EXPLORATION
	en I-EXPLORATION
	dermis I-EXPLORATION
	infiltrado I-EXPLORATION
	mononuclear I-EXPLORATION
	difuso. I-EXPLORATION
	Membrana I-EXPLORATION
	basal I-EXPLORATION
	engrosada. I-EXPLORATION
	IFD I-EXPLORATION
	negativa. I-EXPLORATION
	<EOS> I-EXPLORATION
	Valoración I-EXPLORATION
	cardiológica I-EXPLORATION
	normal. I-EXPLORATION
	<EOS> I-EXPLORATION
	Tratamiento: B-TREATMENT
	Hidrocortisona I-TREATMENT
	1% I-TREATMENT
	tópico, I-TREATMENT
	Pimecrolimus I-TREATMENT
	1%. I-TREATMENT
	Desaparición B-EVOLUTION
	de I-EVOLUTION
	las I-EVOLUTION
	lesiones I-EVOLUTION
	eritematosas I-EVOLUTION
	a I-EVOLUTION
	los I-EVOLUTION
	15 I-EVOLUTION
	días I-EVOLUTION
	y I-EVOLUTION
	persistencia I-EVOLUTION
	de I-EVOLUTION
	lesiones I-EVOLUTION
	atróficas I-EVOLUTION
	con I-EVOLUTION
	puntillado I-EVOLUTION
	petequial I-EVOLUTION
	en I-EVOLUTION
	cuero I-EVOLUTION
	cabelludo, I-EVOLUTION
	normalizando I-EVOLUTION
	las I-EVOLUTION
	enzimas I-EVOLUTION
	hepáticas I-EVOLUTION
	a I-EVOLUTION
	los I-EVOLUTION
	10 I-EVOLUTION
	meses I-EVOLUTION
	de I-EVOLUTION
	vida. I-EVOLUTION
	<EOS> I-EVOLUTION
	Luego, I-EVOLUTION
	a I-EVOLUTION
	la I-EVOLUTION
	madre I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	paciente I-EVOLUTION
	se I-EVOLUTION
	le I-EVOLUTION
	realizó I-EVOLUTION
	diagnóstico I-EVOLUTION
	de I-EVOLUTION
	Síndrome I-EVOLUTION
	(Sme.) I-EVOLUTION
	de I-EVOLUTION
	Sjögren. I-EVOLUTION
	<EOS> I-EVOLUTION

	Paciente B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	77 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	que I-PRESENT_ILLNESS
	acude I-PRESENT_ILLNESS
	al I-PRESENT_ILLNESS
	servicio I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	urgencias I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	dolor I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	ambos I-PRESENT_ILLNESS
	ojos I-PRESENT_ILLNESS
	(AO), I-PRESENT_ILLNESS
	sin I-PRESENT_ILLNESS
	pérdida I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	agudeza I-PRESENT_ILLNESS
	visual I-PRESENT_ILLNESS
	(AV). I-PRESENT_ILLNESS
	Asimismo, I-PRESENT_ILLNESS
	comenta I-PRESENT_ILLNESS
	que I-PRESENT_ILLNESS
	lleva I-PRESENT_ILLNESS
	unos I-PRESENT_ILLNESS
	días I-PRESENT_ILLNESS
	notando I-PRESENT_ILLNESS
	molestias I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	manera I-PRESENT_ILLNESS
	alterna I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	uno I-PRESENT_ILLNESS
	y I-PRESENT_ILLNESS
	otro I-PRESENT_ILLNESS
	ojo. I-PRESENT_ILLNESS
	<EOS> B-FAMILY_HISTORY
	No I-FAMILY_HISTORY
	presenta I-FAMILY_HISTORY
	antecedentes I-FAMILY_HISTORY
	familiares I-FAMILY_HISTORY
	de I-FAMILY_HISTORY
	interés I-FAMILY_HISTORY
	y B-PAST_MEDICAL_HISTORY
	entre I-PAST_MEDICAL_HISTORY
	los I-PAST_MEDICAL_HISTORY
	personales I-PAST_MEDICAL_HISTORY
	destaca I-PAST_MEDICAL_HISTORY
	una I-PAST_MEDICAL_HISTORY
	cardiopatía I-PAST_MEDICAL_HISTORY
	isquémica I-PAST_MEDICAL_HISTORY
	hace I-PAST_MEDICAL_HISTORY
	3 I-PAST_MEDICAL_HISTORY
	años I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	tratamiento I-PAST_MEDICAL_HISTORY
	con: I-PAST_MEDICAL_HISTORY
	Pravastatina I-PAST_MEDICAL_HISTORY
	10 I-PAST_MEDICAL_HISTORY
	mg/24 I-PAST_MEDICAL_HISTORY
	horas, I-PAST_MEDICAL_HISTORY
	Atenolol I-PAST_MEDICAL_HISTORY
	50 I-PAST_MEDICAL_HISTORY
	mg/12 I-PAST_MEDICAL_HISTORY
	horas, I-PAST_MEDICAL_HISTORY
	Ranipril I-PAST_MEDICAL_HISTORY
	2, I-PAST_MEDICAL_HISTORY
	5 I-PAST_MEDICAL_HISTORY
	mg/12 I-PAST_MEDICAL_HISTORY
	horas, I-PAST_MEDICAL_HISTORY
	Acido I-PAST_MEDICAL_HISTORY
	acetilsalicílico I-PAST_MEDICAL_HISTORY
	100 I-PAST_MEDICAL_HISTORY
	mg/24 I-PAST_MEDICAL_HISTORY
	horas I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	Lorazepam I-PAST_MEDICAL_HISTORY
	1 I-PAST_MEDICAL_HISTORY
	mg/24 I-PAST_MEDICAL_HISTORY
	horas. I-PAST_MEDICAL_HISTORY
	<EOS> I-PAST_MEDICAL_HISTORY
	Como B-PRESENT_ILLNESS
	antecedente I-PRESENT_ILLNESS
	personal I-PRESENT_ILLNESS
	más I-PRESENT_ILLNESS
	próximo, I-PRESENT_ILLNESS
	señalar I-PRESENT_ILLNESS
	que I-PRESENT_ILLNESS
	dos I-PRESENT_ILLNESS
	semanas I-PRESENT_ILLNESS
	antes I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	empezar I-PRESENT_ILLNESS
	con I-PRESENT_ILLNESS
	los I-PRESENT_ILLNESS
	problemas I-PRESENT_ILLNESS
	oculares I-PRESENT_ILLNESS
	había I-PRESENT_ILLNESS
	sido I-PRESENT_ILLNESS
	ingresada I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	el I-PRESENT_ILLNESS
	servicio I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	medicina I-PRESENT_ILLNESS
	interna I-PRESENT_ILLNESS
	con I-PRESENT_ILLNESS
	el I-PRESENT_ILLNESS
	diagnóstico I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	Neumonía I-PRESENT_ILLNESS
	neumocócica I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	lóbulo I-PRESENT_ILLNESS
	superior I-PRESENT_ILLNESS
	derecho I-PRESENT_ILLNESS
	tratada I-PRESENT_ILLNESS
	con I-PRESENT_ILLNESS
	Moxifloxacino I-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	dosis I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	400 I-PRESENT_ILLNESS
	mg/24 I-PRESENT_ILLNESS
	horas I-PRESENT_ILLNESS
	durante I-PRESENT_ILLNESS
	10 I-PRESENT_ILLNESS
	días, I-PRESENT_ILLNESS
	con I-PRESENT_ILLNESS
	buena I-PRESENT_ILLNESS
	respuesta. I-PRESENT_ILLNESS
	Tras I-PRESENT_ILLNESS
	el I-PRESENT_ILLNESS
	alta I-PRESENT_ILLNESS
	hospitalaria, I-PRESENT_ILLNESS
	ya I-PRESENT_ILLNESS
	sin I-PRESENT_ILLNESS
	tratamiento I-PRESENT_ILLNESS
	antibiótico, I-PRESENT_ILLNESS
	la I-PRESENT_ILLNESS
	paciente I-PRESENT_ILLNESS
	comienza I-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	referir I-PRESENT_ILLNESS
	molestias I-PRESENT_ILLNESS
	oculares I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	manera I-PRESENT_ILLNESS
	alterna I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	AO. I-PRESENT_ILLNESS
	<EOS> I-PRESENT_ILLNESS
	En B-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	oftalmológica I-EXPLORATION
	se I-EXPLORATION
	objetiva I-EXPLORATION
	una I-EXPLORATION
	AV I-EXPLORATION
	en I-EXPLORATION
	ojo I-EXPLORATION
	derecho I-EXPLORATION
	(OD) I-EXPLORATION
	de I-EXPLORATION
	0, I-EXPLORATION
	6 I-EXPLORATION
	que I-EXPLORATION
	mejora I-EXPLORATION
	a I-EXPLORATION
	0, I-EXPLORATION
	8 I-EXPLORATION
	con I-EXPLORATION
	corrección I-EXPLORATION
	y I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	ojo I-EXPLORATION
	izquierdo I-EXPLORATION
	(OI) I-EXPLORATION
	de I-EXPLORATION
	0, I-EXPLORATION
	3 I-EXPLORATION
	que I-EXPLORATION
	mejora I-EXPLORATION
	a I-EXPLORATION
	0, I-EXPLORATION
	6 I-EXPLORATION
	con I-EXPLORATION
	corrección. I-EXPLORATION
	<EOS> I-EXPLORATION
	En I-EXPLORATION
	el I-EXPLORATION
	segmento I-EXPLORATION
	anterior I-EXPLORATION
	destaca I-EXPLORATION
	una I-EXPLORATION
	reacción I-EXPLORATION
	inflamatoria I-EXPLORATION
	en I-EXPLORATION
	cámara I-EXPLORATION
	anterior I-EXPLORATION
	de I-EXPLORATION
	AO I-EXPLORATION
	(Fenómeno I-EXPLORATION
	de I-EXPLORATION
	tyndall I-EXPLORATION
	de I-EXPLORATION
	células I-EXPLORATION
	+1 I-EXPLORATION
	y I-EXPLORATION
	proteínas I-EXPLORATION
	+1), I-EXPLORATION
	y I-EXPLORATION
	una I-EXPLORATION
	fuerte I-EXPLORATION
	dispersión I-EXPLORATION
	de I-EXPLORATION
	pigmento I-EXPLORATION
	(+/++) I-EXPLORATION
	que I-EXPLORATION
	se I-EXPLORATION
	deposita I-EXPLORATION
	en I-EXPLORATION
	todas I-EXPLORATION
	las I-EXPLORATION
	estructuras: I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	endotelio I-EXPLORATION
	corneal I-EXPLORATION
	de I-EXPLORATION
	forma I-EXPLORATION
	difusa, I-EXPLORATION
	sobre I-EXPLORATION
	el I-EXPLORATION
	iris, I-EXPLORATION
	sinequias I-EXPLORATION
	posteriores I-EXPLORATION
	y I-EXPLORATION
	malla I-EXPLORATION
	trabecular. I-EXPLORATION
	<EOS> I-EXPLORATION
	La I-EXPLORATION
	tensión I-EXPLORATION
	ocular I-EXPLORATION
	era I-EXPLORATION
	de I-EXPLORATION
	9 I-EXPLORATION
	mm I-EXPLORATION
	Hg I-EXPLORATION
	en I-EXPLORATION
	OD I-EXPLORATION
	y I-EXPLORATION
	8 I-EXPLORATION
	mmHg I-EXPLORATION
	en I-EXPLORATION
	OI. I-EXPLORATION
	El I-EXPLORATION
	fondo I-EXPLORATION
	de I-EXPLORATION
	ojo, I-EXPLORATION
	bajo I-EXPLORATION
	midriasis I-EXPLORATION
	farmacológica, I-EXPLORATION
	era I-EXPLORATION
	normal, I-EXPLORATION
	y I-EXPLORATION
	no I-EXPLORATION
	se I-EXPLORATION
	apreció I-EXPLORATION
	reacción I-EXPLORATION
	inflamatoria I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	cámara I-EXPLORATION
	vítrea. I-EXPLORATION
	<EOS> I-EXPLORATION
	Se I-EXPLORATION
	realizó I-EXPLORATION
	una I-EXPLORATION
	historia I-EXPLORATION
	clínica, I-EXPLORATION
	dentro I-EXPLORATION
	del I-EXPLORATION
	protocolo I-EXPLORATION
	de I-EXPLORATION
	uveítis I-EXPLORATION
	seguido I-EXPLORATION
	en I-EXPLORATION
	nuestro I-EXPLORATION
	departamento, I-EXPLORATION
	que I-EXPLORATION
	incluyó I-EXPLORATION
	una I-EXPLORATION
	anamnesis I-EXPLORATION
	por I-EXPLORATION
	aparatos I-EXPLORATION
	y I-EXPLORATION
	la I-EXPLORATION
	solicitud I-EXPLORATION
	de I-EXPLORATION
	las I-EXPLORATION
	exploraciones I-EXPLORATION
	complementarias I-EXPLORATION
	dirigidas, I-EXPLORATION
	sistemático I-EXPLORATION
	de I-EXPLORATION
	sangre, I-EXPLORATION
	bioquímica, I-EXPLORATION
	VDRL, I-EXPLORATION
	FTA-abs I-EXPLORATION
	y I-EXPLORATION
	placa I-EXPLORATION
	de I-EXPLORATION
	tórax. I-EXPLORATION
	<EOS> I-EXPLORATION
	Se B-TREATMENT
	inició I-TREATMENT
	tratamiento I-TREATMENT
	con I-TREATMENT
	midriáticos I-TREATMENT
	y I-TREATMENT
	corticoides I-TREATMENT
	tópicos I-TREATMENT
	cediendo B-EXPLORATION
	el I-EXPLORATION
	cuadro I-EXPLORATION
	en I-EXPLORATION
	pocos I-EXPLORATION
	días, I-EXPLORATION
	manteniéndose, I-EXPLORATION
	en I-EXPLORATION
	las I-EXPLORATION
	sucesivas I-EXPLORATION
	revisiones, I-EXPLORATION
	la I-EXPLORATION
	presencia I-EXPLORATION
	de I-EXPLORATION
	pigmento I-EXPLORATION
	en I-EXPLORATION
	numerosas I-EXPLORATION
	estructuras I-EXPLORATION
	del I-EXPLORATION
	segmento I-EXPLORATION
	anterior I-EXPLORATION
	y I-EXPLORATION
	manteniendo I-EXPLORATION
	una I-EXPLORATION
	presión I-EXPLORATION
	intraocular I-EXPLORATION
	de I-EXPLORATION
	14 I-EXPLORATION
	mmHg I-EXPLORATION
	en I-EXPLORATION
	AO. I-EXPLORATION
	<EOS> I-EXPLORATION
	Las I-EXPLORATION
	exploraciones I-EXPLORATION
	complementarias I-EXPLORATION
	realizadas I-EXPLORATION
	no I-EXPLORATION
	detectaron I-EXPLORATION
	ninguna I-EXPLORATION
	alteración I-EXPLORATION
	significativa. I-EXPLORATION
	<EOS> I-EXPLORATION

	Mujer B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	18 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	sin B-PAST_MEDICAL_HISTORY
	antecedentes I-PAST_MEDICAL_HISTORY
	personales I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	interés, I-PAST_MEDICAL_HISTORY
	que B-PRESENT_ILLNESS
	acudió I-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	urgencias I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	cefalea I-PRESENT_ILLNESS
	holocraneal I-PRESENT_ILLNESS
	con I-PRESENT_ILLNESS
	fiebre I-PRESENT_ILLNESS
	y I-PRESENT_ILLNESS
	vómitos. I-PRESENT_ILLNESS
	<EOS> I-PRESENT_ILLNESS
	A B-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	neurológica I-EXPLORATION
	presentaba I-EXPLORATION
	hipoestesia I-EXPLORATION
	de I-EXPLORATION
	miembro I-EXPLORATION
	superior I-EXPLORATION
	derecho I-EXPLORATION
	y I-EXPLORATION
	dudosa I-EXPLORATION
	rigidez I-EXPLORATION
	de I-EXPLORATION
	nuca, I-EXPLORATION
	sin I-EXPLORATION
	otros I-EXPLORATION
	signos I-EXPLORATION
	meníngeos. I-EXPLORATION
	<EOS> I-EXPLORATION
	La I-EXPLORATION
	tomografía I-EXPLORATION
	axial I-EXPLORATION
	computarizada I-EXPLORATION
	(TAC) I-EXPLORATION
	cerebral I-EXPLORATION
	era I-EXPLORATION
	normal, I-EXPLORATION
	el I-EXPLORATION
	análisis I-EXPLORATION
	del I-EXPLORATION
	líquido I-EXPLORATION
	cefalorraquídeo I-EXPLORATION
	(LCR) I-EXPLORATION
	mostró I-EXPLORATION
	hiperproteinorraquia, I-EXPLORATION
	hipoglucorraquia I-EXPLORATION
	y I-EXPLORATION
	pleocitosis I-EXPLORATION
	(98% I-EXPLORATION
	linfocitos). I-EXPLORATION
	Ante B-TREATMENT
	la I-TREATMENT
	sospecha I-TREATMENT
	de I-TREATMENT
	meningitis I-TREATMENT
	vírica I-TREATMENT
	o I-TREATMENT
	bacteriana I-TREATMENT
	decapitada, I-TREATMENT
	se I-TREATMENT
	instauró I-TREATMENT
	tratamiento I-TREATMENT
	intravenoso I-TREATMENT
	con I-TREATMENT
	aciclovir, I-TREATMENT
	ceftriaxona I-TREATMENT
	y I-TREATMENT
	ampicilina. I-TREATMENT
	<EOS> I-TREATMENT
	A B-EVOLUTION
	los I-EVOLUTION
	3 I-EVOLUTION
	días I-EVOLUTION
	presentó I-EVOLUTION
	disminución I-EVOLUTION
	de I-EVOLUTION
	conciencia, I-EVOLUTION
	midriasis I-EVOLUTION
	arreactiva I-EVOLUTION
	bilateral I-EVOLUTION
	y I-EVOLUTION
	parálisis I-EVOLUTION
	bilateral I-EVOLUTION
	de I-EVOLUTION
	los I-EVOLUTION
	pares I-EVOLUTION
	craneales I-EVOLUTION
	III, I-EVOLUTION
	IV, I-EVOLUTION
	VI, I-EVOLUTION
	VII, I-EVOLUTION
	IX I-EVOLUTION
	y I-EVOLUTION
	X. I-EVOLUTION
	La B-EXPLORATION
	resonancia I-EXPLORATION
	magnética I-EXPLORATION
	nuclear I-EXPLORATION
	(RMN) I-EXPLORATION
	mostró I-EXPLORATION
	realce I-EXPLORATION
	lepto I-EXPLORATION
	y I-EXPLORATION
	paquimeníngeo I-EXPLORATION
	e I-EXPLORATION
	hidrocefalia I-EXPLORATION
	tetraventricular. I-EXPLORATION
	A B-TREATMENT
	pesar I-TREATMENT
	de I-TREATMENT
	los I-TREATMENT
	resultados I-TREATMENT
	microbiológicos I-TREATMENT
	no I-TREATMENT
	concluyentes I-TREATMENT
	(hemocultivos, I-TREATMENT
	Mantoux, I-TREATMENT
	Tinción I-TREATMENT
	tinta I-TREATMENT
	china I-TREATMENT
	y I-TREATMENT
	Ziehl I-TREATMENT
	de I-TREATMENT
	LCR: I-TREATMENT
	todos I-TREATMENT
	negativos), I-TREATMENT
	y I-TREATMENT
	ante I-TREATMENT
	la I-TREATMENT
	sospecha I-TREATMENT
	de I-TREATMENT
	leptomeningitis I-TREATMENT
	tuberculosa I-TREATMENT
	se I-TREATMENT
	modificó I-TREATMENT
	el I-TREATMENT
	tratamiento, I-TREATMENT
	pautándose I-TREATMENT
	inicialmente I-TREATMENT
	isoniacida I-TREATMENT
	600 I-TREATMENT
	mg/día I-TREATMENT
	(más I-TREATMENT
	vitamina I-TREATMENT
	B6), I-TREATMENT
	etambutol I-TREATMENT
	22 I-TREATMENT
	mg/kg/día I-TREATMENT
	y I-TREATMENT
	rifampicina I-TREATMENT
	600 I-TREATMENT
	mg/día; I-TREATMENT
	a I-TREATMENT
	las I-TREATMENT
	48 I-TREATMENT
	horas I-TREATMENT
	se I-TREATMENT
	suspendió I-TREATMENT
	el I-TREATMENT
	etambutol I-TREATMENT
	y I-TREATMENT
	se I-TREATMENT
	añadió I-TREATMENT
	pirazinamida I-TREATMENT
	1, I-TREATMENT
	5 I-TREATMENT
	g/día, I-TREATMENT
	estreptomicina I-TREATMENT
	1g/día I-TREATMENT
	y I-TREATMENT
	dexametasona I-TREATMENT
	24 I-TREATMENT
	mg/día I-TREATMENT
	sustituyendo I-TREATMENT
	la I-TREATMENT
	ampicilina I-TREATMENT
	por I-TREATMENT
	cotrimoxazol. I-TREATMENT
	<EOS> I-TREATMENT
	A B-EVOLUTION
	los I-EVOLUTION
	12 I-EVOLUTION
	días I-EVOLUTION
	la I-EVOLUTION
	agudeza I-EVOLUTION
	visual I-EVOLUTION
	(AV) I-EVOLUTION
	bajó I-EVOLUTION
	a I-EVOLUTION
	amaurosis I-EVOLUTION
	bilateral I-EVOLUTION
	con I-EVOLUTION
	alucinaciones I-EVOLUTION
	visuales. I-EVOLUTION
	La B-EXPLORATION
	funduscopia I-EXPLORATION
	era I-EXPLORATION
	normal. I-EXPLORATION
	Los I-EXPLORATION
	potenciales I-EXPLORATION
	visuales I-EXPLORATION
	evocados I-EXPLORATION
	(PEV) I-EXPLORATION
	mostraron I-EXPLORATION
	una I-EXPLORATION
	onda I-EXPLORATION
	P100 I-EXPLORATION
	muy I-EXPLORATION
	degradada I-EXPLORATION
	con I-EXPLORATION
	latencia I-EXPLORATION
	muy I-EXPLORATION
	aumentada, I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	estimulación I-EXPLORATION
	mono I-EXPLORATION
	y I-EXPLORATION
	binocular. I-EXPLORATION
	<EOS> I-EXPLORATION
	El I-EXPLORATION
	diagnóstico I-EXPLORATION
	de I-EXPLORATION
	meningitis I-EXPLORATION
	tuberculosa I-EXPLORATION
	se I-EXPLORATION
	confirmó I-EXPLORATION
	mediante I-EXPLORATION
	cultivo I-EXPLORATION
	del I-EXPLORATION
	LCR I-EXPLORATION
	en I-EXPLORATION
	medio I-EXPLORATION
	Lowestein. I-EXPLORATION
	<EOS> I-EXPLORATION
	Durante B-TREATMENT
	6 I-TREATMENT
	meses I-TREATMENT
	se I-TREATMENT
	mantuvo I-TREATMENT
	el I-TREATMENT
	tratamiento I-TREATMENT
	tuberculostático I-TREATMENT
	(rifampicina I-TREATMENT
	y I-TREATMENT
	piridoxina) I-TREATMENT
	y I-TREATMENT
	dexametasona. I-TREATMENT
	<EOS> I-TREATMENT
	La B-EVOLUTION
	AV I-EVOLUTION
	mejoró I-EVOLUTION
	lentamente I-EVOLUTION
	y B-EXPLORATION
	al I-EXPLORATION
	año I-EXPLORATION
	presenta I-EXPLORATION
	la I-EXPLORATION
	siguiente I-EXPLORATION
	exploración: I-EXPLORATION
	AV I-EXPLORATION
	bilateral: I-EXPLORATION
	1/1, I-EXPLORATION
	leve I-EXPLORATION
	midriasis I-EXPLORATION
	reactiva, I-EXPLORATION
	sin I-EXPLORATION
	restricciones I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	motilidad I-EXPLORATION
	ocular I-EXPLORATION
	extrínseca I-EXPLORATION
	y I-EXPLORATION
	el I-EXPLORATION
	nervio I-EXPLORATION
	óptico I-EXPLORATION
	presenta I-EXPLORATION
	una I-EXPLORATION
	leve I-EXPLORATION
	palidez I-EXPLORATION
	papilar I-EXPLORATION
	sin I-EXPLORATION
	aumento I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	excavación. I-EXPLORATION
	<EOS> I-EXPLORATION
	La I-EXPLORATION
	perimetría I-EXPLORATION
	computarizada I-EXPLORATION
	en I-EXPLORATION
	ojo I-EXPLORATION
	derecho I-EXPLORATION
	muestra I-EXPLORATION
	una I-EXPLORATION
	reducción I-EXPLORATION
	concéntrica I-EXPLORATION
	con I-EXPLORATION
	respeto I-EXPLORATION
	de I-EXPLORATION
	los I-EXPLORATION
	10º I-EXPLORATION
	centrales, I-EXPLORATION
	y I-EXPLORATION
	en I-EXPLORATION
	ojo I-EXPLORATION
	izquierdo I-EXPLORATION
	una I-EXPLORATION
	reducción I-EXPLORATION
	concéntrica I-EXPLORATION
	en I-EXPLORATION
	hemicampo I-EXPLORATION
	temporal I-EXPLORATION
	y I-EXPLORATION
	parte I-EXPLORATION
	del I-EXPLORATION
	nasal. I-EXPLORATION
	Los I-EXPLORATION
	PVE I-EXPLORATION
	demuestran I-EXPLORATION
	una I-EXPLORATION
	notable I-EXPLORATION
	mejoría I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	onda I-EXPLORATION
	P100 I-EXPLORATION
	en I-EXPLORATION
	voltaje, I-EXPLORATION
	latencia I-EXPLORATION
	y I-EXPLORATION
	morfología. I-EXPLORATION
	<EOS> I-EXPLORATION

	Mujer B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	78 I-PRESENT_ILLNESS
	años, I-PRESENT_ILLNESS
	afáquica B-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	ambos I-PAST_MEDICAL_HISTORY
	ojos I-PAST_MEDICAL_HISTORY
	tras I-PAST_MEDICAL_HISTORY
	haber I-PAST_MEDICAL_HISTORY
	sido I-PAST_MEDICAL_HISTORY
	intervenida I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	cataratas I-PAST_MEDICAL_HISTORY
	veinte I-PAST_MEDICAL_HISTORY
	años I-PAST_MEDICAL_HISTORY
	antes, I-PAST_MEDICAL_HISTORY
	que B-PRESENT_ILLNESS
	desarrolló I-PRESENT_ILLNESS
	un I-PRESENT_ILLNESS
	glaucoma I-PRESENT_ILLNESS
	secundario I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	ojo I-PRESENT_ILLNESS
	derecho I-PRESENT_ILLNESS
	(OD). I-PRESENT_ILLNESS
	Ante B-TREATMENT
	la I-TREATMENT
	falta I-TREATMENT
	de I-TREATMENT
	control I-TREATMENT
	de I-TREATMENT
	su I-TREATMENT
	presión I-TREATMENT
	intraocular I-TREATMENT
	con I-TREATMENT
	el I-TREATMENT
	tratamiento I-TREATMENT
	médico, I-TREATMENT
	se I-TREATMENT
	decidió I-TREATMENT
	la I-TREATMENT
	implantación I-TREATMENT
	de I-TREATMENT
	un I-TREATMENT
	dispositivo I-TREATMENT
	de I-TREATMENT
	drenaje I-TREATMENT
	valvulado I-TREATMENT
	de I-TREATMENT
	Ahmed, I-TREATMENT
	con I-TREATMENT
	parche I-TREATMENT
	de I-TREATMENT
	esclera I-TREATMENT
	recubriendo I-TREATMENT
	el I-TREATMENT
	trayecto I-TREATMENT
	extraocular I-TREATMENT
	del I-TREATMENT
	tubo I-TREATMENT
	y I-TREATMENT
	el I-TREATMENT
	extremo I-TREATMENT
	del I-TREATMENT
	mismo I-TREATMENT
	localizado I-TREATMENT
	en I-TREATMENT
	cámara I-TREATMENT
	anterior. I-TREATMENT
	El B-EVOLUTION
	postoperatorio I-EVOLUTION
	evolucionó I-EVOLUTION
	favorablemente. I-EVOLUTION
	La I-EVOLUTION
	agudeza I-EVOLUTION
	visual I-EVOLUTION
	(AV) I-EVOLUTION
	postoperatoria I-EVOLUTION
	era I-EVOLUTION
	de I-EVOLUTION
	0, I-EVOLUTION
	5 I-EVOLUTION
	en I-EVOLUTION
	OD I-EVOLUTION
	y I-EVOLUTION
	0, I-EVOLUTION
	2 I-EVOLUTION
	en I-EVOLUTION
	ojo I-EVOLUTION
	izquierdo I-EVOLUTION
	(OI). I-EVOLUTION
	La B-TREATMENT
	presión I-TREATMENT
	intraocular I-TREATMENT
	en I-TREATMENT
	OD I-TREATMENT
	era I-TREATMENT
	de I-TREATMENT
	12 I-TREATMENT
	mmHg I-TREATMENT
	en I-TREATMENT
	tratamiento I-TREATMENT
	con I-TREATMENT
	tartrato I-TREATMENT
	de I-TREATMENT
	brimonidina I-TREATMENT
	0, I-TREATMENT
	2%. I-TREATMENT
	El I-TREATMENT
	cuerpo I-TREATMENT
	valvular I-TREATMENT
	estaba I-TREATMENT
	situado I-TREATMENT
	en I-TREATMENT
	el I-TREATMENT
	cuadrante I-TREATMENT
	temporal I-TREATMENT
	superior I-TREATMENT
	y I-TREATMENT
	la I-TREATMENT
	ampolla I-TREATMENT
	era I-TREATMENT
	amplia I-TREATMENT
	y I-TREATMENT
	de I-TREATMENT
	paredes I-TREATMENT
	finas. I-TREATMENT
	El I-TREATMENT
	tubo I-TREATMENT
	quedaba I-TREATMENT
	situado I-TREATMENT
	en I-TREATMENT
	cámara I-TREATMENT
	anterior I-TREATMENT
	y I-TREATMENT
	libre I-TREATMENT
	de I-TREATMENT
	vítreo. I-TREATMENT
	Acudió B-EVOLUTION
	a I-EVOLUTION
	urgencias I-EVOLUTION
	nueve I-EVOLUTION
	meses I-EVOLUTION
	tras I-EVOLUTION
	la I-EVOLUTION
	cirugía I-EVOLUTION
	siendo I-EVOLUTION
	diagnosticada I-EVOLUTION
	de I-EVOLUTION
	conjuntivitis I-EVOLUTION
	aguda I-EVOLUTION
	en I-EVOLUTION
	el I-EVOLUTION
	OD, I-EVOLUTION
	se B-TREATMENT
	instauró I-TREATMENT
	tratamiento I-TREATMENT
	con I-TREATMENT
	medidas I-TREATMENT
	higiénicas I-TREATMENT
	y I-TREATMENT
	colirio I-TREATMENT
	de I-TREATMENT
	tobramicina I-TREATMENT
	1 I-TREATMENT
	gota/8 I-TREATMENT
	horas I-TREATMENT
	(Tobrex I-TREATMENT
	solución I-TREATMENT
	Gotas I-TREATMENT
	oft. I-TREATMENT
	0, I-TREATMENT
	3%; I-TREATMENT
	Alcon I-TREATMENT
	Cusi; I-TREATMENT
	Barcelona; I-TREATMENT
	España) I-TREATMENT
	y I-TREATMENT
	lágrimas I-TREATMENT
	artificiales I-TREATMENT
	a I-TREATMENT
	demanda. I-TREATMENT
	Cuatro B-EVOLUTION
	días I-EVOLUTION
	más I-EVOLUTION
	tarde I-EVOLUTION
	acudió I-EVOLUTION
	a I-EVOLUTION
	revisión I-EVOLUTION
	presentando I-EVOLUTION
	una I-EVOLUTION
	AV I-EVOLUTION
	de I-EVOLUTION
	movimiento I-EVOLUTION
	de I-EVOLUTION
	manos. I-EVOLUTION
	En B-EXPLORATION
	la I-EXPLORATION
	biomicroscopía I-EXPLORATION
	presentaba I-EXPLORATION
	hiperemia I-EXPLORATION
	3-4 I-EXPLORATION
	+, I-EXPLORATION
	blebitis, I-EXPLORATION
	no I-EXPLORATION
	seidel, I-EXPLORATION
	edema I-EXPLORATION
	corneal I-EXPLORATION
	difuso I-EXPLORATION
	de I-EXPLORATION
	3+, I-EXPLORATION
	tyndall I-EXPLORATION
	4+, I-EXPLORATION
	plastrón I-EXPLORATION
	de I-EXPLORATION
	fibrina I-EXPLORATION
	en I-EXPLORATION
	cámara I-EXPLORATION
	anterior, I-EXPLORATION
	no I-EXPLORATION
	hipopion I-EXPLORATION
	y I-EXPLORATION
	PIO I-EXPLORATION
	de I-EXPLORATION
	35 I-EXPLORATION
	mm I-EXPLORATION
	Hg. I-EXPLORATION
	La I-EXPLORATION
	conjuntiva I-EXPLORATION
	que I-EXPLORATION
	recubría I-EXPLORATION
	el I-EXPLORATION
	tubo I-EXPLORATION
	y I-EXPLORATION
	la I-EXPLORATION
	cápsula I-EXPLORATION
	filtrante I-EXPLORATION
	parecía I-EXPLORATION
	íntegra. I-EXPLORATION
	El I-EXPLORATION
	fondo I-EXPLORATION
	de I-EXPLORATION
	ojo I-EXPLORATION
	no I-EXPLORATION
	se I-EXPLORATION
	visualizaba I-EXPLORATION
	por I-EXPLORATION
	opacidad I-EXPLORATION
	de I-EXPLORATION
	medios. I-EXPLORATION
	En I-EXPLORATION
	la I-EXPLORATION
	ecografía I-EXPLORATION
	aparecían I-EXPLORATION
	ecos I-EXPLORATION
	de I-EXPLORATION
	baja I-EXPLORATION
	densidad, I-EXPLORATION
	sin I-EXPLORATION
	signos I-EXPLORATION
	de I-EXPLORATION
	desprendimiento I-EXPLORATION
	de I-EXPLORATION
	retina. I-EXPLORATION
	Ante B-TREATMENT
	el I-TREATMENT
	diagnóstico I-TREATMENT
	de I-TREATMENT
	una I-TREATMENT
	endoftalmitis I-TREATMENT
	aguda I-TREATMENT
	tardía, I-TREATMENT
	se I-TREATMENT
	decidió I-TREATMENT
	iniciar I-TREATMENT
	el I-TREATMENT
	protocolo I-TREATMENT
	existente I-TREATMENT
	en I-TREATMENT
	el I-TREATMENT
	hospital, I-TREATMENT
	con I-TREATMENT
	la I-TREATMENT
	obtención I-TREATMENT
	de I-TREATMENT
	muestras I-TREATMENT
	de I-TREATMENT
	humor I-TREATMENT
	acuoso I-TREATMENT
	y I-TREATMENT
	vítreo, I-TREATMENT
	y I-TREATMENT
	tratamiento I-TREATMENT
	intravenoso I-TREATMENT
	a I-TREATMENT
	base I-TREATMENT
	de I-TREATMENT
	ceftazidima I-TREATMENT
	1 I-TREATMENT
	gramo/8 I-TREATMENT
	horas I-TREATMENT
	y I-TREATMENT
	vancomicina I-TREATMENT
	1 I-TREATMENT
	gramo/12 I-TREATMENT
	horas, I-TREATMENT
	inyección I-TREATMENT
	intravítrea I-TREATMENT
	de I-TREATMENT
	ceftazidima I-TREATMENT
	2, I-TREATMENT
	25 I-TREATMENT
	mg/0, I-TREATMENT
	1 I-TREATMENT
	ml I-TREATMENT
	y I-TREATMENT
	vancomicina I-TREATMENT
	1 I-TREATMENT
	mg/0, I-TREATMENT
	1 I-TREATMENT
	ml I-TREATMENT
	y I-TREATMENT
	colirio I-TREATMENT
	tópico I-TREATMENT
	reforzado I-TREATMENT
	50 I-TREATMENT
	mg/ml I-TREATMENT
	de I-TREATMENT
	vancomicina I-TREATMENT
	y I-TREATMENT
	ceftazidima I-TREATMENT
	cada I-TREATMENT
	hora. I-TREATMENT
	A B-EXPLORATION
	las I-EXPLORATION
	48 I-EXPLORATION
	horas I-EXPLORATION
	el I-EXPLORATION
	resultado I-EXPLORATION
	del I-EXPLORATION
	cultivo I-EXPLORATION
	fue I-EXPLORATION
	Haemophilus I-EXPLORATION
	influenzae I-EXPLORATION
	resistente I-EXPLORATION
	a I-EXPLORATION
	vancomicina I-EXPLORATION
	y I-EXPLORATION
	sensible I-EXPLORATION
	a I-EXPLORATION
	betalactámicos, I-EXPLORATION
	quinolonas, I-EXPLORATION
	rifamicina, I-EXPLORATION
	aminoglicósidos I-EXPLORATION
	y I-EXPLORATION
	tetraciclinas I-EXPLORATION
	por B-TREATMENT
	lo I-TREATMENT
	que I-TREATMENT
	se I-TREATMENT
	suspendió I-TREATMENT
	el I-TREATMENT
	tratamiento I-TREATMENT
	con I-TREATMENT
	vancomicina I-TREATMENT
	y I-TREATMENT
	se I-TREATMENT
	añadió I-TREATMENT
	una I-TREATMENT
	quinolona I-TREATMENT
	intravenosa I-TREATMENT
	y I-TREATMENT
	tópica, I-TREATMENT
	además I-TREATMENT
	de I-TREATMENT
	una I-TREATMENT
	nueva I-TREATMENT
	inyección I-TREATMENT
	intravítrea I-TREATMENT
	de I-TREATMENT
	ceftazidima I-TREATMENT
	y I-TREATMENT
	decadrán. I-TREATMENT
	A I-TREATMENT
	las I-TREATMENT
	72 I-TREATMENT
	horas, I-TREATMENT
	y I-TREATMENT
	ante I-TREATMENT
	la I-TREATMENT
	mala I-TREATMENT
	evolución, I-TREATMENT
	se I-TREATMENT
	decidió I-TREATMENT
	la I-TREATMENT
	retirada I-TREATMENT
	del I-TREATMENT
	dispositivo I-TREATMENT
	de I-TREATMENT
	drenaje, I-TREATMENT
	lavado I-TREATMENT
	de I-TREATMENT
	la I-TREATMENT
	cámara I-TREATMENT
	anterior, I-TREATMENT
	e I-TREATMENT
	inyección I-TREATMENT
	de I-TREATMENT
	ceftazidima I-TREATMENT
	subconjuntival I-TREATMENT
	e I-TREATMENT
	intravítrea. I-TREATMENT
	La I-TREATMENT
	mala I-TREATMENT
	visualización I-TREATMENT
	desestimó I-TREATMENT
	la I-TREATMENT
	práctica I-TREATMENT
	de I-TREATMENT
	vitrectomía. I-TREATMENT
	A I-TREATMENT
	los I-TREATMENT
	cuatro I-TREATMENT
	días, I-TREATMENT
	la I-TREATMENT
	AV I-TREATMENT
	era I-TREATMENT
	de I-TREATMENT
	no I-TREATMENT
	percepción I-TREATMENT
	de I-TREATMENT
	luz I-TREATMENT
	por I-TREATMENT
	lo I-TREATMENT
	que I-TREATMENT
	se I-TREATMENT
	decidió I-TREATMENT
	eviscerar. I-TREATMENT
	<EOS> I-TREATMENT

	Varón B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	36 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	edad, I-PRESENT_ILLNESS
	con B-PAST_MEDICAL_HISTORY
	antecedente I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	ser I-PAST_MEDICAL_HISTORY
	bebedor I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	350 I-PAST_MEDICAL_HISTORY
	gr/alcohol/día, I-PAST_MEDICAL_HISTORY
	fumador I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	1 I-PAST_MEDICAL_HISTORY
	cajetilla/día, I-PAST_MEDICAL_HISTORY
	ExUDVP I-PAST_MEDICAL_HISTORY
	(heroína I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	cocaína), I-PAST_MEDICAL_HISTORY
	VHB I-PAST_MEDICAL_HISTORY
	+, I-PAST_MEDICAL_HISTORY
	VHC I-PAST_MEDICAL_HISTORY
	+, I-PAST_MEDICAL_HISTORY
	VIH I-PAST_MEDICAL_HISTORY
	-, I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	hepatitis I-PAST_MEDICAL_HISTORY
	crónica I-PAST_MEDICAL_HISTORY
	multifactorial I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	estadio I-PAST_MEDICAL_HISTORY
	A I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	Child I-PAST_MEDICAL_HISTORY
	sin I-PAST_MEDICAL_HISTORY
	datos I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	hipertensión I-PAST_MEDICAL_HISTORY
	portal. I-PAST_MEDICAL_HISTORY
	Acude B-PRESENT_ILLNESS
	al I-PRESENT_ILLNESS
	servicio I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	urgencias I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	nuestro I-PRESENT_ILLNESS
	hospital I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	una I-PRESENT_ILLNESS
	pérdida I-PRESENT_ILLNESS
	brusca I-PRESENT_ILLNESS
	e I-PRESENT_ILLNESS
	importante I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	la I-PRESENT_ILLNESS
	AV I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	varias I-PRESENT_ILLNESS
	horas I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	evolución. I-PRESENT_ILLNESS
	<EOS> I-PRESENT_ILLNESS
	El B-EXPLORATION
	estudio I-EXPLORATION
	oftalmológico I-EXPLORATION
	mostraba I-EXPLORATION
	una I-EXPLORATION
	AV I-EXPLORATION
	de I-EXPLORATION
	movimiento I-EXPLORATION
	de I-EXPLORATION
	manos I-EXPLORATION
	en I-EXPLORATION
	ambos I-EXPLORATION
	ojos I-EXPLORATION
	(AO), I-EXPLORATION
	con I-EXPLORATION
	un I-EXPLORATION
	fondo I-EXPLORATION
	de I-EXPLORATION
	ojo I-EXPLORATION
	con I-EXPLORATION
	infiltrados I-EXPLORATION
	en I-EXPLORATION
	polo I-EXPLORATION
	posterior I-EXPLORATION
	y I-EXPLORATION
	desprendimiento I-EXPLORATION
	seroso I-EXPLORATION
	macular. I-EXPLORATION
	El I-EXPLORATION
	resto I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	oftalmológica I-EXPLORATION
	era I-EXPLORATION
	normal. I-EXPLORATION
	Además I-EXPLORATION
	presentaba I-EXPLORATION
	fiebre I-EXPLORATION
	de I-EXPLORATION
	38, I-EXPLORATION
	4ºC I-EXPLORATION
	y I-EXPLORATION
	discreto I-EXPLORATION
	dolor I-EXPLORATION
	abdominal I-EXPLORATION
	a I-EXPLORATION
	la I-EXPLORATION
	palpación I-EXPLORATION
	con I-EXPLORATION
	hepatomegalia I-EXPLORATION
	de I-EXPLORATION
	dos I-EXPLORATION
	traveses I-EXPLORATION
	de I-EXPLORATION
	dedo. I-EXPLORATION
	<EOS> I-EXPLORATION
	Ante B-DERIVED_FROM/TO
	la I-DERIVED_FROM/TO
	sospecha I-DERIVED_FROM/TO
	de I-DERIVED_FROM/TO
	una I-DERIVED_FROM/TO
	pancreatitis I-DERIVED_FROM/TO
	aguda I-DERIVED_FROM/TO
	es I-DERIVED_FROM/TO
	derivado I-DERIVED_FROM/TO
	al I-DERIVED_FROM/TO
	Servicio I-DERIVED_FROM/TO
	de I-DERIVED_FROM/TO
	Medicina I-DERIVED_FROM/TO
	Interna, I-DERIVED_FROM/TO
	que B-EXPLORATION
	confirmada I-EXPLORATION
	el I-EXPLORATION
	diagnóstico I-EXPLORATION
	tras I-EXPLORATION
	los I-EXPLORATION
	estudios I-EXPLORATION
	de I-EXPLORATION
	laboratorio: I-EXPLORATION
	Leucocitos I-EXPLORATION
	12, I-EXPLORATION
	4 I-EXPLORATION
	(4, I-EXPLORATION
	8-10, I-EXPLORATION
	8 I-EXPLORATION
	x103 I-EXPLORATION
	ul); I-EXPLORATION
	Neutrófilos I-EXPLORATION
	88% I-EXPLORATION
	(42,2-75,2); I-EXPLORATION
	Volumen I-EXPLORATION
	Corpuscular I-EXPLORATION
	Medio I-EXPLORATION
	111 I-EXPLORATION
	fl I-EXPLORATION
	(85,9-95,9); I-EXPLORATION
	Bilirrubina I-EXPLORATION
	total I-EXPLORATION
	8, I-EXPLORATION
	23 I-EXPLORATION
	mg/dl I-EXPLORATION
	(0,2-1,0); I-EXPLORATION
	Amilasa I-EXPLORATION
	1.523 I-EXPLORATION
	u/l I-EXPLORATION
	(55-201); I-EXPLORATION
	GOT I-EXPLORATION
	200 I-EXPLORATION
	u/l I-EXPLORATION
	(5-45); I-EXPLORATION
	GPT I-EXPLORATION
	227 I-EXPLORATION
	u/l I-EXPLORATION
	(5-45); I-EXPLORATION
	GGT I-EXPLORATION
	1.346 I-EXPLORATION
	u/l I-EXPLORATION
	(3-52); I-EXPLORATION
	Fosfatasa I-EXPLORATION
	Alcalina I-EXPLORATION
	1.159 I-EXPLORATION
	u/l I-EXPLORATION
	(98-295); I-EXPLORATION
	Fibrinógeno I-EXPLORATION
	157 I-EXPLORATION
	mg/dl I-EXPLORATION
	(200-400) I-EXPLORATION
	y I-EXPLORATION
	de I-EXPLORATION
	imagen I-EXPLORATION
	[tomografía I-EXPLORATIONaxial I-EXPLORATIONcomputerizada I-EXPLORATION(TAC) I-EXPLORATIONy I-EXPLORATIONecografía I-EXPLORATIONabdominales I-EXPLORATIONque I-EXPLORATIONmuestran I-EXPLORATIONhepatopatía I-EXPLORATIONgrasa I-EXPLORATIONy I-EXPLORATIONinfiltración I-EXPLORATIONdel I-EXPLORATIONtejido I-EXPLORATIONperipancreático, I-EXPLORATIONespecialmente I-EXPLORATIONa I-EXPLORATIONla I-EXPLORATIONaltura I-EXPLORATIONde I-EXPLORATIONla I-EXPLORATIONcola I-EXPLORATIONdel I-EXPLORATIONpáncreas, I-EXPLORATIONdonde I-EXPLORATIONla I-EXPLORATIONinfiltración I-EXPLORATIONcontinúa I-EXPLORATIONpor I-EXPLORATIONel I-EXPLORATIONespacio I-EXPLORATIONpararrenal I-EXPLORATIONanterior I-EXPLORATIONizquierdo]. I-EXPLORATION
	La I-EXPLORATION
	angiografía I-EXPLORATION
	fluoresceínica I-EXPLORATION
	mostraba I-EXPLORATION
	inicialmente I-EXPLORATION
	áreas I-EXPLORATION
	de I-EXPLORATION
	no I-EXPLORATION
	perfusión I-EXPLORATION
	capilar, I-EXPLORATION
	que I-EXPLORATION
	se I-EXPLORATION
	correspondían I-EXPLORATION
	con I-EXPLORATION
	la I-EXPLORATION
	presencia I-EXPLORATION
	de I-EXPLORATION
	los I-EXPLORATION
	exudados, I-EXPLORATION
	seguidas I-EXPLORATION
	de I-EXPLORATION
	difusión I-EXPLORATION
	en I-EXPLORATION
	tiempos I-EXPLORATION
	tardíos I-EXPLORATION
	y I-EXPLORATION
	efectos I-EXPLORATION
	pantalla I-EXPLORATION
	provocados I-EXPLORATION
	por I-EXPLORATION
	las I-EXPLORATION
	hemorragias I-EXPLORATION
	retinianas. I-EXPLORATION
	La B-TREATMENT
	resolución I-TREATMENT
	del I-TREATMENT
	cuadro I-TREATMENT
	digestivo I-TREATMENT
	fue I-TREATMENT
	favorable I-TREATMENT
	con I-TREATMENT
	tratamiento I-TREATMENT
	médico I-TREATMENT
	mediante I-TREATMENT
	sueroterapia, I-TREATMENT
	dieta I-TREATMENT
	absoluta I-TREATMENT
	y I-TREATMENT
	antibioticoterapia, I-TREATMENT
	con B-EVOLUTION
	rápida I-EVOLUTION
	mejoría I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	sintomatología I-EVOLUTION
	clínica I-EVOLUTION
	e I-EVOLUTION
	importante I-EVOLUTION
	mejoría I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	analítica I-EVOLUTION
	a I-EVOLUTION
	los I-EVOLUTION
	dos I-EVOLUTION
	semanas, I-EVOLUTION
	aunque B-EXPLORATION
	un I-EXPLORATION
	mes I-EXPLORATION
	después I-EXPLORATION
	presenta I-EXPLORATION
	una I-EXPLORATION
	encefalopatía I-EXPLORATION
	de I-EXPLORATION
	Wernicke I-EXPLORATION
	con I-EXPLORATION
	una I-EXPLORATION
	TAC I-EXPLORATION
	craneal I-EXPLORATION
	normal. I-EXPLORATION
	<EOS> I-EXPLORATION
	A B-EVOLUTION
	los I-EVOLUTION
	dos I-EVOLUTION
	meses I-EVOLUTION
	el I-EVOLUTION
	paciente I-EVOLUTION
	había I-EVOLUTION
	recuperado I-EVOLUTION
	una I-EVOLUTION
	AV I-EVOLUTION
	de I-EVOLUTION
	1 I-EVOLUTION
	en I-EVOLUTION
	AO I-EVOLUTION
	y I-EVOLUTION
	el I-EVOLUTION
	estudio I-EVOLUTION
	de I-EVOLUTION
	fondo I-EVOLUTION
	de I-EVOLUTION
	ojo I-EVOLUTION
	solo I-EVOLUTION
	mostraba I-EVOLUTION
	algún I-EVOLUTION
	pigmento I-EVOLUTION
	residual. I-EVOLUTION
	<EOS> I-EVOLUTION

	Mujer B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	58 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	que I-PRESENT_ILLNESS
	acude I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	urgencia I-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	nuestras I-PRESENT_ILLNESS
	consultas I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	dolor I-PRESENT_ILLNESS
	ocular I-PRESENT_ILLNESS
	unilateral I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	unas I-PRESENT_ILLNESS
	horas I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	evolución I-PRESENT_ILLNESS
	acompañado I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	cierto I-PRESENT_ILLNESS
	grado I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	disminución I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	agudeza I-PRESENT_ILLNESS
	visual. I-PRESENT_ILLNESS
	A B-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	presenta I-EXPLORATION
	inyección I-EXPLORATION
	ciliar, I-EXPLORATION
	midriasis I-EXPLORATION
	media I-EXPLORATION
	arreactiva I-EXPLORATION
	y I-EXPLORATION
	una I-EXPLORATION
	presión I-EXPLORATION
	intraocular I-EXPLORATION
	de I-EXPLORATION
	53 I-EXPLORATION
	mm I-EXPLORATION
	Hg. I-EXPLORATION
	Ante B-EVOLUTION
	este I-EVOLUTION
	cuadro I-EVOLUTION
	se I-EVOLUTION
	establece I-EVOLUTION
	el I-EVOLUTION
	diagnóstico I-EVOLUTION
	presuntivo I-EVOLUTION
	de I-EVOLUTION
	ataque I-EVOLUTION
	agudo I-EVOLUTION
	de I-EVOLUTION
	glaucoma I-EVOLUTION
	de I-EVOLUTION
	ángulo I-EVOLUTION
	estrecho I-EVOLUTION
	y I-EVOLUTION
	se I-EVOLUTION
	procede I-EVOLUTION
	a I-EVOLUTION
	la I-EVOLUTION
	toma I-EVOLUTION
	de I-EVOLUTION
	imágenes I-EVOLUTION
	mediante I-EVOLUTION
	BMU I-EVOLUTION
	y I-EVOLUTION
	OCT. I-EVOLUTION
	El B-EXPLORATION
	OCT I-EXPLORATION
	muestra I-EXPLORATION
	un I-EXPLORATION
	cierre I-EXPLORATION
	angular I-EXPLORATION
	con I-EXPLORATION
	contacto I-EXPLORATION
	entre I-EXPLORATION
	la I-EXPLORATION
	malla I-EXPLORATION
	trabecular I-EXPLORATION
	y I-EXPLORATION
	la I-EXPLORATION
	zona I-EXPLORATION
	más I-EXPLORATION
	periférica I-EXPLORATION
	del I-EXPLORATION
	iris I-EXPLORATION
	en I-EXPLORATION
	los I-EXPLORATION
	cuatro I-EXPLORATION
	cuadrantes. I-EXPLORATION
	De I-EXPLORATION
	igual I-EXPLORATION
	forma I-EXPLORATION
	la I-EXPLORATION
	BMU I-EXPLORATION
	muestra I-EXPLORATION
	una I-EXPLORATION
	disposición I-EXPLORATION
	similar I-EXPLORATION
	del I-EXPLORATION
	ángulo I-EXPLORATION
	en I-EXPLORATION
	los I-EXPLORATION
	360º. I-EXPLORATION
	Se B-TREATMENT
	instaura I-TREATMENT
	el I-TREATMENT
	tratamiento I-TREATMENT
	médico I-TREATMENT
	correspondiente I-TREATMENT
	para I-TREATMENT
	posteriormente I-TREATMENT
	realizar I-TREATMENT
	unas I-TREATMENT
	iridotomías I-TREATMENT
	bilaterales I-TREATMENT
	con I-TREATMENT
	láser I-TREATMENT
	YAG. I-TREATMENT
	Tras B-EXPLORATION
	las I-EXPLORATION
	iridotomías I-EXPLORATION
	se I-EXPLORATION
	realiza I-EXPLORATION
	un I-EXPLORATION
	OCT I-EXPLORATION
	de I-EXPLORATION
	cámara I-EXPLORATION
	anterior I-EXPLORATION
	que I-EXPLORATION
	nos I-EXPLORATION
	muestra I-EXPLORATION
	como I-EXPLORATION
	la I-EXPLORATION
	iridotomía I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	ojo I-EXPLORATION
	del I-EXPLORATION
	ataque I-EXPLORATION
	agudo I-EXPLORATION
	de I-EXPLORATION
	glaucoma I-EXPLORATION
	no I-EXPLORATION
	es I-EXPLORATION
	permeable, I-EXPLORATION
	siendo B-TREATMENT
	necesario I-TREATMENT
	retratar I-TREATMENT
	la I-TREATMENT
	zona I-TREATMENT
	con I-TREATMENT
	nuevos I-TREATMENT
	impactos. I-TREATMENT
	Tras B-EVOLUTION
	este I-EVOLUTION
	segundo I-EVOLUTION
	tratamiento I-EVOLUTION
	se I-EVOLUTION
	realiza I-EVOLUTION
	un I-EVOLUTION
	nuevo I-EVOLUTION
	OCT I-EVOLUTION
	que, I-EVOLUTION
	esta I-EVOLUTION
	vez I-EVOLUTION
	sí, I-EVOLUTION
	muestra I-EVOLUTION
	permeabilidad I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	iridotomía, I-EVOLUTION
	apertura I-EVOLUTION
	del I-EVOLUTION
	ángulo I-EVOLUTION
	y I-EVOLUTION
	profundización I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	cámara I-EVOLUTION
	anterior. I-EVOLUTION
	<EOS> I-EVOLUTION

	Una B-PRESENT_ILLNESS
	mujer I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	25 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	edad I-PRESENT_ILLNESS
	fue B-DERIVED_FROM/TO
	remitida I-DERIVED_FROM/TO
	a I-DERIVED_FROM/TO
	nuestro I-DERIVED_FROM/TO
	servicio I-DERIVED_FROM/TO
	para I-DERIVED_FROM/TO
	confirmar I-DERIVED_FROM/TO
	la I-DERIVED_FROM/TO
	presencia I-DERIVED_FROM/TO
	de I-DERIVED_FROM/TO
	un I-DERIVED_FROM/TO
	síndrome I-DERIVED_FROM/TO
	de I-DERIVED_FROM/TO
	Susac, I-DERIVED_FROM/TO
	debido I-DERIVED_FROM/TO
	a I-DERIVED_FROM/TO
	una I-DERIVED_FROM/TO
	pérdida I-DERIVED_FROM/TO
	visual I-DERIVED_FROM/TO
	bilateral. I-DERIVED_FROM/TO
	La B-PAST_MEDICAL_HISTORY
	paciente I-PAST_MEDICAL_HISTORY
	tenía I-PAST_MEDICAL_HISTORY
	una I-PAST_MEDICAL_HISTORY
	historia I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	alteraciones I-PAST_MEDICAL_HISTORY
	del I-PAST_MEDICAL_HISTORY
	equilibrio, I-PAST_MEDICAL_HISTORY
	ataxia, I-PAST_MEDICAL_HISTORY
	incontinencia I-PAST_MEDICAL_HISTORY
	fecal I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	urinaria, I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	pérdida I-PAST_MEDICAL_HISTORY
	auditiva I-PAST_MEDICAL_HISTORY
	izquierda I-PAST_MEDICAL_HISTORY
	desde I-PAST_MEDICAL_HISTORY
	hacía I-PAST_MEDICAL_HISTORY
	cuatro I-PAST_MEDICAL_HISTORY
	años, I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	estaba I-PAST_MEDICAL_HISTORY
	recibiendo I-PAST_MEDICAL_HISTORY
	corticoides, I-PAST_MEDICAL_HISTORY
	nimodipino I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	anticoagulantes. I-PAST_MEDICAL_HISTORY
	En B-EXPLORATION
	el I-EXPLORATION
	examen I-EXPLORATION
	neurológico I-EXPLORATION
	se I-EXPLORATION
	apreciaba I-EXPLORATION
	una I-EXPLORATION
	paraparesia I-EXPLORATION
	espástica, I-EXPLORATION
	hiperreflexia I-EXPLORATION
	tendinosa I-EXPLORATION
	y I-EXPLORATION
	disfunción I-EXPLORATION
	genitourinaria. I-EXPLORATION
	La I-EXPLORATION
	analítica I-EXPLORATION
	sanguínea I-EXPLORATION
	que I-EXPLORATION
	incluía I-EXPLORATION
	hemograma, I-EXPLORATION
	bioquímica I-EXPLORATION
	general, I-EXPLORATION
	velocidad I-EXPLORATION
	de I-EXPLORATION
	sedimentación I-EXPLORATION
	globular, I-EXPLORATION
	enzima I-EXPLORATION
	conversor I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	angiotensina I-EXPLORATION
	y I-EXPLORATION
	coagulación I-EXPLORATION
	resultaba I-EXPLORATION
	sin I-EXPLORATION
	alteraciones. I-EXPLORATION
	La I-EXPLORATION
	serología I-EXPLORATION
	de I-EXPLORATION
	lúes, I-EXPLORATION
	virus I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	inmunodeficiencia I-EXPLORATION
	humana, I-EXPLORATION
	herpes I-EXPLORATION
	simple, I-EXPLORATION
	hepatitis I-EXPLORATION
	B I-EXPLORATION
	y I-EXPLORATION
	C, I-EXPLORATION
	proteína I-EXPLORATION
	C I-EXPLORATION
	reactiva, I-EXPLORATION
	factor I-EXPLORATION
	reumatoide, I-EXPLORATION
	anticoagulante I-EXPLORATION
	lúpico, I-EXPLORATION
	anticuerpos I-EXPLORATION
	antinucleares, I-EXPLORATION
	anticardiolipina, I-EXPLORATION
	y I-EXPLORATION
	antifosfolípido I-EXPLORATION
	fue I-EXPLORATION
	negativa. I-EXPLORATION
	La I-EXPLORATION
	radiografía I-EXPLORATION
	de I-EXPLORATION
	tórax, I-EXPLORATION
	electrocardiograma, I-EXPLORATION
	ecocardiografía I-EXPLORATION
	y I-EXPLORATION
	tomografía I-EXPLORATION
	axial I-EXPLORATION
	computerizada I-EXPLORATION
	craneal I-EXPLORATION
	no I-EXPLORATION
	presentaban I-EXPLORATION
	alteraciones. I-EXPLORATION
	El I-EXPLORATION
	líquido I-EXPLORATION
	cefalorraquídeo I-EXPLORATION
	(LCR) I-EXPLORATION
	era I-EXPLORATION
	de I-EXPLORATION
	aspecto I-EXPLORATION
	claro I-EXPLORATION
	y I-EXPLORATION
	con I-EXPLORATION
	presión I-EXPLORATION
	de I-EXPLORATION
	apertura I-EXPLORATION
	normal, I-EXPLORATION
	con I-EXPLORATION
	ligero I-EXPLORATION
	aumento I-EXPLORATION
	de I-EXPLORATION
	proteínas, I-EXPLORATION
	y I-EXPLORATION
	resto I-EXPLORATION
	de I-EXPLORATION
	fórmula I-EXPLORATION
	normal. I-EXPLORATION
	La I-EXPLORATION
	serología I-EXPLORATION
	en I-EXPLORATION
	LCR I-EXPLORATION
	para I-EXPLORATION
	borrelia, I-EXPLORATION
	virus I-EXPLORATION
	de I-EXPLORATION
	Epstein-Barr, I-EXPLORATION
	citomegalovirus I-EXPLORATION
	y I-EXPLORATION
	lúes, I-EXPLORATION
	además I-EXPLORATION
	de I-EXPLORATION
	los I-EXPLORATION
	cultivos I-EXPLORATION
	habituales I-EXPLORATION
	resultaron I-EXPLORATION
	negativos. I-EXPLORATION
	La I-EXPLORATION
	detección I-EXPLORATION
	de I-EXPLORATION
	bandas I-EXPLORATION
	oligoclonales I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	mismo I-EXPLORATION
	también I-EXPLORATION
	resultó I-EXPLORATION
	negativa. I-EXPLORATION
	La I-EXPLORATION
	Resonancia I-EXPLORATION
	Magnética I-EXPLORATION
	Nuclear I-EXPLORATION
	(RMN) I-EXPLORATION
	cerebral I-EXPLORATION
	mostraba I-EXPLORATION
	múltiples I-EXPLORATION
	áreas I-EXPLORATION
	focales I-EXPLORATION
	de I-EXPLORATION
	hiperintensidad I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	sustancia I-EXPLORATION
	blanca I-EXPLORATION
	periventricular I-EXPLORATION
	y I-EXPLORATION
	pericallosa, I-EXPLORATION
	y I-EXPLORATION
	en I-EXPLORATION
	las I-EXPLORATION
	regiones I-EXPLORATION
	del I-EXPLORATION
	centro I-EXPLORATION
	semioval. I-EXPLORATION
	Los I-EXPLORATION
	tests I-EXPLORATION
	audiométricos I-EXPLORATION
	estándares I-EXPLORATION
	revelaron I-EXPLORATION
	pérdida I-EXPLORATION
	auditiva I-EXPLORATION
	neurosensorial, I-EXPLORATION
	asimétrica, I-EXPLORATION
	de I-EXPLORATION
	predominio I-EXPLORATION
	izquierdo, I-EXPLORATION
	para I-EXPLORATION
	las I-EXPLORATION
	bajas I-EXPLORATION
	frecuencias. I-EXPLORATION
	A I-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	oftalmológica, I-EXPLORATION
	su I-EXPLORATION
	agudeza I-EXPLORATION
	visual I-EXPLORATION
	era I-EXPLORATION
	de I-EXPLORATION
	20/25 I-EXPLORATION
	en I-EXPLORATION
	ambos I-EXPLORATION
	ojos. I-EXPLORATION
	La I-EXPLORATION
	campimetría I-EXPLORATION
	de I-EXPLORATION
	Goldmann I-EXPLORATION
	(Haag-Streit, I-EXPLORATION
	Berna, I-EXPLORATION
	Suiza) I-EXPLORATION
	mostró I-EXPLORATION
	una I-EXPLORATION
	cuadrantanopsia I-EXPLORATION
	inferior I-EXPLORATION
	bitemporal. I-EXPLORATION
	En I-EXPLORATION
	la I-EXPLORATION
	biomicroscopía I-EXPLORATION
	del I-EXPLORATION
	segmento I-EXPLORATION
	anterior I-EXPLORATION
	no I-EXPLORATION
	se I-EXPLORATION
	apreciaban I-EXPLORATION
	hallazgos I-EXPLORATION
	destacables. I-EXPLORATION
	El I-EXPLORATION
	examen I-EXPLORATION
	funduscópico I-EXPLORATION
	reveló I-EXPLORATION
	una I-EXPLORATION
	microangiopatía I-EXPLORATION
	retiniana I-EXPLORATION
	periférica, I-EXPLORATION
	apreciándose I-EXPLORATION
	amputación I-EXPLORATION
	de I-EXPLORATION
	vasos I-EXPLORATION
	con I-EXPLORATION
	cúmulos I-EXPLORATION
	de I-EXPLORATION
	microaneurismas I-EXPLORATION
	en I-EXPLORATION
	ambos I-EXPLORATION
	ojos. I-EXPLORATION
	No I-EXPLORATION
	se I-EXPLORATION
	observaron I-EXPLORATION
	signos I-EXPLORATION
	de I-EXPLORATION
	inflamación I-EXPLORATION
	o I-EXPLORATION
	células I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	vítreo, I-EXPLORATION
	ni I-EXPLORATION
	envainamiento I-EXPLORATION
	de I-EXPLORATION
	los I-EXPLORATION
	vasos I-EXPLORATION
	retinianos. I-EXPLORATION
	La I-EXPLORATION
	angiografía I-EXPLORATION
	fluoresceínica I-EXPLORATION
	(AGF) I-EXPLORATION
	demostró I-EXPLORATION
	signos I-EXPLORATION
	de I-EXPLORATION
	isquemia I-EXPLORATION
	en I-EXPLORATION
	las I-EXPLORATION
	áreas I-EXPLORATION
	correspondientes I-EXPLORATION
	a I-EXPLORATION
	las I-EXPLORATION
	oclusiones I-EXPLORATION
	arteriolares. I-EXPLORATION
	El I-EXPLORATION
	diagnóstico I-EXPLORATION
	de I-EXPLORATION
	síndrome I-EXPLORATION
	de I-EXPLORATION
	Susac I-EXPLORATION
	se I-EXPLORATION
	basó I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	asociación I-EXPLORATION
	de I-EXPLORATION
	encefalopatía I-EXPLORATION
	con I-EXPLORATION
	hallazgos I-EXPLORATION
	típicos I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	RMN, I-EXPLORATION
	microangiopatía I-EXPLORATION
	retiniana I-EXPLORATION
	y I-EXPLORATION
	pérdida I-EXPLORATION
	auditiva I-EXPLORATION
	neurosensorial. I-EXPLORATION
	<EOS> I-EXPLORATION
	Debido B-TREATMENT
	a I-TREATMENT
	la I-TREATMENT
	evidente I-TREATMENT
	isquemia I-TREATMENT
	retiniana I-TREATMENT
	periférica I-TREATMENT
	apreciada I-TREATMENT
	en I-TREATMENT
	la I-TREATMENT
	AGF, I-TREATMENT
	se I-TREATMENT
	le I-TREATMENT
	realizó I-TREATMENT
	fotocoagulación I-TREATMENT
	retiniana I-TREATMENT
	con I-TREATMENT
	láser I-TREATMENT
	en I-TREATMENT
	las I-TREATMENT
	áreas I-TREATMENT
	isquémicas I-TREATMENT
	de I-TREATMENT
	forma I-TREATMENT
	profiláctica, I-TREATMENT
	manteniéndose I-TREATMENT
	estable I-TREATMENT
	el I-TREATMENT
	cuadro I-TREATMENT
	visual I-TREATMENT
	desde I-TREATMENT
	entonces. I-TREATMENT
	Al B-EVOLUTION
	cabo I-EVOLUTION
	de I-EVOLUTION
	dos I-EVOLUTION
	años I-EVOLUTION
	no I-EVOLUTION
	ha I-EVOLUTION
	habido I-EVOLUTION
	variaciones I-EVOLUTION
	significativas I-EVOLUTION
	tanto I-EVOLUTION
	en I-EVOLUTION
	el I-EVOLUTION
	estado I-EVOLUTION
	neurológico I-EVOLUTION
	como I-EVOLUTION
	auditivo. I-EVOLUTION
	<EOS> I-EVOLUTION

	Varón, B-PRESENT_ILLNESS
	hijo B-PAST_MEDICAL_HISTORY
	único, I-PAST_MEDICAL_HISTORY
	nacido I-PAST_MEDICAL_HISTORY
	a I-PAST_MEDICAL_HISTORY
	las I-PAST_MEDICAL_HISTORY
	cuarenta I-PAST_MEDICAL_HISTORY
	semanas I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	gestación I-PAST_MEDICAL_HISTORY
	por I-PAST_MEDICAL_HISTORY
	cesárea. I-PAST_MEDICAL_HISTORY
	Como B-FAMILY_HISTORY
	antecedentes I-FAMILY_HISTORY
	familiares I-FAMILY_HISTORY
	destacar I-FAMILY_HISTORY
	que I-FAMILY_HISTORY
	su I-FAMILY_HISTORY
	madre I-FAMILY_HISTORY
	presentaba I-FAMILY_HISTORY
	diabetes I-FAMILY_HISTORY
	mellitus I-FAMILY_HISTORY
	no I-FAMILY_HISTORY
	insulinodependiente I-FAMILY_HISTORY
	desde I-FAMILY_HISTORY
	los I-FAMILY_HISTORY
	17 I-FAMILY_HISTORY
	años I-FAMILY_HISTORY
	y I-FAMILY_HISTORY
	no I-FAMILY_HISTORY
	existir I-FAMILY_HISTORY
	consaguinidad I-FAMILY_HISTORY
	entre I-FAMILY_HISTORY
	los I-FAMILY_HISTORY
	padres. I-FAMILY_HISTORY
	<EOS> I-FAMILY_HISTORY
	A B-PRESENT_ILLNESS
	los I-PRESENT_ILLNESS
	cuatro I-PRESENT_ILLNESS
	meses I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	vida, I-PRESENT_ILLNESS
	sufre I-PRESENT_ILLNESS
	una I-PRESENT_ILLNESS
	parada I-PRESENT_ILLNESS
	cardiorrespiratoria, I-PRESENT_ILLNESS
	(diagnosticado I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	cardiomiopatía I-PRESENT_ILLNESS
	dilatada) I-PRESENT_ILLNESS
	(1). I-PRESENT_ILLNESS
	Durante B-EVOLUTION
	su I-EVOLUTION
	ingreso I-EVOLUTION
	hospitalario I-EVOLUTION
	comienza I-EVOLUTION
	con I-EVOLUTION
	fotofobia I-EVOLUTION
	y I-EVOLUTION
	nistagmus I-EVOLUTION
	intermitente, I-EVOLUTION
	y B-EXPLORATION
	se I-EXPLORATION
	recomienda I-EXPLORATION
	revisión I-EXPLORATION
	oftalmológica I-EXPLORATION
	en I-EXPLORATION
	su I-EXPLORATION
	lugar I-EXPLORATION
	de I-EXPLORATION
	origen. I-EXPLORATION
	<EOS> I-EXPLORATION
	El I-EXPLORATION
	niño I-EXPLORATION
	presenta I-EXPLORATION
	un I-EXPLORATION
	retraso I-EXPLORATION
	psicomotor I-EXPLORATION
	por I-EXPLORATION
	lo I-EXPLORATION
	que I-EXPLORATION
	se I-EXPLORATION
	solicita I-EXPLORATION
	una I-EXPLORATION
	Resonancia I-EXPLORATION
	Magnética I-EXPLORATION
	Nuclear I-EXPLORATION
	(RMN) I-EXPLORATION
	y B-TREATMENT
	comienza I-TREATMENT
	desde I-TREATMENT
	el I-TREATMENT
	año I-TREATMENT
	de I-TREATMENT
	vida I-TREATMENT
	con I-TREATMENT
	tratamiento I-TREATMENT
	de I-TREATMENT
	estimulación I-TREATMENT
	precoz, I-TREATMENT
	consiguiendo I-TREATMENT
	en I-TREATMENT
	ocho I-TREATMENT
	meses I-TREATMENT
	los I-TREATMENT
	objetivos I-TREATMENT
	propuestos. I-TREATMENT
	En B-EXPLORATION
	la I-EXPLORATION
	RMN I-EXPLORATION
	se I-EXPLORATION
	observan I-EXPLORATION
	pequeñas I-EXPLORATION
	áreas I-EXPLORATION
	de I-EXPLORATION
	aumento I-EXPLORATION
	de I-EXPLORATION
	señal I-EXPLORATION
	en I-EXPLORATION
	T2 I-EXPLORATION
	y I-EXPLORATION
	FLAIR I-EXPLORATION
	en I-EXPLORATION
	las I-EXPLORATION
	regiones I-EXPLORATION
	periatriales I-EXPLORATION
	y I-EXPLORATION
	sustancia I-EXPLORATION
	blanca I-EXPLORATION
	temporal. I-EXPLORATION
	<EOS> I-EXPLORATION
	A B-DERIVED_FROM/TO
	los I-DERIVED_FROM/TO
	dos I-DERIVED_FROM/TO
	años I-DERIVED_FROM/TO
	es I-DERIVED_FROM/TO
	remitido I-DERIVED_FROM/TO
	a I-DERIVED_FROM/TO
	nuestro I-DERIVED_FROM/TO
	Hospital I-DERIVED_FROM/TO
	para I-DERIVED_FROM/TO
	estudio I-DERIVED_FROM/TO
	ecográfico I-DERIVED_FROM/TO
	y I-DERIVED_FROM/TO
	oftalmológico. I-DERIVED_FROM/TO
	Se B-EXPLORATION
	solicita I-EXPLORATION
	un I-EXPLORATION
	ERG I-EXPLORATION
	que I-EXPLORATION
	muestra I-EXPLORATION
	ausencia I-EXPLORATION
	de I-EXPLORATION
	respuestas, I-EXPLORATION
	y I-EXPLORATION
	Potenciales I-EXPLORATION
	Evocados I-EXPLORATION
	Visuales I-EXPLORATION
	(PEV) I-EXPLORATION
	normales. I-EXPLORATION
	Oftalmoscópicamente I-EXPLORATION
	muestra I-EXPLORATION
	nistagmus I-EXPLORATION
	con I-EXPLORATION
	fotofobia I-EXPLORATION
	intensa. I-EXPLORATION
	El I-EXPLORATION
	segmento I-EXPLORATION
	anterior I-EXPLORATION
	y I-EXPLORATION
	el I-EXPLORATION
	fondo I-EXPLORATION
	de I-EXPLORATION
	ojo I-EXPLORATION
	son I-EXPLORATION
	normales. I-EXPLORATION
	<EOS> I-EXPLORATION
	Como I-EXPLORATION
	el I-EXPLORATION
	diagnóstico I-EXPLORATION
	clínico I-EXPLORATION
	es I-EXPLORATION
	sugestivo I-EXPLORATION
	de I-EXPLORATION
	Síndrome I-EXPLORATION
	de I-EXPLORATION
	Alström, I-EXPLORATION
	se I-EXPLORATION
	solicita I-EXPLORATION
	un I-EXPLORATION
	estudio I-EXPLORATION
	genético I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	que I-EXPLORATION
	tras I-EXPLORATION
	analizar I-EXPLORATION
	los I-EXPLORATION
	exones I-EXPLORATION
	10, I-EXPLORATION
	16 I-EXPLORATION
	y I-EXPLORATION
	un I-EXPLORATION
	segmento I-EXPLORATION
	del I-EXPLORATION
	exón I-EXPLORATION
	8 I-EXPLORATION
	del I-EXPLORATION
	gen I-EXPLORATION
	ALMS-1 I-EXPLORATION
	(3) I-EXPLORATION
	donde I-EXPLORATION
	se I-EXPLORATION
	encuentran I-EXPLORATION
	las I-EXPLORATION
	mutaciones I-EXPLORATION
	descritas I-EXPLORATION
	hasta I-EXPLORATION
	el I-EXPLORATION
	momento, I-EXPLORATION
	amplificado I-EXPLORATION
	por I-EXPLORATION
	PCR I-EXPLORATION
	y I-EXPLORATION
	secuenciación I-EXPLORATION
	automatizada, I-EXPLORATION
	no I-EXPLORATION
	se I-EXPLORATION
	detectan I-EXPLORATION
	mutaciones, I-EXPLORATION
	sin I-EXPLORATION
	embargo, I-EXPLORATION
	estos I-EXPLORATION
	resultados I-EXPLORATION
	no I-EXPLORATION
	excluyen I-EXPLORATION
	el I-EXPLORATION
	diagnóstico. I-EXPLORATION
	<EOS> I-EXPLORATION

	Mujer B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	28 I-PRESENT_ILLNESS
	años, I-PRESENT_ILLNESS
	con B-PAST_MEDICAL_HISTORY
	antecedentes I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	«Síndrome I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	múltiples I-PAST_MEDICAL_HISTORY
	puntos I-PAST_MEDICAL_HISTORY
	blancos I-PAST_MEDICAL_HISTORY
	evanescentes» I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	ambos I-PAST_MEDICAL_HISTORY
	ojos I-PAST_MEDICAL_HISTORY
	hace I-PAST_MEDICAL_HISTORY
	7 I-PAST_MEDICAL_HISTORY
	años I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	buena I-PAST_MEDICAL_HISTORY
	respuesta I-PAST_MEDICAL_HISTORY
	a I-PAST_MEDICAL_HISTORY
	corticoterapia I-PAST_MEDICAL_HISTORY
	oral. I-PAST_MEDICAL_HISTORY
	Acude B-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	urgencias I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	nuestro I-PRESENT_ILLNESS
	hospital I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	disminución I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	agudeza I-PRESENT_ILLNESS
	visual I-PRESENT_ILLNESS
	bilateral I-PRESENT_ILLNESS
	y I-PRESENT_ILLNESS
	cefalea I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	15 I-PRESENT_ILLNESS
	días I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	evolución. I-PRESENT_ILLNESS
	A B-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	oftalmológica I-EXPLORATION
	presenta I-EXPLORATION
	una I-EXPLORATION
	agudeza I-EXPLORATION
	visual I-EXPLORATION
	de I-EXPLORATION
	3/10 I-EXPLORATION
	con I-EXPLORATION
	reacción I-EXPLORATION
	inflamatoria I-EXPLORATION
	en I-EXPLORATION
	cámara I-EXPLORATION
	anterior I-EXPLORATION
	y I-EXPLORATION
	desprendimiento I-EXPLORATION
	de I-EXPLORATION
	retina I-EXPLORATION
	exudativo I-EXPLORATION
	bilateral. I-EXPLORATION
	Se B-TREATMENT
	inicia I-TREATMENT
	tratamiento I-TREATMENT
	corticoideo I-TREATMENT
	oral I-TREATMENT
	a I-TREATMENT
	altas I-TREATMENT
	dosis I-TREATMENT
	(80 I-TREATMENT
	mg I-TREATMENT
	de I-TREATMENT
	prednisona), I-TREATMENT
	constatándose I-TREATMENT
	una I-TREATMENT
	buena I-TREATMENT
	respuesta I-TREATMENT
	inicial. I-TREATMENT
	Al B-EVOLUTION
	mes I-EVOLUTION
	del I-EVOLUTION
	tratamiento I-EVOLUTION
	se I-EVOLUTION
	observa I-EVOLUTION
	una I-EVOLUTION
	recidiva I-EVOLUTION
	del I-EVOLUTION
	desprendimiento I-EVOLUTION
	de I-EVOLUTION
	retina I-EVOLUTION
	foveal I-EVOLUTION
	en I-EVOLUTION
	el I-EVOLUTION
	ojo I-EVOLUTION
	izquierdo, I-EVOLUTION
	por I-EVOLUTION
	lo I-EVOLUTION
	que I-EVOLUTION
	se I-EVOLUTION
	asocia I-EVOLUTION
	a I-EVOLUTION
	su I-EVOLUTION
	tratamiento I-EVOLUTION
	CyA I-EVOLUTION
	(dosis I-EVOLUTION
	inicial I-EVOLUTION
	de I-EVOLUTION
	4 I-EVOLUTION
	mg/kg/día). I-EVOLUTION
	Tras I-EVOLUTION
	nueve I-EVOLUTION
	meses I-EVOLUTION
	de I-EVOLUTION
	seguimiento, I-EVOLUTION
	presenta I-EVOLUTION
	una I-EVOLUTION
	agudeza I-EVOLUTION
	visual I-EVOLUTION
	de I-EVOLUTION
	unidad I-EVOLUTION
	en I-EVOLUTION
	el I-EVOLUTION
	ojo I-EVOLUTION
	derecho I-EVOLUTION
	y I-EVOLUTION
	de I-EVOLUTION
	8/10 I-EVOLUTION
	en I-EVOLUTION
	el I-EVOLUTION
	ojo I-EVOLUTION
	izquierdo I-EVOLUTION
	con I-EVOLUTION
	movilización I-EVOLUTION
	pigmentaria I-EVOLUTION
	en I-EVOLUTION
	cuatro I-EVOLUTION
	cuadrantes I-EVOLUTION
	y I-EVOLUTION
	fibrosis I-EVOLUTION
	subretiniana. I-EVOLUTION
	<EOS> I-EVOLUTION

	Mujer B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	67 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	remitida B-DERIVED_FROM/TO
	de I-DERIVED_FROM/TO
	otro I-DERIVED_FROM/TO
	centro I-DERIVED_FROM/TO
	para I-DERIVED_FROM/TO
	tratamiento I-DERIVED_FROM/TO
	de I-DERIVED_FROM/TO
	carcinoma I-DERIVED_FROM/TO
	de I-DERIVED_FROM/TO
	células I-DERIVED_FROM/TO
	sebáceas I-DERIVED_FROM/TO
	de I-DERIVED_FROM/TO
	ojo I-DERIVED_FROM/TO
	derecho I-DERIVED_FROM/TO
	intervenido I-DERIVED_FROM/TO
	en I-DERIVED_FROM/TO
	seis I-DERIVED_FROM/TO
	ocasiones. I-DERIVED_FROM/TO
	Debutó B-PRESENT_ILLNESS
	como I-PRESENT_ILLNESS
	una I-PRESENT_ILLNESS
	lesión I-PRESENT_ILLNESS
	pediculada I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	conjuntiva I-PRESENT_ILLNESS
	tarsal I-PRESENT_ILLNESS
	superior. I-PRESENT_ILLNESS
	La B-EXPLORATION
	biopsia I-EXPLORATION
	realizada I-EXPLORATION
	se I-EXPLORATION
	informó I-EXPLORATION
	como I-EXPLORATION
	carcinoma I-EXPLORATION
	sebáceo. I-EXPLORATION
	Se B-TREATMENT
	hicieron I-TREATMENT
	varias I-TREATMENT
	ampliaciones I-TREATMENT
	de I-TREATMENT
	márgenes I-TREATMENT
	quirúrgicos I-TREATMENT
	de I-TREATMENT
	lamela I-TREATMENT
	posterior I-TREATMENT
	de I-TREATMENT
	párpado I-TREATMENT
	superior I-TREATMENT
	derecho, I-TREATMENT
	hasta I-TREATMENT
	encontrar I-TREATMENT
	límites I-TREATMENT
	libre I-TREATMENT
	de I-TREATMENT
	tumor. I-TREATMENT
	Las B-EXPLORATION
	piezas I-EXPLORATION
	se I-EXPLORATION
	informaron I-EXPLORATION
	como I-EXPLORATION
	carcinoma I-EXPLORATION
	sebáceo I-EXPLORATION
	con I-EXPLORATION
	diseminación I-EXPLORATION
	pagetoide. I-EXPLORATION
	<EOS> I-EXPLORATION
	La B-EVOLUTION
	paciente I-EVOLUTION
	refería I-EVOLUTION
	inflamación I-EVOLUTION
	crónica I-EVOLUTION
	palpebral I-EVOLUTION
	y I-EVOLUTION
	conjuntival. I-EVOLUTION
	A B-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	destacaba I-EXPLORATION
	leve I-EXPLORATION
	engrosamiento I-EXPLORATION
	de I-EXPLORATION
	tercio I-EXPLORATION
	externo I-EXPLORATION
	del I-EXPLORATION
	borde I-EXPLORATION
	libre I-EXPLORATION
	de I-EXPLORATION
	párpado I-EXPLORATION
	superior I-EXPLORATION
	derecho. I-EXPLORATION
	En I-EXPLORATION
	la I-EXPLORATION
	biomicroscopía I-EXPLORATION
	presentaba: I-EXPLORATION
	conjuntiva I-EXPLORATION
	bulbar I-EXPLORATION
	superior I-EXPLORATION
	irregular I-EXPLORATION
	y I-EXPLORATION
	muy I-EXPLORATION
	eritematosa, I-EXPLORATION
	área I-EXPLORATION
	de I-EXPLORATION
	6 I-EXPLORATION
	mm I-EXPLORATION
	de I-EXPLORATION
	amplitud I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	que I-EXPLORATION
	se I-EXPLORATION
	observaba I-EXPLORATION
	una I-EXPLORATION
	desestructuración I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	arquitectura I-EXPLORATION
	limbar, I-EXPLORATION
	con I-EXPLORATION
	infiltración I-EXPLORATION
	de I-EXPLORATION
	las I-EXPLORATION
	empalizadas I-EXPLORATION
	de I-EXPLORATION
	Vogt I-EXPLORATION
	por I-EXPLORATION
	cordones I-EXPLORATION
	amarillentos I-EXPLORATION
	de I-EXPLORATION
	aspecto I-EXPLORATION
	sebáceo I-EXPLORATION
	y I-EXPLORATION
	conjuntivalización I-EXPLORATION
	del I-EXPLORATION
	epitelio I-EXPLORATION
	corneal I-EXPLORATION
	superior, I-EXPLORATION
	acortamiento I-EXPLORATION
	de I-EXPLORATION
	fórnix I-EXPLORATION
	superior I-EXPLORATION
	y I-EXPLORATION
	simbléfaron I-EXPLORATION
	en I-EXPLORATION
	zona I-EXPLORATION
	del I-EXPLORATION
	canto I-EXPLORATION
	externo. I-EXPLORATION
	No I-EXPLORATION
	se I-EXPLORATION
	observó I-EXPLORATION
	afectación I-EXPLORATION
	ganglionar I-EXPLORATION
	a I-EXPLORATION
	la I-EXPLORATION
	palpación. I-EXPLORATION
	La I-EXPLORATION
	TC I-EXPLORATION
	de I-EXPLORATION
	cráneo, I-EXPLORATION
	abdomen I-EXPLORATION
	y I-EXPLORATION
	tórax I-EXPLORATION
	era I-EXPLORATION
	normal. I-EXPLORATION
	La I-EXPLORATION
	gammagrafía I-EXPLORATION
	ósea I-EXPLORATION
	era I-EXPLORATION
	normal. I-EXPLORATION
	<EOS> I-EXPLORATION
	Se B-TREATMENT
	realizó I-TREATMENT
	blefarectomía I-TREATMENT
	en I-TREATMENT
	cuña I-TREATMENT
	de I-TREATMENT
	la I-TREATMENT
	zona I-TREATMENT
	engrosada I-TREATMENT
	del I-TREATMENT
	párpado I-TREATMENT
	superior I-TREATMENT
	derecho I-TREATMENT
	y I-TREATMENT
	mapeo I-TREATMENT
	de I-TREATMENT
	biopsias I-TREATMENT
	conjuntivales. I-TREATMENT
	La B-EXPLORATION
	pieza I-EXPLORATION
	principal I-EXPLORATION
	se I-EXPLORATION
	informó I-EXPLORATION
	como I-EXPLORATION
	carcinoma I-EXPLORATION
	sebáceo. I-EXPLORATION
	Las I-EXPLORATION
	muestras I-EXPLORATION
	conjuntivales I-EXPLORATION
	estaban I-EXPLORATION
	libres I-EXPLORATION
	de I-EXPLORATION
	tumor. I-EXPLORATION
	<EOS> I-EXPLORATION
	Ampliamos B-TREATMENT
	la I-TREATMENT
	blefarectomía I-TREATMENT
	y I-TREATMENT
	esperamos I-TREATMENT
	a I-TREATMENT
	poder I-TREATMENT
	instaurar I-TREATMENT
	tratamiento I-TREATMENT
	de I-TREATMENT
	la I-TREATMENT
	superficie I-TREATMENT
	ocular I-TREATMENT
	con I-TREATMENT
	colirio I-TREATMENT
	de I-TREATMENT
	mitomicina I-TREATMENT
	C. I-TREATMENT
	No B-EVOLUTION
	se I-EVOLUTION
	pudo I-EVOLUTION
	seguir I-EVOLUTION
	la I-EVOLUTION
	evolución I-EVOLUTION
	del I-EVOLUTION
	caso I-EVOLUTION
	ya I-EVOLUTION
	que I-EVOLUTION
	la I-EVOLUTION
	paciente I-EVOLUTION
	decidió I-EVOLUTION
	seguir I-EVOLUTION
	con I-EVOLUTION
	el I-EVOLUTION
	tratamiento I-EVOLUTION
	en I-EVOLUTION
	su I-EVOLUTION
	ciudad I-EVOLUTION
	de I-EVOLUTION
	residencia. I-EVOLUTION
	<EOS> I-EVOLUTION

	Un B-PRESENT_ILLNESS
	varón I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	58 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	acudió I-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	Urgencias I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	una I-PRESENT_ILLNESS
	diplopía I-PRESENT_ILLNESS
	binocular I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	instauración I-PRESENT_ILLNESS
	subaguda I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	al I-PRESENT_ILLNESS
	menos I-PRESENT_ILLNESS
	3 I-PRESENT_ILLNESS
	meses I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	evolución I-PRESENT_ILLNESS
	atribuida I-PRESENT_ILLNESS
	inicialmente I-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	los I-PRESENT_ILLNESS
	efectos I-PRESENT_ILLNESS
	secundarios I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	quimioterapia. I-PRESENT_ILLNESS
	El B-PAST_MEDICAL_HISTORY
	paciente I-PAST_MEDICAL_HISTORY
	había I-PAST_MEDICAL_HISTORY
	sido I-PAST_MEDICAL_HISTORY
	tratado I-PAST_MEDICAL_HISTORY
	con I-PAST_MEDICAL_HISTORY
	ciclos I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	carboxiplatino/taxol I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	radioterapia I-PAST_MEDICAL_HISTORY
	concomitante I-PAST_MEDICAL_HISTORY
	por I-PAST_MEDICAL_HISTORY
	un I-PAST_MEDICAL_HISTORY
	carcinoma I-PAST_MEDICAL_HISTORY
	pulmonar I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	células I-PAST_MEDICAL_HISTORY
	grandes I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	estadio I-PAST_MEDICAL_HISTORY
	T2N3M0 I-PAST_MEDICAL_HISTORY
	diagnosticado I-PAST_MEDICAL_HISTORY
	hacía I-PAST_MEDICAL_HISTORY
	7 I-PAST_MEDICAL_HISTORY
	meses. I-PAST_MEDICAL_HISTORY
	En B-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	oftalmológica, I-EXPLORATION
	la I-EXPLORATION
	AV I-EXPLORATION
	mejor I-EXPLORATION
	corregida I-EXPLORATION
	era I-EXPLORATION
	de I-EXPLORATION
	0, I-EXPLORATION
	9 I-EXPLORATION
	en I-EXPLORATION
	ojo I-EXPLORATION
	derecho I-EXPLORATION
	(OD) I-EXPLORATION
	y I-EXPLORATION
	de I-EXPLORATION
	0, I-EXPLORATION
	8 I-EXPLORATION
	en I-EXPLORATION
	ojo I-EXPLORATION
	izquierdo I-EXPLORATION
	(OI). I-EXPLORATION
	Ambas I-EXPLORATION
	pupilas I-EXPLORATION
	estaban I-EXPLORATION
	en I-EXPLORATION
	midriasis I-EXPLORATION
	media I-EXPLORATION
	con I-EXPLORATION
	escasa I-EXPLORATION
	reactividad I-EXPLORATION
	a I-EXPLORATION
	la I-EXPLORATION
	luz I-EXPLORATION
	y I-EXPLORATION
	convergencia. I-EXPLORATION
	Respecto I-EXPLORATION
	a I-EXPLORATION
	la I-EXPLORATION
	motilidad I-EXPLORATION
	ocular I-EXPLORATION
	extrínseca, I-EXPLORATION
	se I-EXPLORATION
	objetivaba I-EXPLORATION
	una I-EXPLORATION
	exotropía I-EXPLORATION
	de I-EXPLORATION
	-50 I-EXPLORATION
	dp I-EXPLORATION
	(dioptrías I-EXPLORATION
	prismátricas) I-EXPLORATION
	con I-EXPLORATION
	dominancia I-EXPLORATION
	OD I-EXPLORATION
	pero I-EXPLORATION
	con I-EXPLORATION
	capacidad I-EXPLORATION
	de I-EXPLORATION
	fijación I-EXPLORATION
	alternante. I-EXPLORATION
	En I-EXPLORATION
	el I-EXPLORATION
	OD I-EXPLORATION
	se I-EXPLORATION
	observaba I-EXPLORATION
	una I-EXPLORATION
	limitación I-EXPLORATION
	de I-EXPLORATION
	las I-EXPLORATION
	supraducciones I-EXPLORATION
	(+++) I-EXPLORATION
	y I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	aducción I-EXPLORATION
	(++) I-EXPLORATION
	pero I-EXPLORATION
	con I-EXPLORATION
	conservación I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	abducción. I-EXPLORATION
	El I-EXPLORATION
	OI I-EXPLORATION
	presentaba I-EXPLORATION
	un I-EXPLORATION
	ptosis I-EXPLORATION
	palpebral I-EXPLORATION
	casi I-EXPLORATION
	total I-EXPLORATION
	y I-EXPLORATION
	una I-EXPLORATION
	severa I-EXPLORATION
	limitación I-EXPLORATION
	de I-EXPLORATION
	las I-EXPLORATION
	supraducciones I-EXPLORATION
	(+++), I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	aducción I-EXPLORATION
	(++) I-EXPLORATION
	y I-EXPLORATION
	de I-EXPLORATION
	las I-EXPLORATION
	infraducciones I-EXPLORATION
	(+++) I-EXPLORATION
	con I-EXPLORATION
	conservación I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	abducción. I-EXPLORATION
	La I-EXPLORATION
	biomicroscopía I-EXPLORATION
	del I-EXPLORATION
	segmento I-EXPLORATION
	anterior I-EXPLORATION
	era I-EXPLORATION
	normal I-EXPLORATION
	así I-EXPLORATION
	como I-EXPLORATION
	la I-EXPLORATION
	tensión I-EXPLORATION
	ocular I-EXPLORATION
	de I-EXPLORATION
	ambos I-EXPLORATION
	ojos I-EXPLORATION
	(AO). I-EXPLORATION
	En I-EXPLORATION
	el I-EXPLORATION
	fondo I-EXPLORATION
	de I-EXPLORATION
	ojo I-EXPLORATION
	tampoco I-EXPLORATION
	se I-EXPLORATION
	hallaron I-EXPLORATION
	alteraciones I-EXPLORATION
	patológicas. I-EXPLORATION
	En I-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	neurológica I-EXPLORATION
	el I-EXPLORATION
	paciente I-EXPLORATION
	no I-EXPLORATION
	mostraba I-EXPLORATION
	ninguna I-EXPLORATION
	alteración I-EXPLORATION
	clínica. I-EXPLORATION
	<EOS> I-EXPLORATION
	Se I-EXPLORATION
	le I-EXPLORATION
	realizó I-EXPLORATION
	una I-EXPLORATION
	resonancia I-EXPLORATION
	magnética I-EXPLORATION
	(RM) I-EXPLORATION
	cerebral I-EXPLORATION
	que I-EXPLORATION
	evidenció I-EXPLORATION
	la I-EXPLORATION
	existencia I-EXPLORATION
	una I-EXPLORATION
	lesión I-EXPLORATION
	solitaria I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	región I-EXPLORATION
	posterior I-EXPLORATION
	del I-EXPLORATION
	suelo I-EXPLORATION
	del I-EXPLORATION
	III I-EXPLORATION
	ventrículo. I-EXPLORATION
	Dicha I-EXPLORATION
	lesión I-EXPLORATION
	tenía I-EXPLORATION
	un I-EXPLORATION
	aspecto I-EXPLORATION
	anular I-EXPLORATION
	hiperintenso, I-EXPLORATION
	con I-EXPLORATION
	una I-EXPLORATION
	porción I-EXPLORATION
	central I-EXPLORATION
	hipointensa I-EXPLORATION
	sugestiva I-EXPLORATION
	de I-EXPLORATION
	necrosis, I-EXPLORATION
	y I-EXPLORATION
	afectaba I-EXPLORATION
	bilateralmente I-EXPLORATION
	a I-EXPLORATION
	los I-EXPLORATION
	núcleos I-EXPLORATION
	y I-EXPLORATION
	fascículos I-EXPLORATION
	del I-EXPLORATION
	III I-EXPLORATION
	nervio I-EXPLORATION
	craneal I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	mesencéfalo I-EXPLORATION
	central. I-EXPLORATION
	<EOS> I-EXPLORATION

	Mujer B-PRESENT_ILLNESS
	hispana I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	33 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	edad, I-PRESENT_ILLNESS
	sin B-PAST_MEDICAL_HISTORY
	antecedentes I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	interés, I-PAST_MEDICAL_HISTORY
	que B-PRESENT_ILLNESS
	queja I-PRESENT_ILLNESS
	una I-PRESENT_ILLNESS
	disminución I-PRESENT_ILLNESS
	progresiva I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	visión I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	el I-PRESENT_ILLNESS
	ojo I-PRESENT_ILLNESS
	izquierdo I-PRESENT_ILLNESS
	(OI). I-PRESENT_ILLNESS
	<EOS> I-PRESENT_ILLNESS
	En B-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	destaca I-EXPLORATION
	una I-EXPLORATION
	agudeza I-EXPLORATION
	visual I-EXPLORATION
	(AV) I-EXPLORATION
	de I-EXPLORATION
	0, I-EXPLORATION
	05 I-EXPLORATION
	en I-EXPLORATION
	OI. I-EXPLORATION
	En I-EXPLORATION
	el I-EXPLORATION
	fondo I-EXPLORATION
	de I-EXPLORATION
	ojo I-EXPLORATION
	(FO) I-EXPLORATION
	del I-EXPLORATION
	OI I-EXPLORATION
	se I-EXPLORATION
	observa I-EXPLORATION
	una I-EXPLORATION
	masa I-EXPLORATION
	papilar I-EXPLORATION
	elevada, I-EXPLORATION
	polipoidea, I-EXPLORATION
	intensamente I-EXPLORATION
	pigmentada I-EXPLORATION
	así I-EXPLORATION
	como I-EXPLORATION
	ristras I-EXPLORATION
	de I-EXPLORATION
	pigmento I-EXPLORATION
	móvil I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	cavidad I-EXPLORATION
	vítrea. I-EXPLORATION
	El I-EXPLORATION
	resto I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	oftalmológica I-EXPLORATION
	es I-EXPLORATION
	normal. I-EXPLORATION
	<EOS> I-EXPLORATION
	En I-EXPLORATION
	la I-EXPLORATION
	angiofluoresceingrafía I-EXPLORATION
	(AFG) I-EXPLORATION
	se I-EXPLORATION
	apreció I-EXPLORATION
	un I-EXPLORATION
	efecto I-EXPLORATION
	pantalla. I-EXPLORATION
	<EOS> I-EXPLORATION
	La I-EXPLORATION
	ecografía I-EXPLORATION
	mostró I-EXPLORATION
	una I-EXPLORATION
	lesión I-EXPLORATION
	sólida. I-EXPLORATION
	En I-EXPLORATION
	modo I-EXPLORATION
	A I-EXPLORATION
	se I-EXPLORATION
	observó I-EXPLORATION
	una I-EXPLORATION
	reflectividad I-EXPLORATION
	interna I-EXPLORATION
	muy I-EXPLORATION
	elevada I-EXPLORATION
	sin I-EXPLORATION
	movimiento I-EXPLORATION
	vascular I-EXPLORATION
	espontáneo. I-EXPLORATION
	<EOS> I-EXPLORATION
	En I-EXPLORATION
	aquel I-EXPLORATION
	momento I-EXPLORATION
	fueron I-EXPLORATION
	consultados I-EXPLORATION
	varios I-EXPLORATION
	expertos. I-EXPLORATION
	Unos I-EXPLORATION
	se I-EXPLORATION
	inclinaron I-EXPLORATION
	por I-EXPLORATION
	un I-EXPLORATION
	diagnóstico I-EXPLORATION
	de I-EXPLORATION
	melanoma I-EXPLORATION
	maligno I-EXPLORATION
	y I-EXPLORATION
	otros I-EXPLORATION
	por I-EXPLORATION
	melanocitoma. I-EXPLORATION
	<EOS> I-EXPLORATION
	La B-TREATMENT
	decisión I-TREATMENT
	adoptada I-TREATMENT
	fue I-TREATMENT
	seguir I-TREATMENT
	observando I-TREATMENT
	a I-TREATMENT
	la I-TREATMENT
	paciente. I-TREATMENT
	A B-EVOLUTION
	lo I-EVOLUTION
	largo I-EVOLUTION
	de I-EVOLUTION
	diecinueve I-EVOLUTION
	años I-EVOLUTION
	la I-EVOLUTION
	lesión I-EVOLUTION
	aumentó I-EVOLUTION
	paulatinamente I-EVOLUTION
	de I-EVOLUTION
	tamaño I-EVOLUTION
	sin I-EVOLUTION
	cambios I-EVOLUTION
	rápidos I-EVOLUTION
	en I-EVOLUTION
	su I-EVOLUTION
	configuración I-EVOLUTION
	por I-EVOLUTION
	lo I-EVOLUTION
	que I-EVOLUTION
	el I-EVOLUTION
	diagnóstico I-EVOLUTION
	de I-EVOLUTION
	melanocitoma I-EVOLUTION
	seguía I-EVOLUTION
	siendo I-EVOLUTION
	el I-EVOLUTION
	más I-EVOLUTION
	apropiado. I-EVOLUTION
	La I-EVOLUTION
	paciente I-EVOLUTION
	acabó I-EVOLUTION
	por I-EVOLUTION
	perder I-EVOLUTION
	completamente I-EVOLUTION
	la I-EVOLUTION
	visión I-EVOLUTION
	del I-EVOLUTION
	OI I-EVOLUTION
	y I-EVOLUTION
	la I-EVOLUTION
	funduscopia I-EVOLUTION
	llegó I-EVOLUTION
	a I-EVOLUTION
	ser I-EVOLUTION
	impracticable, I-EVOLUTION
	al I-EVOLUTION
	principio I-EVOLUTION
	a I-EVOLUTION
	causa I-EVOLUTION
	del I-EVOLUTION
	pigmento I-EVOLUTION
	vítreo I-EVOLUTION
	y I-EVOLUTION
	posteriormente I-EVOLUTION
	por I-EVOLUTION
	una I-EVOLUTION
	catarata. I-EVOLUTION
	<EOS> I-EVOLUTION
	A I-EVOLUTION
	los I-EVOLUTION
	19 I-EVOLUTION
	años I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	primera I-EVOLUTION
	visita I-EVOLUTION
	la I-EVOLUTION
	paciente I-EVOLUTION
	empezó I-EVOLUTION
	a I-EVOLUTION
	aquejar I-EVOLUTION
	intenso I-EVOLUTION
	dolor I-EVOLUTION
	debido I-EVOLUTION
	a I-EVOLUTION
	un I-EVOLUTION
	glaucoma I-EVOLUTION
	agudo I-EVOLUTION
	con I-EVOLUTION
	inflamación I-EVOLUTION
	en I-EVOLUTION
	cámara I-EVOLUTION
	anterior I-EVOLUTION
	y I-EVOLUTION
	seclusión I-EVOLUTION
	pupilar I-EVOLUTION
	sin I-EVOLUTION
	rubeosis I-EVOLUTION
	por B-TREATMENT
	lo I-TREATMENT
	que I-TREATMENT
	se I-TREATMENT
	decidió I-TREATMENT
	la I-TREATMENT
	enucleación. I-TREATMENT
	<EOS> I-TREATMENT
	En B-EXPLORATION
	el I-EXPLORATION
	examen I-EXPLORATION
	anatomopatológico I-EXPLORATION
	del I-EXPLORATION
	globo I-EXPLORATION
	ocular I-EXPLORATION
	: I-EXPLORATION
	el I-EXPLORATION
	ángulo I-EXPLORATION
	camerular I-EXPLORATION
	está I-EXPLORATION
	abierto, I-EXPLORATION
	contiene I-EXPLORATION
	abundantes I-EXPLORATION
	macrófagos I-EXPLORATION
	llenos I-EXPLORATION
	de I-EXPLORATION
	pigmento I-EXPLORATION
	que I-EXPLORATION
	infiltran I-EXPLORATION
	la I-EXPLORATION
	malla I-EXPLORATION
	trabecular, I-EXPLORATION
	rodean I-EXPLORATION
	el I-EXPLORATION
	canal I-EXPLORATION
	de I-EXPLORATION
	Schlemm, I-EXPLORATION
	tapizan I-EXPLORATION
	la I-EXPLORATION
	superficie I-EXPLORATION
	anterior I-EXPLORATION
	del I-EXPLORATION
	iris, I-EXPLORATION
	y I-EXPLORATION
	aparecen I-EXPLORATION
	sobre I-EXPLORATION
	la I-EXPLORATION
	cápsula I-EXPLORATION
	posterior I-EXPLORATION
	del I-EXPLORATION
	cristalino, I-EXPLORATION
	entre I-EXPLORATION
	los I-EXPLORATION
	procesos I-EXPLORATION
	ciliares I-EXPLORATION
	y I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	vítreo I-EXPLORATION
	anterior. I-EXPLORATION
	El I-EXPLORATION
	cristalino I-EXPLORATION
	es I-EXPLORATION
	cataratoso. I-EXPLORATION
	Emergiendo I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	cabeza I-EXPLORATION
	del I-EXPLORATION
	nervio I-EXPLORATION
	óptico I-EXPLORATION
	y I-EXPLORATION
	extendiéndose I-EXPLORATION
	por I-EXPLORATION
	la I-EXPLORATION
	retina I-EXPLORATION
	yuxtapapilar I-EXPLORATION
	se I-EXPLORATION
	aprecia I-EXPLORATION
	un I-EXPLORATION
	tumor I-EXPLORATION
	densamente I-EXPLORATION
	pigmentado I-EXPLORATION
	compuesto I-EXPLORATION
	por I-EXPLORATION
	células I-EXPLORATION
	grandes I-EXPLORATION
	poliédricas I-EXPLORATION
	con I-EXPLORATION
	citoplasma I-EXPLORATION
	abundante I-EXPLORATION
	y I-EXPLORATION
	núcleos I-EXPLORATION
	picnóticos I-EXPLORATION
	pequeños. I-EXPLORATION
	La I-EXPLORATION
	mayoría I-EXPLORATION
	de I-EXPLORATION
	las I-EXPLORATION
	células I-EXPLORATION
	son I-EXPLORATION
	anucleoladas I-EXPLORATION
	pero I-EXPLORATION
	unas I-EXPLORATION
	pocas I-EXPLORATION
	tienen I-EXPLORATION
	nucléolos I-EXPLORATION
	pequeños. I-EXPLORATION
	El I-EXPLORATION
	tumor I-EXPLORATION
	muestra I-EXPLORATION
	focos I-EXPLORATION
	de I-EXPLORATION
	necrosis I-EXPLORATION
	en I-EXPLORATION
	su I-EXPLORATION
	superficie, I-EXPLORATION
	con I-EXPLORATION
	siembra I-EXPLORATION
	de I-EXPLORATION
	macrófagos I-EXPLORATION
	llenos I-EXPLORATION
	de I-EXPLORATION
	pigmento I-EXPLORATION
	sobre I-EXPLORATION
	la I-EXPLORATION
	membrana I-EXPLORATION
	limitante I-EXPLORATION
	interna I-EXPLORATION
	y I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	vítreo. I-EXPLORATION
	En I-EXPLORATION
	algunas I-EXPLORATION
	áreas I-EXPLORATION
	se I-EXPLORATION
	observan I-EXPLORATION
	células I-EXPLORATION
	fusiformes I-EXPLORATION
	intensamente I-EXPLORATION
	pigmentadas. I-EXPLORATION
	Las I-EXPLORATION
	células I-EXPLORATION
	pigmentadas I-EXPLORATION
	en I-EXPLORATION
	muchas I-EXPLORATION
	áreas I-EXPLORATION
	se I-EXPLORATION
	extienden I-EXPLORATION
	a I-EXPLORATION
	lo I-EXPLORATION
	largo I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	membrana I-EXPLORATION
	limitante I-EXPLORATION
	interna I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	retina I-EXPLORATION
	llegando I-EXPLORATION
	hasta I-EXPLORATION
	la I-EXPLORATION
	ora I-EXPLORATION
	serrata. I-EXPLORATION
	Las I-EXPLORATION
	preparaciones I-EXPLORATION
	decoloradas I-EXPLORATION
	del I-EXPLORATION
	tumor I-EXPLORATION
	muestran I-EXPLORATION
	características I-EXPLORATION
	citológicas I-EXPLORATION
	benignas I-EXPLORATION
	propias I-EXPLORATION
	de I-EXPLORATION
	las I-EXPLORATION
	células I-EXPLORATION
	del I-EXPLORATION
	melanocitoma. I-EXPLORATION
	El I-EXPLORATION
	tumor I-EXPLORATION
	no I-EXPLORATION
	revela I-EXPLORATION
	actividad I-EXPLORATION
	mitótica, I-EXPLORATION
	no I-EXPLORATION
	se I-EXPLORATION
	observa I-EXPLORATION
	evidencia I-EXPLORATION
	de I-EXPLORATION
	melanoma I-EXPLORATION
	maligno I-EXPLORATION
	ni I-EXPLORATION
	de I-EXPLORATION
	extensión I-EXPLORATION
	extraocular. I-EXPLORATION
	<EOS> I-EXPLORATION

	Varón B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	70 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	remitido I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	disminución I-PRESENT_ILLNESS
	progresiva I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	visión I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	ojo I-PRESENT_ILLNESS
	derecho I-PRESENT_ILLNESS
	(OD) I-PRESENT_ILLNESS
	y I-PRESENT_ILLNESS
	escotoma I-PRESENT_ILLNESS
	central I-PRESENT_ILLNESS
	relativo, I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	6 I-PRESENT_ILLNESS
	meses I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	evolución. I-PRESENT_ILLNESS
	Sin B-PAST_MEDICAL_HISTORY
	antecedentes I-PAST_MEDICAL_HISTORY
	oftalmológicos I-PAST_MEDICAL_HISTORY
	personales I-PAST_MEDICAL_HISTORY
	ni I-PAST_MEDICAL_HISTORY
	familiares I-PAST_MEDICAL_HISTORY
	conocidos. I-PAST_MEDICAL_HISTORY
	Diabetes I-PAST_MEDICAL_HISTORY
	mellitus I-PAST_MEDICAL_HISTORY
	tipo I-PAST_MEDICAL_HISTORY
	2, I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	tres I-PAST_MEDICAL_HISTORY
	años I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	evolución, I-PAST_MEDICAL_HISTORY
	con I-PAST_MEDICAL_HISTORY
	buen I-PAST_MEDICAL_HISTORY
	control I-PAST_MEDICAL_HISTORY
	metabólico, I-PAST_MEDICAL_HISTORY
	e I-PAST_MEDICAL_HISTORY
	hipertensión I-PAST_MEDICAL_HISTORY
	arterial I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	tratamiento. I-PAST_MEDICAL_HISTORY
	<EOS> I-PAST_MEDICAL_HISTORY
	La B-EXPLORATION
	mejor I-EXPLORATION
	agudeza I-EXPLORATION
	visual I-EXPLORATION
	con I-EXPLORATION
	corrección I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	exploración I-EXPLORATION
	inicial I-EXPLORATION
	era I-EXPLORATION
	de I-EXPLORATION
	4/10 I-EXPLORATION
	en I-EXPLORATION
	OD I-EXPLORATION
	(+1, I-EXPLORATION
	75; I-EXPLORATION
	-1.00×95o) I-EXPLORATION
	y I-EXPLORATION
	8/10 I-EXPLORATION
	en I-EXPLORATION
	ojo I-EXPLORATION
	izquierdo I-EXPLORATION
	(OI) I-EXPLORATION
	(+1, I-EXPLORATION
	75; I-EXPLORATION
	-1, I-EXPLORATION
	50×85o). I-EXPLORATION
	La I-EXPLORATION
	biomicroscopia I-EXPLORATION
	del I-EXPLORATION
	polo I-EXPLORATION
	anterior I-EXPLORATION
	era I-EXPLORATION
	normal. I-EXPLORATION
	En I-EXPLORATION
	el I-EXPLORATION
	fondo I-EXPLORATION
	de I-EXPLORATION
	ojo I-EXPLORATION
	se I-EXPLORATION
	observaba I-EXPLORATION
	la I-EXPLORATION
	presencia I-EXPLORATION
	de I-EXPLORATION
	una I-EXPLORATION
	lesión I-EXPLORATION
	amarillenta, I-EXPLORATION
	sobreelevada I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	área I-EXPLORATION
	macular I-EXPLORATION
	del I-EXPLORATION
	OD I-EXPLORATION
	y I-EXPLORATION
	alteración I-EXPLORATION
	pigmentaria I-EXPLORATION
	macular I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	OI. I-EXPLORATION
	No I-EXPLORATION
	se I-EXPLORATION
	encontraron I-EXPLORATION
	signos I-EXPLORATION
	de I-EXPLORATION
	retinopatía I-EXPLORATION
	diabética I-EXPLORATION
	en I-EXPLORATION
	ninguno I-EXPLORATION
	de I-EXPLORATION
	los I-EXPLORATION
	ojos. I-EXPLORATION
	La I-EXPLORATION
	tomografía I-EXPLORATION
	de I-EXPLORATION
	coherencia I-EXPLORATION
	óptica I-EXPLORATION
	(OCT) I-EXPLORATION
	mostraba, I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	área I-EXPLORATION
	macular I-EXPLORATION
	del I-EXPLORATION
	OD, I-EXPLORATION
	la I-EXPLORATION
	presencia I-EXPLORATION
	de I-EXPLORATION
	una I-EXPLORATION
	masa I-EXPLORATION
	de I-EXPLORATION
	reflectividad I-EXPLORATION
	media, I-EXPLORATION
	por I-EXPLORATION
	encima I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	banda I-EXPLORATION
	del I-EXPLORATION
	epitelio I-EXPLORATION
	pigmentario, I-EXPLORATION
	con I-EXPLORATION
	levantamiento I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	retina I-EXPLORATION
	neurosensorial, I-EXPLORATION
	sin I-EXPLORATION
	evidencia I-EXPLORATION
	de I-EXPLORATION
	fluido I-EXPLORATION
	intrarretiniano I-EXPLORATION
	ni I-EXPLORATION
	subretiniano. I-EXPLORATION
	En I-EXPLORATION
	la I-EXPLORATION
	angiografía I-EXPLORATION
	fluoresceínica I-EXPLORATION
	(AGF) I-EXPLORATION
	podía I-EXPLORATION
	comprobarse I-EXPLORATION
	la I-EXPLORATION
	presencia I-EXPLORATION
	de I-EXPLORATION
	una I-EXPLORATION
	lesión I-EXPLORATION
	hiperfluorescente I-EXPLORATION
	con I-EXPLORATION
	centro I-EXPLORATION
	de I-EXPLORATION
	hipofluorescencia, I-EXPLORATION
	que I-EXPLORATION
	aumentaba I-EXPLORATION
	de I-EXPLORATION
	intensidad I-EXPLORATION
	en I-EXPLORATION
	fases I-EXPLORATION
	tardías I-EXPLORATION
	pero I-EXPLORATION
	sin I-EXPLORATION
	difusión I-EXPLORATION
	del I-EXPLORATION
	contraste, I-EXPLORATION
	que I-EXPLORATION
	confirmaría I-EXPLORATION
	el I-EXPLORATION
	diagnóstico I-EXPLORATION
	de I-EXPLORATION
	DFVA. I-EXPLORATION
	Las I-EXPLORATION
	pruebas I-EXPLORATION
	electrofisiológicas, I-EXPLORATION
	tanto I-EXPLORATION
	el I-EXPLORATION
	electrorretinograma I-EXPLORATION
	como I-EXPLORATION
	el I-EXPLORATION
	electrooculograma, I-EXPLORATION
	fueron I-EXPLORATION
	normales. I-EXPLORATION
	<EOS> I-EXPLORATION
	A I-EXPLORATION
	partir I-EXPLORATION
	de I-EXPLORATION
	ese I-EXPLORATION
	momento I-EXPLORATION
	se I-EXPLORATION
	establecieron I-EXPLORATION
	controles I-EXPLORATION
	oftalmológicos I-EXPLORATION
	periódicos, I-EXPLORATION
	en I-EXPLORATION
	los I-EXPLORATION
	que I-EXPLORATION
	se I-EXPLORATION
	evidenció I-EXPLORATION
	la I-EXPLORATION
	regresión I-EXPLORATION
	progresiva I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	lesión I-EXPLORATION
	viteliforme I-EXPLORATION
	y I-EXPLORATION
	la I-EXPLORATION
	evolución I-EXPLORATION
	hacia I-EXPLORATION
	la I-EXPLORATION
	atrofia I-EXPLORATION
	del I-EXPLORATION
	epitelio I-EXPLORATION
	pigmentario I-EXPLORATION
	macular I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	OD. I-EXPLORATION
	La I-EXPLORATION
	visión I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	OI I-EXPLORATION
	se I-EXPLORATION
	mantuvo I-EXPLORATION
	estable I-EXPLORATION
	(7/10), I-EXPLORATION
	a I-EXPLORATION
	pesar I-EXPLORATION
	de I-EXPLORATION
	que I-EXPLORATION
	las I-EXPLORATION
	alteraciones I-EXPLORATION
	pigmentarias I-EXPLORATION
	maculares I-EXPLORATION
	eran I-EXPLORATION
	cada I-EXPLORATION
	vez I-EXPLORATION
	más I-EXPLORATION
	evidentes. I-EXPLORATION
	<EOS> I-EXPLORATION
	Dos B-EVOLUTION
	años I-EVOLUTION
	y I-EVOLUTION
	medio I-EVOLUTION
	después I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	primera I-EVOLUTION
	visita, I-EVOLUTION
	el I-EVOLUTION
	paciente I-EVOLUTION
	consulta I-EVOLUTION
	por I-EVOLUTION
	disminución I-EVOLUTION
	brusca I-EVOLUTION
	de I-EVOLUTION
	visión I-EVOLUTION
	en I-EVOLUTION
	el I-EVOLUTION
	OI I-EVOLUTION
	(2/10), I-EVOLUTION
	coincidiendo I-EVOLUTION
	con I-EVOLUTION
	la I-EVOLUTION
	aparición I-EVOLUTION
	de I-EVOLUTION
	un I-EVOLUTION
	desprendimiento I-EVOLUTION
	macular I-EVOLUTION
	serohemorrágico I-EVOLUTION
	en I-EVOLUTION
	dicho I-EVOLUTION
	ojo. I-EVOLUTION
	La B-EXPLORATION
	OCT I-EXPLORATION
	mostraba I-EXPLORATION
	un I-EXPLORATION
	importante I-EXPLORATION
	levantamiento I-EXPLORATION
	macular I-EXPLORATION
	con I-EXPLORATION
	desprendimiento I-EXPLORATION
	del I-EXPLORATION
	epitelio I-EXPLORATION
	pigmentario, I-EXPLORATION
	quistes I-EXPLORATION
	intrarretinianos I-EXPLORATION
	y I-EXPLORATION
	presencia I-EXPLORATION
	de I-EXPLORATION
	líquido I-EXPLORATION
	subretiniano I-EXPLORATION
	(LSR) I-EXPLORATION
	en I-EXPLORATION
	los I-EXPLORATION
	bordes I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	lesión. I-EXPLORATION
	Mediante I-EXPLORATION
	AGF I-EXPLORATION
	se I-EXPLORATION
	comprobó I-EXPLORATION
	la I-EXPLORATION
	existencia I-EXPLORATION
	de I-EXPLORATION
	una I-EXPLORATION
	membrana I-EXPLORATION
	neovascular I-EXPLORATION
	oculta I-EXPLORATION
	con I-EXPLORATION
	difusión I-EXPLORATION
	tardía I-EXPLORATION
	del I-EXPLORATION
	colorante. I-EXPLORATION
	En B-TREATMENT
	este I-TREATMENT
	momento I-TREATMENT
	se I-TREATMENT
	decidió I-TREATMENT
	realizar I-TREATMENT
	tratamiento I-TREATMENT
	en I-TREATMENT
	el I-TREATMENT
	OI I-TREATMENT
	con I-TREATMENT
	ranibizumab I-TREATMENT
	intravítreo, I-TREATMENT
	a I-TREATMENT
	la I-TREATMENT
	dosis I-TREATMENT
	habitualmente I-TREATMENT
	utilizada I-TREATMENT
	para I-TREATMENT
	el I-TREATMENT
	tratamiento I-TREATMENT
	de I-TREATMENT
	la I-TREATMENT
	degeneración I-TREATMENT
	macular I-TREATMENT
	exudativa I-TREATMENT
	(0,5mg/0,05ml). I-TREATMENT
	<EOS> I-TREATMENT
	A B-EVOLUTION
	las I-EVOLUTION
	4 I-EVOLUTION
	semanas I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	inyección I-EVOLUTION
	la I-EVOLUTION
	agudeza I-EVOLUTION
	visual I-EVOLUTION
	había I-EVOLUTION
	mejorado I-EVOLUTION
	a I-EVOLUTION
	3/10 I-EVOLUTION
	en I-EVOLUTION
	el I-EVOLUTION
	OI, I-EVOLUTION
	con I-EVOLUTION
	reabsorción I-EVOLUTION
	prácticamente I-EVOLUTION
	completa I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	hemorragia I-EVOLUTION
	macular, I-EVOLUTION
	apreciándose I-EVOLUTION
	una I-EVOLUTION
	mínima I-EVOLUTION
	cantidad I-EVOLUTION
	de I-EVOLUTION
	LSR I-EVOLUTION
	en I-EVOLUTION
	la I-EVOLUTION
	tomografía. I-EVOLUTION
	Tras I-EVOLUTION
	8 I-EVOLUTION
	semanas, I-EVOLUTION
	la I-EVOLUTION
	AV I-EVOLUTION
	era I-EVOLUTION
	de I-EVOLUTION
	4/10, I-EVOLUTION
	comprobándose I-EVOLUTION
	en I-EVOLUTION
	la I-EVOLUTION
	OCT I-EVOLUTION
	una I-EVOLUTION
	disminución I-EVOLUTION
	importante I-EVOLUTION
	del I-EVOLUTION
	grosor I-EVOLUTION
	macular I-EVOLUTION
	central I-EVOLUTION
	con I-EVOLUTION
	mínima I-EVOLUTION
	fibrosis I-EVOLUTION
	subretiniana. I-EVOLUTION
	En I-EVOLUTION
	el I-EVOLUTION
	control I-EVOLUTION
	de I-EVOLUTION
	los I-EVOLUTION
	3 I-EVOLUTION
	meses, I-EVOLUTION
	la I-EVOLUTION
	visión I-EVOLUTION
	en I-EVOLUTION
	el I-EVOLUTION
	OI I-EVOLUTION
	había I-EVOLUTION
	descendido I-EVOLUTION
	(2/10), I-EVOLUTION
	evidenciándose I-EVOLUTION
	en I-EVOLUTION
	la I-EVOLUTION
	OCT I-EVOLUTION
	un I-EVOLUTION
	aumento I-EVOLUTION
	del I-EVOLUTION
	espesor I-EVOLUTION
	macular I-EVOLUTION
	superior I-EVOLUTION
	a I-EVOLUTION
	100micras, I-EVOLUTION
	con I-EVOLUTION
	presencia I-EVOLUTION
	de I-EVOLUTION
	líquido I-EVOLUTION
	subretiniano, I-EVOLUTION
	por B-TREATMENT
	lo I-TREATMENT
	que I-TREATMENT
	se I-TREATMENT
	decide I-TREATMENT
	realizar I-TREATMENT
	segunda I-TREATMENT
	inyección I-TREATMENT
	de I-TREATMENT
	ranibizumab. I-TREATMENT
	La B-EVOLUTION
	respuesta I-EVOLUTION
	a I-EVOLUTION
	esta I-EVOLUTION
	segunda I-EVOLUTION
	inyección I-EVOLUTION
	fue I-EVOLUTION
	favorable, I-EVOLUTION
	y I-EVOLUTION
	a I-EVOLUTION
	las I-EVOLUTION
	12 I-EVOLUTION
	semanas I-EVOLUTION
	se I-EVOLUTION
	pudo I-EVOLUTION
	comprobar I-EVOLUTION
	la I-EVOLUTION
	reabsorción I-EVOLUTION
	completa I-EVOLUTION
	del I-EVOLUTION
	fluido I-EVOLUTION
	subretiniano, I-EVOLUTION
	quedando I-EVOLUTION
	una I-EVOLUTION
	mínima I-EVOLUTION
	fibrosis I-EVOLUTION
	subretiniana I-EVOLUTION
	como I-EVOLUTION
	resultado I-EVOLUTION
	del I-EVOLUTION
	cierre I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	membrana I-EVOLUTION
	neovascular. I-EVOLUTION
	<EOS> I-EVOLUTION
	Doce I-EVOLUTION
	meses I-EVOLUTION
	después I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	última I-EVOLUTION
	inyección I-EVOLUTION
	la I-EVOLUTION
	agudeza I-EVOLUTION
	visual I-EVOLUTION
	se I-EVOLUTION
	mantiene I-EVOLUTION
	estable I-EVOLUTION
	en I-EVOLUTION
	el I-EVOLUTION
	OI I-EVOLUTION
	(6/10), I-EVOLUTION
	sin I-EVOLUTION
	signos I-EVOLUTION
	de I-EVOLUTION
	reactivación I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	membrana I-EVOLUTION
	y I-EVOLUTION
	sin I-EVOLUTION
	complicaciones I-EVOLUTION
	derivadas I-EVOLUTION
	del I-EVOLUTION
	tratamiento I-EVOLUTION
	intravítreo. I-EVOLUTION
	<EOS> I-EVOLUTION

	Embarazada B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	40 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	multípara B-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	tres, I-PAST_MEDICAL_HISTORY
	serología I-PAST_MEDICAL_HISTORY
	VIH I-PAST_MEDICAL_HISTORY
	negativo, I-PAST_MEDICAL_HISTORY
	cursó I-PAST_MEDICAL_HISTORY
	con I-PAST_MEDICAL_HISTORY
	sífilis I-PAST_MEDICAL_HISTORY
	latente I-PAST_MEDICAL_HISTORY
	precoz I-PAST_MEDICAL_HISTORY
	diagnosticada I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	la I-PAST_MEDICAL_HISTORY
	semana I-PAST_MEDICAL_HISTORY
	28 I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	embarazo I-PAST_MEDICAL_HISTORY
	(VDRL I-PAST_MEDICAL_HISTORY
	no I-PAST_MEDICAL_HISTORY
	reactivo I-PAST_MEDICAL_HISTORY
	a I-PAST_MEDICAL_HISTORY
	las I-PAST_MEDICAL_HISTORY
	12 I-PAST_MEDICAL_HISTORY
	semanas I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	gestación, I-PAST_MEDICAL_HISTORY
	VDRL I-PAST_MEDICAL_HISTORY
	1: I-PAST_MEDICAL_HISTORY
	128 I-PAST_MEDICAL_HISTORY
	a I-PAST_MEDICAL_HISTORY
	las I-PAST_MEDICAL_HISTORY
	28 I-PAST_MEDICAL_HISTORY
	semanas I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	VDRL I-PAST_MEDICAL_HISTORY
	1: I-PAST_MEDICAL_HISTORY
	32 I-PAST_MEDICAL_HISTORY
	a I-PAST_MEDICAL_HISTORY
	las I-PAST_MEDICAL_HISTORY
	31 I-PAST_MEDICAL_HISTORY
	semanas, I-PAST_MEDICAL_HISTORY
	MHA-TP I-PAST_MEDICAL_HISTORY
	(microhemagglutination-Treponema I-PAST_MEDICAL_HISTORY
	pallidum I-PAST_MEDICAL_HISTORY
	test) I-PAST_MEDICAL_HISTORY
	positivo. I-PAST_MEDICAL_HISTORY
	Tratada I-PAST_MEDICAL_HISTORY
	junto I-PAST_MEDICAL_HISTORY
	a I-PAST_MEDICAL_HISTORY
	su I-PAST_MEDICAL_HISTORY
	pareja I-PAST_MEDICAL_HISTORY
	3 I-PAST_MEDICAL_HISTORY
	semanas I-PAST_MEDICAL_HISTORY
	antes I-PAST_MEDICAL_HISTORY
	del I-PAST_MEDICAL_HISTORY
	inicio I-PAST_MEDICAL_HISTORY
	del I-PAST_MEDICAL_HISTORY
	trabajo I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	parto. I-PAST_MEDICAL_HISTORY
	Sin I-PAST_MEDICAL_HISTORY
	historia I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	sífilis I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	embarazos I-PAST_MEDICAL_HISTORY
	previos I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	pareja I-PAST_MEDICAL_HISTORY
	estable I-PAST_MEDICAL_HISTORY
	hace I-PAST_MEDICAL_HISTORY
	más I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	2 I-PAST_MEDICAL_HISTORY
	años. I-PAST_MEDICAL_HISTORY
	Ingresó B-PRESENT_ILLNESS
	al I-PRESENT_ILLNESS
	Servicio I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	Urgencia I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	rotura I-PRESENT_ILLNESS
	prematura I-PRESENT_ILLNESS
	ovular I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	30 I-PRESENT_ILLNESS
	h I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	evolución I-PRESENT_ILLNESS
	administrándose B-TREATMENT
	corticoides I-TREATMENT
	y I-TREATMENT
	6 I-TREATMENT
	dosis I-TREATMENT
	de I-TREATMENT
	ampicilina. I-TREATMENT
	Se B-EXPLORATION
	realizó I-EXPLORATION
	RPR I-EXPLORATION
	en I-EXPLORATION
	parto I-EXPLORATION
	que I-EXPLORATION
	resultó I-EXPLORATION
	no I-EXPLORATION
	reactivo I-EXPLORATION
	(no I-EXPLORATION
	se I-EXPLORATION
	realizó I-EXPLORATION
	VDRL). I-EXPLORATION
	<EOS> I-EXPLORATION
	Nació B-EVOLUTION
	RN I-EVOLUTION
	por I-EVOLUTION
	parto I-EVOLUTION
	vaginal I-EVOLUTION
	de I-EVOLUTION
	34 I-EVOLUTION
	semanas, I-EVOLUTION
	pequeño I-EVOLUTION
	para I-EVOLUTION
	la I-EVOLUTION
	edad I-EVOLUTION
	gestacional I-EVOLUTION
	(PEG) I-EVOLUTION
	peso I-EVOLUTION
	de I-EVOLUTION
	1.920 I-EVOLUTION
	g, I-EVOLUTION
	con I-EVOLUTION
	cianosis I-EVOLUTION
	generalizada, I-EVOLUTION
	sin I-EVOLUTION
	esfuerzo I-EVOLUTION
	respiratorio, I-EVOLUTION
	APGAR I-EVOLUTION
	6-8, I-EVOLUTION
	requiriendo B-TREATMENT
	ventilación I-TREATMENT
	a I-TREATMENT
	presión I-TREATMENT
	positiva. I-TREATMENT
	Cursó I-TREATMENT
	con I-TREATMENT
	enfermedad I-TREATMENT
	de I-TREATMENT
	membrana I-TREATMENT
	hialina I-TREATMENT
	(EMH) I-TREATMENT
	administrándose I-TREATMENT
	surfactante, I-TREATMENT
	sin I-TREATMENT
	embargo, I-TREATMENT
	por I-TREATMENT
	compromiso I-TREATMENT
	respiratorio I-TREATMENT
	progresivo I-TREATMENT
	debió I-TREATMENT
	conectarse I-TREATMENT
	a I-TREATMENT
	ventilación I-TREATMENT
	mecánica. I-TREATMENT
	Evolucionó B-EVOLUTION
	grave I-EVOLUTION
	con I-EVOLUTION
	altos I-EVOLUTION
	requerimientos I-EVOLUTION
	de I-EVOLUTION
	oxígeno, I-EVOLUTION
	con I-EVOLUTION
	deterioro I-EVOLUTION
	del I-EVOLUTION
	estado I-EVOLUTION
	general, I-EVOLUTION
	se I-EVOLUTION
	agregó I-EVOLUTION
	ictericia I-EVOLUTION
	generalizada, I-EVOLUTION
	petequias I-EVOLUTION
	múltiples, I-EVOLUTION
	sangrado I-EVOLUTION
	en I-EVOLUTION
	sitios I-EVOLUTION
	de I-EVOLUTION
	punción I-EVOLUTION
	e I-EVOLUTION
	hipertensión I-EVOLUTION
	pulmonar I-EVOLUTION
	por B-TREATMENT
	lo I-TREATMENT
	que I-TREATMENT
	debió I-TREATMENT
	iniciarse I-TREATMENT
	drogas I-TREATMENT
	vasoactivas. I-TREATMENT
	Al B-EXPLORATION
	examen I-EXPLORATION
	físico I-EXPLORATION
	destacaba: I-EXPLORATION
	abdomen I-EXPLORATION
	globuloso, I-EXPLORATION
	hepato-esplenomegalia I-EXPLORATION
	(ambos I-EXPLORATION
	en I-EXPLORATION
	3 I-EXPLORATION
	cm I-EXPLORATION
	bajo I-EXPLORATION
	reborde I-EXPLORATION
	costal), I-EXPLORATION
	petequias, I-EXPLORATION
	edema I-EXPLORATION
	de I-EXPLORATION
	pared I-EXPLORATION
	abdominal I-EXPLORATION
	y I-EXPLORATION
	extremidades, I-EXPLORATION
	y I-EXPLORATION
	descamación I-EXPLORATION
	palmo-plantar. I-EXPLORATION
	Inició B-TREATMENT
	tratamiento I-TREATMENT
	con I-TREATMENT
	penicilina I-TREATMENT
	sódica I-TREATMENT
	y I-TREATMENT
	gentamicina I-TREATMENT
	i.v. I-TREATMENT
	por I-TREATMENT
	sospecha I-TREATMENT
	de I-TREATMENT
	sepsis I-TREATMENT
	precoz. I-TREATMENT
	<EOS> I-TREATMENT
	Se B-EXPLORATION
	recibió I-EXPLORATION
	resultado I-EXPLORATION
	del I-EXPLORATION
	VDRL I-EXPLORATION
	en I-EXPLORATION
	sangre I-EXPLORATION
	del I-EXPLORATION
	RN I-EXPLORATION
	1: I-EXPLORATION
	64, I-EXPLORATION
	no I-EXPLORATION
	se I-EXPLORATION
	realizó I-EXPLORATION
	punción I-EXPLORATION
	lumbar I-EXPLORATION
	(PL) I-EXPLORATION
	en I-EXPLORATION
	ese I-EXPLORATION
	momento I-EXPLORATION
	por I-EXPLORATION
	gravedad I-EXPLORATION
	y I-EXPLORATION
	trombocitopenia I-EXPLORATION
	marcada. I-EXPLORATION
	Los I-EXPLORATION
	exámenes I-EXPLORATION
	de I-EXPLORATION
	laboratorio I-EXPLORATION
	iniciales I-EXPLORATION
	se I-EXPLORATION
	muestran I-EXPLORATION
	en I-EXPLORATION
	la I-EXPLORATION
	tabla I-EXPLORATION
	1. I-EXPLORATION
	<EOS> I-EXPLORATION
	Se I-EXPLORATION
	asumió I-EXPLORATION
	diagnóstico I-EXPLORATION
	probable I-EXPLORATION
	de I-EXPLORATION
	sífilis I-EXPLORATION
	congénita I-EXPLORATION
	y I-EXPLORATION
	sepsis I-EXPLORATION
	precoz, I-EXPLORATION
	se I-EXPLORATION
	decidió I-EXPLORATION
	completar I-EXPLORATION
	estudio I-EXPLORATION
	para I-EXPLORATION
	pesquisa I-EXPLORATION
	de I-EXPLORATION
	daño I-EXPLORATION
	multisistémico. I-EXPLORATION
	Se I-EXPLORATION
	realizó I-EXPLORATION
	ecocardiografía, I-EXPLORATION
	ecografía I-EXPLORATION
	abdominal I-EXPLORATION
	y I-EXPLORATION
	ecografía I-EXPLORATION
	cerebral I-EXPLORATION
	que I-EXPLORATION
	resultaron I-EXPLORATION
	normales. I-EXPLORATION
	Los I-EXPLORATION
	hemocultivos I-EXPLORATION
	fueron I-EXPLORATION
	negativos. I-EXPLORATION
	Completó B-EVOLUTION
	tratamiento I-EVOLUTION
	antibiótico I-EVOLUTION
	con I-EVOLUTION
	7 I-EVOLUTION
	días I-EVOLUTION
	de I-EVOLUTION
	gentamicina I-EVOLUTION
	iv I-EVOLUTION
	y I-EVOLUTION
	14 I-EVOLUTION
	de I-EVOLUTION
	penicilina I-EVOLUTION
	sódica I-EVOLUTION
	iv., I-EVOLUTION
	lográndose I-EVOLUTION
	disminuir I-EVOLUTION
	progresivamente I-EVOLUTION
	las I-EVOLUTION
	drogas I-EVOLUTION
	vasoactivas I-EVOLUTION
	hasta I-EVOLUTION
	su I-EVOLUTION
	suspensión. I-EVOLUTION
	<EOS> I-EVOLUTION
	En B-EXPLORATION
	contexto I-EXPLORATION
	de I-EXPLORATION
	transaminasas I-EXPLORATION
	elevadas I-EXPLORATION
	y I-EXPLORATION
	hepatomegalia I-EXPLORATION
	se I-EXPLORATION
	completó I-EXPLORATION
	estudio I-EXPLORATION
	con I-EXPLORATION
	serología I-EXPLORATION
	para I-EXPLORATION
	Hepatitis I-EXPLORATION
	B I-EXPLORATION
	y I-EXPLORATION
	C I-EXPLORATION
	que I-EXPLORATION
	resultaron I-EXPLORATION
	negativas. I-EXPLORATION
	No I-EXPLORATION
	se I-EXPLORATION
	realizó I-EXPLORATION
	estudio I-EXPLORATION
	de I-EXPLORATION
	citomegalovirus I-EXPLORATION
	(CMV). I-EXPLORATION
	Se I-EXPLORATION
	logró I-EXPLORATION
	realizar I-EXPLORATION
	PL I-EXPLORATION
	a I-EXPLORATION
	los I-EXPLORATION
	28 I-EXPLORATION
	días I-EXPLORATION
	de I-EXPLORATION
	vida, I-EXPLORATION
	resultando I-EXPLORATION
	citoquímico I-EXPLORATION
	de I-EXPLORATION
	líquido I-EXPLORATION
	cefalorraquídeo I-EXPLORATION
	(LCR) I-EXPLORATION
	normal I-EXPLORATION
	y I-EXPLORATION
	VDRL I-EXPLORATION
	no I-EXPLORATION
	reactivo, I-EXPLORATION
	con I-EXPLORATION
	VDRL I-EXPLORATION
	en I-EXPLORATION
	sangre I-EXPLORATION
	de I-EXPLORATION
	1: I-EXPLORATION
	32. I-EXPLORATION
	Radiografía I-EXPLORATION
	de I-EXPLORATION
	huesos I-EXPLORATION
	largos I-EXPLORATION
	y I-EXPLORATION
	fondo I-EXPLORATION
	de I-EXPLORATION
	ojo I-EXPLORATION
	no I-EXPLORATION
	mostraron I-EXPLORATION
	alteraciones. I-EXPLORATION
	Durante B-EVOLUTION
	el I-EVOLUTION
	primer I-EVOLUTION
	mes I-EVOLUTION
	de I-EVOLUTION
	hospitalización I-EVOLUTION
	evolucionó I-EVOLUTION
	favorablemente I-EVOLUTION
	del I-EVOLUTION
	punto I-EVOLUTION
	de I-EVOLUTION
	vista I-EVOLUTION
	clínico, I-EVOLUTION
	con I-EVOLUTION
	mejoría I-EVOLUTION
	de I-EVOLUTION
	pruebas I-EVOLUTION
	hepáticas I-EVOLUTION
	pero I-EVOLUTION
	con I-EVOLUTION
	mal I-EVOLUTION
	incremento I-EVOLUTION
	ponderal. I-EVOLUTION
	<EOS> I-EVOLUTION

	Adolescente B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	16 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	procedente B-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	zona I-PAST_MEDICAL_HISTORY
	rural I-PAST_MEDICAL_HISTORY
	lejana, I-PAST_MEDICAL_HISTORY
	con I-PAST_MEDICAL_HISTORY
	altura I-PAST_MEDICAL_HISTORY
	superior I-PAST_MEDICAL_HISTORY
	a I-PAST_MEDICAL_HISTORY
	2.500 I-PAST_MEDICAL_HISTORY
	m I-PAST_MEDICAL_HISTORY
	sobre I-PAST_MEDICAL_HISTORY
	el I-PAST_MEDICAL_HISTORY
	nivel I-PAST_MEDICAL_HISTORY
	del I-PAST_MEDICAL_HISTORY
	mar, I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	el I-PAST_MEDICAL_HISTORY
	Departamento I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	Nariño-Colombia, I-PAST_MEDICAL_HISTORY
	con B-PRESENT_ILLNESS
	cuadro I-PRESENT_ILLNESS
	clínico I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	3 I-PRESENT_ILLNESS
	meses I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	evolución I-PRESENT_ILLNESS
	consistente I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	aparición I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	masa I-PRESENT_ILLNESS
	abdominal I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	hipocondrio I-PRESENT_ILLNESS
	izquierdo. I-PRESENT_ILLNESS
	El B-EXPLORATION
	paciente I-EXPLORATION
	nunca I-EXPLORATION
	antes I-EXPLORATION
	había I-EXPLORATION
	tenido I-EXPLORATION
	contacto I-EXPLORATION
	con I-EXPLORATION
	un I-EXPLORATION
	servicio I-EXPLORATION
	de I-EXPLORATION
	salud. I-EXPLORATION
	<EOS> I-EXPLORATION
	Ingresó I-EXPLORATION
	al I-EXPLORATION
	Hospital I-EXPLORATION
	con I-EXPLORATION
	disnea I-EXPLORATION
	de I-EXPLORATION
	pequeños I-EXPLORATION
	esfuerzos, I-EXPLORATION
	cianosis I-EXPLORATION
	peribucal, I-EXPLORATION
	conjuntivas I-EXPLORATION
	hipercrómicas I-EXPLORATION
	y I-EXPLORATION
	soplo I-EXPLORATION
	holosistólico I-EXPLORATION
	en I-EXPLORATION
	todos I-EXPLORATION
	los I-EXPLORATION
	focos I-EXPLORATION
	grado I-EXPLORATION
	IV/VI, I-EXPLORATION
	de I-EXPLORATION
	predominio I-EXPLORATION
	tricuspídeo, I-EXPLORATION
	con I-EXPLORATION
	reforzamiento I-EXPLORATION
	de I-EXPLORATION
	segundo I-EXPLORATION
	ruido. I-EXPLORATION
	En I-EXPLORATION
	abdomen, I-EXPLORATION
	masa I-EXPLORATION
	no I-EXPLORATION
	móvil, I-EXPLORATION
	con I-EXPLORATION
	bordes I-EXPLORATION
	definidos, I-EXPLORATION
	con I-EXPLORATION
	diámetro I-EXPLORATION
	de I-EXPLORATION
	14 I-EXPLORATION
	x I-EXPLORATION
	15 I-EXPLORATION
	cm, I-EXPLORATION
	indolora, I-EXPLORATION
	localizada I-EXPLORATION
	en I-EXPLORATION
	dorso I-EXPLORATION
	izquierdo I-EXPLORATION
	llegando I-EXPLORATION
	hasta I-EXPLORATION
	hipogastrio. I-EXPLORATION
	Dedos I-EXPLORATION
	en I-EXPLORATION
	palillo I-EXPLORATION
	de I-EXPLORATION
	tambor I-EXPLORATION
	y I-EXPLORATION
	extremidades I-EXPLORATION
	inferiores I-EXPLORATION
	con I-EXPLORATION
	edema I-EXPLORATION
	grado I-EXPLORATION
	I. I-EXPLORATION
	<EOS> I-EXPLORATION
	Se I-EXPLORATION
	decidió I-EXPLORATION
	hospitalizar I-EXPLORATION
	para I-EXPLORATION
	estudio I-EXPLORATION
	de I-EXPLORATION
	la I-EXPLORATION
	masa I-EXPLORATION
	abdominal, I-EXPLORATION
	diagnóstico I-EXPLORATION
	y I-EXPLORATION
	compensación I-EXPLORATION
	de I-EXPLORATION
	patología I-EXPLORATION
	cardiovascular. I-EXPLORATION
	<EOS> I-EXPLORATION
	El I-EXPLORATION
	hemograma I-EXPLORATION
	de I-EXPLORATION
	ingreso I-EXPLORATION
	mostró I-EXPLORATION
	marcado I-EXPLORATION
	aumento I-EXPLORATION
	de I-EXPLORATION
	glóbulos I-EXPLORATION
	rojos I-EXPLORATION
	(9.320.000/mm3), I-EXPLORATION
	hemoglobina I-EXPLORATION
	de I-EXPLORATION
	19, I-EXPLORATION
	9 I-EXPLORATION
	g/dL, I-EXPLORATION
	hematocrito I-EXPLORATION
	de I-EXPLORATION
	66%, I-EXPLORATION
	glóbulos I-EXPLORATION
	blancos I-EXPLORATION
	3.500/mm3, I-EXPLORATION
	plaquetas I-EXPLORATION
	48.000/mm3, I-EXPLORATION
	ácido I-EXPLORATION
	úrico I-EXPLORATION
	10, I-EXPLORATION
	5 I-EXPLORATION
	mg/dL. I-EXPLORATION
	<EOS> I-EXPLORATION
	El I-EXPLORATION
	ecocardiograma I-EXPLORATION
	reportó I-EXPLORATION
	dilatación I-EXPLORATION
	severa I-EXPLORATION
	de I-EXPLORATION
	cavidades I-EXPLORATION
	derechas, I-EXPLORATION
	insuficiencia I-EXPLORATION
	tricuspídea I-EXPLORATION
	e I-EXPLORATION
	hipertensión I-EXPLORATION
	pulmonar I-EXPLORATION
	(HTP) I-EXPLORATION
	severa I-EXPLORATION
	a I-EXPLORATION
	nivel I-EXPLORATION
	suprasistémico, I-EXPLORATION
	(presión I-EXPLORATION
	sistólica I-EXPLORATION
	arterial I-EXPLORATION
	pulmonar- I-EXPLORATION
	PSAP: I-EXPLORATION
	115 I-EXPLORATION
	mmHg). I-EXPLORATION
	<EOS> I-EXPLORATION
	Se I-EXPLORATION
	realizó I-EXPLORATION
	tomografía I-EXPLORATION
	computarizada I-EXPLORATION
	(TC) I-EXPLORATION
	de I-EXPLORATION
	abdomen I-EXPLORATION
	con I-EXPLORATION
	medio I-EXPLORATION
	de I-EXPLORATION
	contraste I-EXPLORATION
	endovenoso, I-EXPLORATION
	que I-EXPLORATION
	mostró I-EXPLORATION
	grandes I-EXPLORATION
	masa I-EXPLORATION
	tumoral I-EXPLORATION
	intrarrenales I-EXPLORATION
	bilaterales, I-EXPLORATION
	de I-EXPLORATION
	mayor I-EXPLORATION
	tamaño I-EXPLORATION
	gran I-EXPLORATION
	tamaño I-EXPLORATION
	y I-EXPLORATION
	de I-EXPLORATION
	crecimiento I-EXPLORATION
	exofítico I-EXPLORATION
	a I-EXPLORATION
	izquierda I-EXPLORATION
	y I-EXPLORATION
	con I-EXPLORATION
	marcado I-EXPLORATION
	adelgazamiento I-EXPLORATION
	del I-EXPLORATION
	parénquima I-EXPLORATION
	en I-EXPLORATION
	ambos I-EXPLORATION
	riñones. I-EXPLORATION
	El I-EXPLORATION
	examen I-EXPLORATION
	mostró I-EXPLORATION
	además I-EXPLORATION
	adenopatías I-EXPLORATION
	retroperitoneales I-EXPLORATION
	múltiples I-EXPLORATION
	y I-EXPLORATION
	lesiones I-EXPLORATION
	osteolíticas I-EXPLORATION
	vertebrales. I-EXPLORATION
	La I-EXPLORATION
	TC I-EXPLORATION
	de I-EXPLORATION
	tórax I-EXPLORATION
	no I-EXPLORATION
	mostró I-EXPLORATION
	alteraciones I-EXPLORATION
	en I-EXPLORATION
	el I-EXPLORATION
	parénquima I-EXPLORATION
	pulmonar. I-EXPLORATION
	<EOS> I-EXPLORATION
	Por B-TREATMENT
	sospecha I-TREATMENT
	de I-TREATMENT
	HTP I-TREATMENT
	severa I-TREATMENT
	con I-TREATMENT
	signos I-TREATMENT
	clínicos I-TREATMENT
	de I-TREATMENT
	hipoxia I-TREATMENT
	crónica, I-TREATMENT
	se I-TREATMENT
	le I-TREATMENT
	administró I-TREATMENT
	sildenafil I-TREATMENT
	y I-TREATMENT
	oxígeno I-TREATMENT
	como I-TREATMENT
	vasodilatadores I-TREATMENT
	pulmonares, I-TREATMENT
	furosemida I-TREATMENT
	para I-TREATMENT
	manejo I-TREATMENT
	de I-TREATMENT
	su I-TREATMENT
	sobrecarga I-TREATMENT
	hídrica I-TREATMENT
	y I-TREATMENT
	alopurinol I-TREATMENT
	como I-TREATMENT
	tratamiento I-TREATMENT
	de I-TREATMENT
	hiperuricemia I-TREATMENT
	para I-TREATMENT
	prevenir I-TREATMENT
	lesión I-TREATMENT
	renal. I-TREATMENT
	<EOS> I-TREATMENT
	La B-EXPLORATION
	biopsia I-EXPLORATION
	de I-EXPLORATION
	médula I-EXPLORATION
	ósea I-EXPLORATION
	reportó I-EXPLORATION
	hiperplasia I-EXPLORATION
	eritroide I-EXPLORATION
	sin I-EXPLORATION
	evidencia I-EXPLORATION
	de I-EXPLORATION
	infiltración, I-EXPLORATION
	por I-EXPLORATION
	lo I-EXPLORATION
	que I-EXPLORATION
	se I-EXPLORATION
	descartó I-EXPLORATION
	linfoma. I-EXPLORATION
	Por I-EXPLORATION
	riesgo I-EXPLORATION
	anestésico, I-EXPLORATION
	secundario I-EXPLORATION
	a I-EXPLORATION
	HTP, I-EXPLORATION
	se I-EXPLORATION
	realizó I-EXPLORATION
	biopsia I-EXPLORATION
	renal I-EXPLORATION
	con I-EXPLORATION
	Trucut I-EXPLORATION
	guiada I-EXPLORATION
	por I-EXPLORATION
	Ecografía, I-EXPLORATION
	cuyo I-EXPLORATION
	reporte I-EXPLORATION
	de I-EXPLORATION
	patología I-EXPLORATION
	confirmó I-EXPLORATION
	diagnóstico I-EXPLORATION
	de I-EXPLORATION
	HEM. I-EXPLORATION
	<EOS> I-EXPLORATION
	Se B-EVOLUTION
	ha I-EVOLUTION
	realizado I-EVOLUTION
	seguimiento I-EVOLUTION
	durante I-EVOLUTION
	8 I-EVOLUTION
	meses, I-EVOLUTION
	sin I-EVOLUTION
	cambios I-EVOLUTION
	significativos I-EVOLUTION
	en I-EVOLUTION
	su I-EVOLUTION
	evolución. I-EVOLUTION
	<EOS> I-EVOLUTION

	Paciente B-PRESENT_ILLNESS
	femenino I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	6 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	edad I-PRESENT_ILLNESS
	con B-PAST_MEDICAL_HISTORY
	antecedentes I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	epilepsia I-PAST_MEDICAL_HISTORY
	secundaria I-PAST_MEDICAL_HISTORY
	a I-PAST_MEDICAL_HISTORY
	extensa I-PAST_MEDICAL_HISTORY
	alteración I-PAST_MEDICAL_HISTORY
	del I-PAST_MEDICAL_HISTORY
	desarrollo I-PAST_MEDICAL_HISTORY
	cortical I-PAST_MEDICAL_HISTORY
	hemisférico I-PAST_MEDICAL_HISTORY
	derecho. I-PAST_MEDICAL_HISTORY
	Presentó B-PRESENT_ILLNESS
	estatus I-PRESENT_ILLNESS
	epiléptico I-PRESENT_ILLNESS
	refractario I-PRESENT_ILLNESS
	que B-TREATMENT
	re I-TREATMENT
	quirió I-TREATMENT
	ingreso I-TREATMENT
	a I-TREATMENT
	Unidad I-TREATMENT
	de I-TREATMENT
	Cuidados I-TREATMENT
	Intensivos I-TREATMENT
	para I-TREATMENT
	soporte I-TREATMENT
	vital I-TREATMENT
	y I-TREATMENT
	tratamiento, I-TREATMENT
	el I-TREATMENT
	que I-TREATMENT
	incluyó I-TREATMENT
	como I-TREATMENT
	terapia I-TREATMENT
	de I-TREATMENT
	tercera I-TREATMENT
	línea I-TREATMENT
	infusión I-TREATMENT
	intravenosa I-TREATMENT
	continua I-TREATMENT
	de I-TREATMENT
	propofol I-TREATMENT
	en I-TREATMENT
	dosis I-TREATMENT
	progresivas I-TREATMENT
	hasta I-TREATMENT
	alcanzar I-TREATMENT
	una I-TREATMENT
	tasa I-TREATMENT
	10 I-TREATMENT
	mg/kg/h. I-TREATMENT
	Cursó B-EVOLUTION
	con I-EVOLUTION
	compromiso I-EVOLUTION
	hemodinámico I-EVOLUTION
	y I-EVOLUTION
	a I-EVOLUTION
	las I-EVOLUTION
	24 I-EVOLUTION
	h I-EVOLUTION
	de I-EVOLUTION
	iniciado I-EVOLUTION
	el I-EVOLUTION
	tratamiento I-EVOLUTION
	se I-EVOLUTION
	observó I-EVOLUTION
	alza I-EVOLUTION
	de I-EVOLUTION
	la I-EVOLUTION
	creatinifosfokinasa I-EVOLUTION
	(CK), I-EVOLUTION
	acidosis I-EVOLUTION
	metabólica I-EVOLUTION
	y I-EVOLUTION
	lactacidemia I-EVOLUTION
	elevada, I-EVOLUTION
	y B-TREATMENT
	luego I-TREATMENT
	de I-TREATMENT
	descartar I-TREATMENT
	otras I-TREATMENT
	causas I-TREATMENT
	se I-TREATMENT
	planteó I-TREATMENT
	el I-TREATMENT
	dianóstico I-TREATMENT
	de I-TREATMENT
	SIP I-TREATMENT
	por I-TREATMENT
	lo I-TREATMENT
	que I-TREATMENT
	se I-TREATMENT
	suspendió I-TREATMENT
	la I-TREATMENT
	droga, I-TREATMENT
	logrando B-EVOLUTION
	esta I-EVOLUTION
	bilización I-EVOLUTION
	hemodinámica I-EVOLUTION
	a I-EVOLUTION
	las I-EVOLUTION
	24 I-EVOLUTION
	h. I-EVOLUTION
	<EOS> I-EVOLUTION

	Mujer B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	58 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	que B-PAST_MEDICAL_HISTORY
	presentaba I-PAST_MEDICAL_HISTORY
	como I-PAST_MEDICAL_HISTORY
	enfermedad I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	base I-PAST_MEDICAL_HISTORY
	leucemia I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	4 I-PAST_MEDICAL_HISTORY
	años I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	evolución, I-PAST_MEDICAL_HISTORY
	que I-PAST_MEDICAL_HISTORY
	precisaba I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	transfusiones I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	derivados I-PAST_MEDICAL_HISTORY
	hemáticos I-PAST_MEDICAL_HISTORY
	con I-PAST_MEDICAL_HISTORY
	cierta I-PAST_MEDICAL_HISTORY
	frecuencia. I-PAST_MEDICAL_HISTORY
	Tras B-PRESENT_ILLNESS
	presentar I-PRESENT_ILLNESS
	una I-PRESENT_ILLNESS
	síndrome I-PRESENT_ILLNESS
	constitucional I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	los I-PRESENT_ILLNESS
	últimos I-PRESENT_ILLNESS
	meses, I-PRESENT_ILLNESS
	se I-PRESENT_ILLNESS
	le I-PRESENT_ILLNESS
	había I-PRESENT_ILLNESS
	detectado I-PRESENT_ILLNESS
	una I-PRESENT_ILLNESS
	masa I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	pared I-PRESENT_ILLNESS
	costal I-PRESENT_ILLNESS
	derecha I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	4 I-PRESENT_ILLNESS
	cm I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	diámetro, I-PRESENT_ILLNESS
	que I-PRESENT_ILLNESS
	fue I-PRESENT_ILLNESS
	diagnosticada I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	múcor. I-PRESENT_ILLNESS
	<EOS> I-PRESENT_ILLNESS
	Planteamos B-TREATMENT
	intervención I-TREATMENT
	quirúrgica I-TREATMENT
	para I-TREATMENT
	resecar I-TREATMENT
	la I-TREATMENT
	lesión I-TREATMENT
	con I-TREATMENT
	3 I-TREATMENT
	cm I-TREATMENT
	de I-TREATMENT
	margen. I-TREATMENT
	Al I-TREATMENT
	estar I-TREATMENT
	situada I-TREATMENT
	en I-TREATMENT
	la I-TREATMENT
	proximidad I-TREATMENT
	de I-TREATMENT
	la I-TREATMENT
	línea I-TREATMENT
	axilar I-TREATMENT
	anterior, I-TREATMENT
	llevamos I-TREATMENT
	a I-TREATMENT
	cabo I-TREATMENT
	la I-TREATMENT
	reconstrucción I-TREATMENT
	con I-TREATMENT
	un I-TREATMENT
	colgajo I-TREATMENT
	de I-TREATMENT
	músculo I-TREATMENT
	dorsal I-TREATMENT
	ancho I-TREATMENT
	con I-TREATMENT
	isla I-TREATMENT
	de I-TREATMENT
	piel I-TREATMENT
	desepidermizada I-TREATMENT
	de I-TREATMENT
	8 I-TREATMENT
	por I-TREATMENT
	12 I-TREATMENT
	cm I-TREATMENT
	; I-TREATMENT
	se I-TREATMENT
	anclaron I-TREATMENT
	puntos I-TREATMENT
	de I-TREATMENT
	sutura I-TREATMENT
	desde I-TREATMENT
	los I-TREATMENT
	bordes I-TREATMENT
	costales I-TREATMENT
	hasta I-TREATMENT
	la I-TREATMENT
	dermis I-TREATMENT
	del I-TREATMENT
	colgajo, I-TREATMENT
	para I-TREATMENT
	así I-TREATMENT
	dar I-TREATMENT
	continuidad I-TREATMENT
	a I-TREATMENT
	la I-TREATMENT
	propia I-TREATMENT
	pared I-TREATMENT
	costal. I-TREATMENT
	La B-EVOLUTION
	paciente I-EVOLUTION
	recibió I-EVOLUTION
	el I-EVOLUTION
	alta I-EVOLUTION
	hospitalaria I-EVOLUTION
	una I-EVOLUTION
	semana I-EVOLUTION
	más I-EVOLUTION
	tarde, I-EVOLUTION
	sin I-EVOLUTION
	problemas I-EVOLUTION
	ventilatorios I-EVOLUTION
	ni I-EVOLUTION
	respiración I-EVOLUTION
	paradójica. I-EVOLUTION
	No I-EVOLUTION
	han I-EVOLUTION
	aparecido I-EVOLUTION
	recidivas I-EVOLUTION
	ni I-EVOLUTION
	complicaciones I-EVOLUTION
	tras I-EVOLUTION
	24 I-EVOLUTION
	meses I-EVOLUTION
	de I-EVOLUTION
	seguimiento I-EVOLUTION
	postoperatorio. I-EVOLUTION
	<EOS> I-EVOLUTION

	Mujer B-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	25 I-PRESENT_ILLNESS
	años I-PRESENT_ILLNESS
	diagnosticada B-PAST_MEDICAL_HISTORY
	clínicamente I-PAST_MEDICAL_HISTORY
	de I-PAST_MEDICAL_HISTORY
	miocardiopatía I-PAST_MEDICAL_HISTORY
	hipertrófica I-PAST_MEDICAL_HISTORY
	obstructiva I-PAST_MEDICAL_HISTORY
	en I-PAST_MEDICAL_HISTORY
	tratamiento I-PAST_MEDICAL_HISTORY
	farmacológico I-PAST_MEDICAL_HISTORY
	con I-PAST_MEDICAL_HISTORY
	antiarrítmicos I-PAST_MEDICAL_HISTORY
	(Amiodarona) I-PAST_MEDICAL_HISTORY
	y I-PAST_MEDICAL_HISTORY
	betabloqueantes I-PAST_MEDICAL_HISTORY
	(Propanolol). I-PAST_MEDICAL_HISTORY
	La B-FAMILY_HISTORY
	madre I-FAMILY_HISTORY
	había I-FAMILY_HISTORY
	fallecido I-FAMILY_HISTORY
	súbitamente I-FAMILY_HISTORY
	a I-FAMILY_HISTORY
	los I-FAMILY_HISTORY
	48 I-FAMILY_HISTORY
	años I-FAMILY_HISTORY
	por I-FAMILY_HISTORY
	la I-FAMILY_HISTORY
	misma I-FAMILY_HISTORY
	enfermedad. I-FAMILY_HISTORY
	Una B-PRESENT_ILLNESS
	noche I-PRESENT_ILLNESS
	salió I-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	cenar I-PRESENT_ILLNESS
	con I-PRESENT_ILLNESS
	los I-PRESENT_ILLNESS
	compañeros I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	trabajo I-PRESENT_ILLNESS
	regresando I-PRESENT_ILLNESS
	al I-PRESENT_ILLNESS
	domicilio I-PRESENT_ILLNESS
	sobre I-PRESENT_ILLNESS
	las I-PRESENT_ILLNESS
	4 I-PRESENT_ILLNESS
	horas I-PRESENT_ILLNESS
	de I-PRESENT_ILLNESS
	la I-PRESENT_ILLNESS
	madrugada. I-PRESENT_ILLNESS
	No I-PRESENT_ILLNESS
	manifestó I-PRESENT_ILLNESS
	ninguna I-PRESENT_ILLNESS
	sintomatología I-PRESENT_ILLNESS
	y I-PRESENT_ILLNESS
	se I-PRESENT_ILLNESS
	acostó I-PRESENT_ILLNESS
	en I-PRESENT_ILLNESS
	el I-PRESENT_ILLNESS
	sofá I-PRESENT_ILLNESS
	del I-PRESENT_ILLNESS
	salón. I-PRESENT_ILLNESS
	Poco I-PRESENT_ILLNESS
	después I-PRESENT_ILLNESS
	el I-PRESENT_ILLNESS
	perro I-PRESENT_ILLNESS
	comenzó I-PRESENT_ILLNESS
	a I-PRESENT_ILLNESS
	ladrar I-PRESENT_ILLNESS
	por I-PRESENT_ILLNESS
	lo I-PRESENT_ILLNESS
	que I-PRESENT_ILLNESS
	el I-PRESENT_ILLNESS
	padre I-PRESENT_ILLNESS
	se I-PRESENT_ILLNESS
	levantó I-PRESENT_ILLNESS
	encontrándola I-PRESENT_ILLNESS
	inconsciente. I-PRESENT_ILLNESS
	Se B-EVOLUTION
	avisó I-EVOLUTION
	a I-EVOLUTION
	los I-EVOLUTION
	servicios I-EVOLUTION
	de I-EVOLUTION
	emergencia I-EVOLUTION
	061 I-EVOLUTION
	que I-EVOLUTION
	se I-EVOLUTION
	limitaron I-EVOLUTION
	a I-EVOLUTION
	constatar I-EVOLUTION
	el I-EVOLUTION
	fallecimiento. I-EVOLUTION
	<EOS> I-EVOLUTION